

第1日

D A Y 1

3月6日(木)

Thursday, March 6, 2025

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

Special Session

- SS** Importance and Reality of Oncocardiology based on Komuro Group Study
腫瘍循環器学の重要性と実態：小室班研究を踏まえて 121

Special Lecture

- SP1** Near infrared photoimmunotherapy (NIR-PIT) of cancer
がんの近赤外光線免疫療法 (光免疫療法) 115

Presidential Session

- PS1** Lung Cancer / Thoracic Cancer, Hematologic Malignancies
呼吸器 血液 115

ASCO/JSMO Joint Symposium

- AJS** Drugging the Undruggable Targets 133

SIOG/JSMO Joint Symposium

- SJS** Lessons to Learn from the Leading Nations in Geriatric Oncology
老年腫瘍学先進国から学ぶべきこと 133

Joint Symposium

- JS1** JCA/JSO/JSMO initiatives for precision oncology
Precision Oncology に対する JCA/JSO/JSMO の取り組み 120
- JS2** Timing of consulting cardiologists in cancer treatment and subsequent follow-up
がん診療における循環器医に相談するタイミングとその後のフォローアップ 122
- JS3** Next generation Precision oncology and genetic medicine
がん診療と遺伝子医療の新時代 123

Presidential Symposium

- PSY1** Clinical application of whole genome sequencing
全ゲノムシーケンシスの臨床実装 116
- PSY2** How to use uninsured medicines recommended by genomic medicine?
ゲノム医療で推奨された保険適応外薬をどのように使うか? 118
- PSY3** Open discussion for the revision of conditional approval system from
Ministry of Health, Labour and Welfare in 2024
激論！『条件付き承認制度』の活用はドラッグ・ロス対策に有用か！？ 132

Symposium

- SY1** New multimodal treatment strategy for GI cancer
消化管がんにおける長期生存、治癒、臓器温存を目指すための多様な
アプローチと将来展望 117

SY2	Current Status and Prospects of Treatment Strategies for Thyroid Cancer 甲状腺癌に対する治療戦略の現状と展望	117
SY3	Cutting edge of genomic medicine and novel therapy in hematologic malignancies 血液がんゲノム医療と治療の新展開	123
SY4	Tumor board for patients with bone metastasis - management of a conference that maximize multidisciplinary expertise- 多職種の専門性を引き出す骨転移カンファレンス～多職種の役割と運営の実際～	125
SY5	Next-generation regimen management through multi-disciplinary collaboration 多職種連携による次世代レジメン管理	126
SY6	New drug treatments for gynecological cancers 婦人科がんの新規薬物療法について	132
SY7	How do we select the partner for the combination immunotherapy? 複合免疫療法を考える	135
SY8	Challenges for implementation of translational research in clinical trials トランスレーショナルリサーチを実装した臨床試験の推進	136

Committee Program

CP1-1	禁煙推進セッション	158
CP1-2	SNS ワーキンググループシンポジウム オンコロジー領域における SNS 利用	158
CP2	Educational activities on Medical Oncology in Asia-Pacific region アジア・パシフィック地域の各学会における腫瘍内科教育の取り組み	158
CP3	Generative AI will brighten the future of medical oncology! 生成 AI が腫瘍内科の未来を明るくする！！	159
CP4	How do we communicate the appeal of Medical Oncology? 【JSMO University】 腫瘍内科の魅力をどのように伝えるか？	160

Meet the Experts

ME1	Perioperative Pembrolizumab + Chemotherapy for Gastric and Gastroesophageal Junction Cancer: KEYNOTE-585 Asian Subgroup	161
ME2	Developing a Career in Clinical Trials	161
ME3	Spatial transcriptome analysis on tumor microenvironment	161
ME4	Pharmacotherapy and supportive care for aging head and neck cancer patients	162
ME5	The pancancer genomic landscape: biology, test strategies and precision medicine guidance	162
ME6	Precision Therapy in Gastric Cancer	162
ME7	Challenges in diagnosis and treatment of rare T-cell lymphomas	162

Highlight of the Day

HoD1	Highlight of the Day 1	119
-------------	------------------------	-----

第1会場 (神戸ポートピアホテル 南館1階 ポートピアホール)

8:30-11:10 Presidential Session 1

PS1 Lung Cancer / Thoracic Cancer, Hematologic Malignancies
呼吸器 血液

E L O

- Chairs :** Shun Lu (Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine)
Nagio Takigawa (Department of General Internal Medicine 4, Kawasaki Medical School)
- Discussants :** Byoung Chul Cho (Yonsei Cancer Center, Yonsei University College of Medicine)
Hiroshi Nokihara (Department of Respiratory Medicine, Center Hospital of the National Center for Global Health and Medicine)
Takehito Shukuya (Department of Respiratory Medicine, Juntendo University)
Jorge Cortes (Georgia Cancer Center at Augusta University)
- 司会 :** Shun Lu (Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine)
瀧川 奈義夫 (川崎医科大学 総合内科学4)
- ディスカッサント :** Byoung Chul Cho (Yonsei Cancer Center, Yonsei University College of Medicine)
軒原 浩 (国際医療研究センター病院)
宿谷 威仁 (順天堂大学 呼吸器内科)
Jorge Cortes (Georgia Cancer Center at Augusta University)

PS1-1 Phase II trial of Carboplatin + Nab-paclitaxel + Atezolizumab Combination for TTF-1 Negative Advanced Non-Sq NSCLC

Yoshimasa Shiraishi (Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University)

TTF-1 陰性の進行非扁平上皮非小細胞肺癌に対するカルボプラチン + nab- パクリタキセル + アテゾリズマブ併用療法の第II相試験 : F1NE TUNE (LOGIK2102)

白石 祥理 (九州大学病院 呼吸器内科)

PS1-2 Pharmacokinetics and safety of adjuvant alectinib in Japanese patients (pts) from ALINA with resected ALK-positive NSCLC

Hidehito Horinouchi (Department of Thoracic Oncology, National Cancer Center Hospital)

完全切除後のALK遺伝子転座陽性非小細胞肺癌に対する術後Alectinibの第III相試験 (ALINA試験): 日本人薬物動態、安全性解析

堀之内 秀仁 (国立がん研究センター中央病院)

PS1-3 Phase I/II study of tificemalimab combined with toripalimab in patients with previously treated advanced lung cancer

Ying Cheng (Jilin Cancer Hospital)

PS1-4 In-depth Responder Analysis of PhALLCON, a Phase 3 Trial of Ponatinib Versus Imatinib in Newly Diagnosed Ph+ ALL

Encore

Yosuke Minami (National Cancer Center Hospital East)

14:00-15:00 Special Lecture 1 / 特別講演 1

SP1 Near infrared photoimmunotherapy (NIR-PIT) of cancer
がんの近赤外光線免疫療法 (光免疫療法)

L O

- Chair :** Hironobu Minami (Division of Medical Oncology/Hematology, Graduate School of Medicine, Kobe University)
- 司会 :** 南 博信 (神戸大学大学院医学研究科 腫瘍・血液内科)

SP1-1 Near infrared photoimmunotherapy (NIR-PIT) of cancer

Hisataka Kobayashi (National Cancer Institute, NIH)

がんの近赤外光線免疫療法 (光免疫療法)

小林 久隆 (米国国立がん研究所)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Room 14
Meet the Experts
Poster

16:10-17:40 Presidential Symposium 1 / 会長企画シンポジウム 1

PSY1 Clinical application of whole genome sequencing
全ゲノムシーケンズの臨床実装



Chairs : Takashi Kohno (Center for Cancer Genomics and Advanced Therapeutics, National Cancer Center)
Edwin Cuppen (Hartwig Medical Foundation)
司会 : 河野 隆志 (国立がん研究センター がんゲノム情報管理センター)
Edwin Cuppen (Hartwig Medical Foundation)

PSY1-1 Whole genome analyses contributing to the prevention, diagnosis, and treatment of lung cancer - Introduction to the Symposium

Takashi Kohno (Center for Cancer Genomics and Advanced Therapeutics, National Cancer Center)

肺がんの予防、診断、治療に資する全ゲノム解析 一本シンポジウムの導入として—
河野 隆志 (国立がん研究センター がんゲノム情報管理センター)

PSY1-2 Clinical Implementation of Whole Genome Sequencing in the Netherlands

Edwin Cuppen (Hartwig Medical Foundation)

PSY1-3 The Current State of Clinical Implementation of Whole Genome Sequencing in Japan

Kuniko Sunami (National Cancer Center Hospital)

本邦における全ゲノム解析の臨床実装に向けた取り組み
角南 久仁子 (国立がん研究センター中央病院)

PSY1-4 Clinical applications of whole genome sequencing in childhood cancer

Motohiro Kato (Department of Pediatrics, the University of Tokyo)

小児がんにおける全ゲノム解析の臨床応用
加藤 元博 (東京大学医学部附属病院 小児科)

PSY1-5 Clinical implementation of whole genome sequencing

Tatsuhiko Shibata (Laboratory of Molecular Medicine, The Institute of Medical Science, The University of Tokyo)

全ゲノムシーケンズの臨床実装
柴田 龍弘 (東京大学 医科学研究所 ゲノム医科学分野)

第2会場 (神戸ポートピアホテル 南館1階 大輪田A)

8:30-10:00 Symposium 1 / シンポジウム 1

SY1 New multimodal treatment strategy for GI cancer
消化管がんにおける長期生存、治癒、臓器温存を目指すための多様なアプローチと将来展望

E O

- Chairs : Izuma Nakayama (Gastrointestinal Oncology, National Cancer Center Hospital East)
Elizabeth Smith (Oxford Cancer)
- Discussants : Filippo Pietrantonio (Fondazione IRCCS Istituto Nazionale dei Tumori)
Yukihide Kanemitsu (Department of Colorectal Surgery, National Cancer Center)
Yoshiaki Nakamura (National Cancer Center Hospital East)
Hiroki Osumi (Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research)
Itaru Yasufuku (Department of Clinical Anatomy Development Studies, Gifu University Graduate School of Medicine)
- 司会 : 中山 巖馬 (国立がん研究センター東病院 消化管内科)
Elizabeth Smith (Oxford Cancer)
- ディスカッサント : Filippo Pietrantonio (Fondazione IRCCS Istituto Nazionale dei Tumori)
金光 幸秀 (国立がん研究センター中央病院 大腸外科)
中村 能章 (国立がん研究センター東病院)
大隅 寛木 (公益財団法人がん研究会 有明病院 消化器化学療法科)
安福 至 (岐阜大学大学院医学系研究科 臨床解剖開発学講座)

SY1-1 < Keynote Lecture 1 / 基調講演 1 >
Redefining the Path to Cure: The Rise of Non-Operative Management in Upper GI Cancer

Izuma Nakayama (Gastrointestinal Oncology, National Cancer Center Hospital East)
治癒を目指す新たな道を求めて : 切除可能上部消化管がんにおける非手術治療の将来展望
中山 巖馬 (国立がん研究センター東病院 消化管内科)

SY1-2 < Keynote Lecture 2 / 基調講演 2 >
NONOPERATIVE MANAGEMENT IN LOWER GI CANCERS
Filippo Pietrantonio (Fondazione IRCCS Istituto Nazionale dei Tumori)

10:10-11:40 Symposium 2 / シンポジウム 2

SY2 Current Status and Prospects of Treatment Strategies for Thyroid Cancer
甲状腺癌に対する治療戦略の現状と展望

E O

- Chairs : Tomoya Yokota (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)
Hisham Mehanna (InHANSE, College of Medicine and Health, University of Birmingham)
- 司会 : 横田 知哉 (静岡県立静岡がんセンター 消化器内科)
Hisham Mehanna (InHANSE, College of Medicine and Health, University of Birmingham)

SY2-1 **Recent updates in molecular targeted agents for thyroid cancer**
Bhumsuk Keam (Department of Internal Medicine, Seoul National University Hospital)

SY2-2 **Current status of systemic therapy for radioiodine-refractory differentiated thyroid cancer**
Naoki Fukuda (Department of Medical Oncology, The Cancer Institute Hospital of JFCR)
ヨード不応性分化型甲状腺がんに対する薬物療法のエビデンスと今後の課題
福田 直樹 (がん研究会 有明病院 総合腫瘍科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

SY2-3 **Current status and future perspectives on the treatment of anaplastic thyroid cancer**
Tomohiro Enokida (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)

甲状腺癌未分化癌における治療戦略の現状と展望
榎田 智弘 (国立がん研究センター東病院 頭頸部内科)

SY2-4 **Current Status and Prospects of Treatment Strategies for Thyroid Cancer in Japan**
Ken-ichi Ito (Division of Breast and Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine)

本邦の甲状腺癌に対する個別化治療の現状と展望
伊藤 研一 (信州大学医学部 外科学教室 乳腺内分泌外科学分野)

14:00-15:30 Presidential Symposium 2 / 会長企画シンポジウム 2

PSY2 How to use uninsured medicines recommended by genomic medicine? **L O**
ゲノム医療で推奨された保険適応外薬をどのように使うか?

Chairs : Manabu Muto (Department of Medical Oncology, Kyoto University Graduate School of Medicine)
Katsutoshi Oda (Division of Integrative Genomics, The University of Tokyo)

司会 : 武藤 学 (京都大学大学院医学研究科 腫瘍内科学講座)
織田 克利 (東京大学大学院 統合ゲノム学)

PSY2-1 **< Keynote Lecture / 基調講演 >**
Challenges and Future Opportunities in Drug Access for Precision Cancer Medicine in Japan

Sadakatsu Ikeda (Institute of Science Tokyo)
がんゲノム医療時代における薬剤アクセスの課題
池田 貞勝 (東京科学大学)

PSY2-2 **Off-Label Drug Use under Japanese Health Insurance System**
Tatsuya Suzuki (National Cancer Center Hospital)

保険外用治療費制度について～治験、先進医療、患者申出療養など～
鈴木 達也 (国立がん研究センター中央病院)

PSY2-3 **Current Status of Off-Label Drug Use in Pediatric Oncology**
Junko Takita (Department of Pediatrics, Graduate School of Medicine, Kyoto University)

小児がん領域における保険適応外薬使用の現状
滝田 順子 (京都大学大学院医学研究科発達小児科)

PSY2-4 **Off-label drug use for cancer patients**
Shinsuke Amano (Japan Federation of Cancer Patient Groups)

がん患者にとっての保険適応外薬使用
天野 慎介 (一般社団法人全国がん患者団体連合会)

PSY2-5 **Health insurance system and new drug coverage in Japan**
Takashi Oshio (Institute of Economic Research, Hitotsubashi University)

日本の保険医療制度と新規医薬品の保険収載
小塩 隆士 (一橋大学経済研究所)

16:30-17:20 Highlight of the Day 【呼吸器、血液】 /
Highlight of the Day 【Thoracic Oncology / Hematology Oncology】

HoD1 Highlight of the Day 1



Chairs : Seiji Yano (Department of Respiratory Medicine, Kanazawa University)
Tetsuji Takayama (Department of Gastroenterology and Oncology, Tokushima University
Graduate School of Biomedical Sciences)

司会 : 矢野 聖二 (金沢大学医薬保健研究域医学系呼吸器内科学)
高山 哲治 (徳島大学大学院医歯薬学研究部消化器内科学分野)

Hod1-1 Takehito Shukuya (Department of Respiratory Medicine, Juntendo University School of
Medicine)

宿谷 威仁 (順天堂大学 呼吸器内科)

Hod1-2 Yosuke Minami (Department of Hematology, National Cancer Center Hospital East)

南 陽介 (国立がん研究センター東病院 血液腫瘍科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

第3会場 (神戸ポートピアホテル 南館 1階 大輪田 B)

8:30-10:30 Joint Symposium 1 (JCA / JSCO / JSMO) /
 合同シンポジウム 1 (日本癌学会 / 日本癌治療学会 / 日本臨床腫瘍学会)

JS1 JCA/JSCO/JSMO initiatives for precision oncology
 Precision Oncology に対する JCA/JSCO/JSMO の取り組み **E**

Chairs : Takashi Kohno (Center for Cancer Genomics and Advanced Therapeutics, National Cancer Center)
 Manabu Muto (Department of Medical Oncology, Kyoto University Graduate School of Medicine)
 Seiji Yano (Department of Respiratory Medicine, Kanazawa University)
 司会 : 河野 隆志 (国立がん研究センター がんゲノム情報管理センター)
 武藤 学 (京都大学大学院医学研究科 腫瘍内科学講座)
 矢野 聖二 (金沢大学医薬保健研究域医学系呼吸器内科学)

JS1-1 Biomarkers for CLK inhibitor CTX-712 treatment response in myeloid neoplasms:
Encore Paving the way toward clinical trials
 Seishi Ogawa (Department of Pathology and Tumor Biology, Kyoto University)

スプライシング異常に対する創薬
 小川 誠司 (京都大学大学院医学研究科腫瘍生物学講座)

JS1-2 Elucidation of the Resistance Mechanisms to Cancer Immunotherapy
 Hiroyoshi Nishikawa (Division of Cancer Immunology, Research Institute, National Cancer Center Japan)
がん免疫治療の抵抗性機序の解明と克服
 西川 博嘉 (国立がん研究センター 研究所腫瘍免疫研究分野)

JS1-3 Prospects for navigation surgery using AI technology
 Masaaki Ito (National Cancer Center Hospital East)
AI 技術を用いた navigation surgery の展望
 伊藤 雅昭 (国立がん研究センター 東病院)

JS1-4 Longitudinal Tumor-Informed ctDNA Dynamics for Monitoring Tumor Burden in
 Advanced Cancers
 Satoshi Nishizuka (Iwate Medical University Institute for Biomedical Sciences)
腫瘍由来変異特異的時系列 ctDNA 動態による進行がん体内腫瘍量モニタリング
 西塚 哲 (岩手医科大学医薬学総合研究所)

JS1-5 Development of novel CAR-T cell therapy: from blood cancers to solid tumors
 Yozo Nakazawa (Department of Pediatrics, Shinshu University School of Medicine)
新規 CAR-T 細胞療法の開発: 血液がんから固形がんへ
 中沢 洋三 (信州大学医学部小児医学教室)

JS1-6 Development of a novel antibody-drug conjugate with a CAF-mediated
 mechanism of action targeting Glypican-1
 Tetsuji Naka (Division of Allergy and Rheumatology, Department of Internal Medicine, School of
 Medicine Iwate Medical University, Institute for Biomedical Science of Iwate Medical University)
Glypican-1 を標的とする CAF を介した作用機序を有する新規抗体薬物複合体の開発
 仲 哲治 (岩手医科大学医学部 リウマチ・膠原病・アレルギー内科)

SS Importance and Reality of Oncocardiology based on Komuro Group Study
 腫瘍循環器学の重要性と実態：小室班研究を踏まえて


Chair : Hironobu Minami (Division of Medical Oncology/Hematology, Graduate School of Medicine, Kobe University)
 司会 : 南 博信 (神戸大学大学院医学研究科 腫瘍・血液内科)

SS-1 Oncologists should learn onco-cardiology

Hironobu Minami (Division of Medical Oncology/Hematology, Graduate School of Medicine, Kobe University)

がん薬物治療における循環器学の重要性

南 博信 (神戸大学大学院医学研究科 腫瘍・血液内科)

SS-2 Current status and issues in onco-cardiology practice as revealed by a survey of the Ministry of Health, Labour and Welfare Science Research Fund

Issei Komuro (International University of Health and Welfare)

厚生労働科研の調査から明らかになった腫瘍循環器診療の現状と課題

小室 一成 (国際医療福祉大学)

14:00-15:20 Oral Session 1

01 Hematologic Malignancies
 血液


Chairs : Noriko Fukuhara (Department of Hematology, Tohoku University Hospital)
 Kazuyuki Shimada (Department of Hematology and Oncology, Nagoya University Graduate School of Medicine)

Discussants : Eisei Kondo (Dept. of Hematology, Kawasaki Medical School)
 Satoshi Iyama (Department of Hematology, Sapporo Medical University School of Medicine)

司会 : 福原 規子 (東北大学病院血液内科)
 島田 和之 (名古屋大学医学部附属病院血液内科)

ディスクサント : 近藤 英生 (川崎医科大学 血液内科学)
 井山 諭 (札幌医科大学 血液内科学)

01-1 Ibrutinib Plus Venetoclax in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Phase 3 SYMPATICO Study

Marek Trnny (General University Hospital in Prague)

01-2 Sonrotoclax + Zanubrutinib Has High uMRD Rates and Good Tolerability in Ongoing Phase 1/1b Study in Treatment-Naive CLL

Minoru Kanaya (Blood Disorders Center, Aikku Hospital)

未治療の CLL を対象とした進行中の第 1/1b 相試験におけるソノロトクラクス + ザヌブルチニブの高い uMRD 率と良好な忍容性

金谷 穰 (愛育病院)

01-3 Epcoritamab + Lenalidomide (E-Len) in Patients with Relapsed/Refractory (R/R) DLBCL: Updated Results from EPCORE NHL-5

Won Seog Kim (Samsung Medical Center, Center for Hematologic Malignancy, Seoul, South Korea)

01-4 Tolerability of Asciminib vs Investigator-Selected (IS) TKIs in Phase 3 ASC4FIRST Study in Newly Diagnosed CML Patients

Cortes E Jorge (Georgia Cancer Center, Augusta University)

15:30-17:30 Joint Symposium 2 (JCS / JOCS / JSMO) /
合同シンポジウム 2 (日本循環器学会 / 日本腫瘍循環器学会 / 日本臨床腫瘍学会)

JS2 Timing of consulting cardiologists in cancer treatment and subsequent follow-up
がん診療における循環器医に相談するタイミングと今後のフォローアップ

Chairs : Yuko Tanabe (Toranomon Hospital)
Yoshihiro Fukumoto (Cardiovascular Medicine, Kurume University School of Medicine)
司会 : 田辺 裕子 (虎の門病院 臨床腫瘍科)
福本 義弘 (久留米大学 心臓・血管内科)

JS2-1 Differences between oncologists and cardiologists regarding the indications for
invasive treatment of cardiovascular disease in cancer patients

Mikio Mukai (Osaka Center for Cancer and Cardiovascular Disease Prevention)

がん患者に合併する循環器疾患に対する治療適応において腫瘍医と循環器医の相違
向井 幹夫 (大阪がん循環器病予防センター)

JS2-2 Cancer care and follow-up: When to consult a cardiologist

Yoichi Naito (Department of General Internal Medicine, National Cancer Center Hospital East)

がん診療における循環器医に相談するタイミングと今後のフォローアップ
内藤 陽一 (国立がん研究センター東病院 総合内科)

JS2-3 The role of hematologists in providing care to patients with cardio-oncology
problems

Kazuhiro Bandai (Hyogo Prefectural Amagasaki General Medical Center)

血液内科医の立場から
万代 和宏 (兵庫県立尼崎総合医療センター)

JS2-4 Cancer associated thrombosis: Multidisciplinary collaboration and follow-up

Yoshihiro Tanaka (Gastroenterological Surgery, Gifu University)

がん関連血栓症 - 多職種連携とフォローアップ -
田中 善宏 (岐阜大学附属病院 消化器外科)

JS2-5 Enhancing Efficiency in Cardio-Oncology Clinics: Addressing the Growing Burden
of CV Complications in Cancer Patients

Tatsuhiko Shibata (Kurume University School of Medicine, Department of Internal Medicine,
Division of Cardiovascular Medicine)

限りあるリソースをふまえた腫瘍循環器外来の実践: がん治療の進歩に伴う心血管合併症への
戦略的アプローチ
柴田 龍宏 (久留米大学医学部内科学講座 心臓・血管内科部門)

JS2-6 A Cardiovascular Interventionalist's Perspective

Yoshihisa Nakagawa (Department of Cardiovascular Medicine, Shiga University of Medical
Science)

循環器インターベンション医の立場から
中川 義久 (滋賀医科大学循環器内科)

第4会場 (神戸ポートピアホテル 南館1階 大輪田C)

8:30-10:00 Symposium 3 / シンポジウム 3

SY3 Cutting edge of genomic medicine and novel therapy in hematologic malignancies
血液がんゲノム医療と治療の新展開

E O

Chairs : Kennosuke Karube (Department of Pathology and Laboratory Medicine, Nagoya University School of Medicine)
Yosuke Minami (Department of Hematology, National Cancer Center Hospital East)
司会 : 加留部 謙之輔 (名古屋大学大学院 臓器病態診断学 / 病院病理部)
南 陽介 (国立がん研究センター東病院 血液腫瘍科)

SY3-1 Utilization of cancer genome medicine in the pathological diagnosis of lymphoid neoplasms

Kennosuke Karube (Department of Pathology and Laboratory Medicine, Nagoya University School of Medicine)

ゲノム医療時代におけるリンパ腫病理診断

加留部 謙之輔 (名古屋大学大学院 臓器病態診断学 / 病院病理部)

SY3-2 From Biomarker Discovery to Clinical Decision Making: Multi-Omic Approaches in Non-Hodgkin Lymphoma (NHL)

Nathan Fowler (BostonGene, Corp.)

SY3-3 Genomic profiling and Precision Medicine for Leukemia Therapy

Yosuke Minami (Department of Hematology, National Cancer Center Hospital East)

難治性白血病ゲノムと克服療法

南 陽介 (国立がん研究センター東病院 血液腫瘍科)

SY3-4 Novel therapy based on genomic analysis in leukemia

Jorge E Cortes (Georgia Cancer Center)

14:00-16:00 Joint Symposium 3 (JSHG / JSMO) /

合同シンポジウム 3 (日本人類遺伝学会 / 日本臨床腫瘍学会)

【協力】厚生労働科学研究費補助金 がん対策推進総合研究事業「ゲノム情報に応じたがん予防にかかる指針の策定と遺伝性腫瘍に関する医療・社会体制の整備および国民の理解と参画に関する研究」班

JS3 Next generation Precision oncology and genetic medicine
がん診療と遺伝子医療の新時代

Chairs : Issei Imoto (Aichi Cancer Center Research Institute)
Katsuya Tsuchihara (EPOC, National Cancer Center Japan)
司会 : 井本 逸勢 (愛知県がんセンター 研究所)
土原 一哉 (国立がん研究センター 先端医療開発センター)

JS3-1 Cancer Genomic Medicine in Japan

Akira Chiba (Ministry of Health, Labour and Welfare)

がんゲノム医療における国の取組について

千葉 晶輝 (厚生労働省)

JS3-2 Guidance for hereditary cancer syndrome with multigene panel testing (MGPT) ver. 2025

Akira Hirasawa (Department of Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)

「遺伝性腫瘍症候群に関する多遺伝子パネル検査 (Multi-Gene Panel Testing:MGPT) の手引き 2025年版」の刊行について

平沢 晃 (岡山大学学術研究院医歯薬学域 臨床遺伝子医療学分野)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

JS3-3 **Presumed Germline Pathogenic Variant**
 Takeshi Kuwata (National Cancer Center Hospital East)
Presumed Germline Pathogenic Variant 開示手順
 桑田 健 (国立がん研究センター東病院)

JS3-4 **Significance and future prospects for clinical implementation of whole genome sequencing**
 Motohiro Kato (Department of Pediatrics, the University of Tokyo)
全ゲノム解析の臨床実装における意義と将来展望
 加藤 元博 (東京大学医学部附属病院)

JS3-5 **Expectation for clinical implementation of MGPT and Patient and public involvement in MGPT**
 Izumi Okawara (Japanese NF1 patient group named as To Smile)
MGPTの臨床実装への期待と患者・市民参画 (PPI)
 大河原 和泉 (レックリングハウゼン病患者会 To Smile)

16:10-17:10 Oral Session 2

02 Gastrointestinal Cancer 1 消化管 1 **E**

Chairs : Satoshi Yuki (Department of Gastroenterology and Hepatology, Hokkaido University Hospital)
 Akihito Kawazoe (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan)
 Discussants : Hanneke van Laarhoven (Amsterdam UMC, Department of Medical Oncology)
 Yukiya Narita (Department of Clinical Oncology, Aichi Cancer Center Hospital)
 司会 : 結城 敏志 (北海道大学病院 消化器内科)
 川添 彬人 (国立がん研究センター東病院消化管内科)
 ディスカッション : Hanneke van Laarhoven (Amsterdam UMC, Department of Medical Oncology)
 成田 有季哉 (愛知県がんセンター)

02-1 **Nivolumab + ipilimumab vs chemotherapy in MSI-H/dMMR metastatic colorectal cancer: CheckMate 8HW Asian subgroup analysis**
 Takayuki Yoshino (National Cancer Center Hospital East)
高頻度マイクロサテライト不安定性・ミスマッチ修復機構欠損の進行大腸がんにおけるニボルマブ及びイピリムマブの併用療法 vs 化学療法 : CheckMate 8HW アジア人サブ集団解析
 吉野 孝之 (国立がん研究センター東病院)

02-2 **ECOG performance status deterioration with fruquintinib in metastatic colorectal cancer: Post hoc analysis of FRESCO-2**
Encore
 Hisato Kawakami (Department of Clinical Oncology, Tohoku University Graduate School of Medicine)

02-3 **ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer**
Encore
 Yasutoshi Kuboki (Department of Experimental Therapeutics, National Cancer Center Hospital East)
進行性固形がんを対象とした新規 c-Met 標的抗体薬物複合体 ABBV-400: 結腸直腸がんにおける結果
 久保木 恭利 (国立がん研究センター東病院)

第5会場 (神戸ポートピアホテル 南館 B1階 トパース)

8:30-10:00 Symposium 4 / シンポジウム 4

SY4

Tumor board for patients with bone metastasis - management of a conference that maximize multidisciplinary expertise-
多職種専門性を引き出す骨転移カンファレンス～多職種の役割と運営の実践～



Chairs : Tetsuhiro Yoshinami (Center for Cancer Genomics and Personalized Medicine, Osaka University Hospital)
Chie Watanabe (Showa University School of Nursing & Rehabilitation Sciences)
司会 : 吉波 哲大 (大阪大学医学部附属病院 がんゲノム医療センター)
渡邊 知映 (昭和大学 保健医療学部)

SY4-1 < Keynote Lecture / 基調講演 >

Issues and problems with bone metastasis cancer boards

Hiroyuki Shibata (Akita University Graduate School of Medicine)

骨転移がんボードの実践と問題点

柴田 浩行 (秋田大学大学院医学系研究科臨床腫瘍学講座)

SY4-2 Transdisciplinary management of skeletal metastasis in cancer patients

Tatsuya Takagi (Palliative Medicine/Orthopedics/Rehabilitation Medicine, Juntendo University)

職種・診療科横断的な骨転移診療

高木 辰哉 (順天堂大学 緩和医療学研究室・整形外科・リハビリテーション科)

SY4-3 The Role of Radiation Oncologists in Bone Metastasis Conferences

Hisayasu Nagakura (Department of Radiology, KKR Sapporo Medical Center)

骨転移カンファレンスにおける放射線治療医の役割

永倉 久泰 (KKR 札幌医療センター放射線科)

SY4-4 As active role of rehabilitation therapists at the meeting of multiple professionals for the patient with bone metastasis

Kazunari Abe (Department of Rehabilitation Sciences, Honamino-sato Clinic)

骨転移診療、多職種カンファレンスでリハビリテーション専門職が発揮する役割

安部 能成 (穂波の郷クリニック リハビリ研究科)

SY4-5 The Role of Nurses in the Multidisciplinary Management of Bone Metastasis in Cancer

Shinobu Uto (Department of Nursing, Keio University Hospital)

骨転移診療、多職種カンファレンスで看護師が発揮する役割

宇土 しのぶ (慶應義塾大学病院看護部)

SY4-6 Let's make it happen in the hospital! ~Know-how to organize a bone metastasis conference ~

Teruhisa Azuma (Nara Prefecture General Medical Center)

院内開催を実現しよう! ~骨転移カンファレンスの開催のノウハウ~

東 光久 (奈良県総合医療センター)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Room 14
Meet the Experts
Poster

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Room 14
Meet the Experts
Poster

10:10-11:30 Oral Session 3

03 Multidisciplinary Team Program
多職種連携プログラム



Chairs : Terufumi Kato (Department of Thoracic Oncology, Kanagawa Cancer Center)
Junya Sato (Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences)
Discussants : Kenichi Suzuki (Department of Clinical Pharmacology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences)
Tomomi Fujisawa (Gunma prefectural cancer center)
司会 : 加藤 晃史 (神奈川県立がんセンター呼吸器内科)
佐藤 淳也 (湘南医療大学 薬学部)
アシスタント : 鈴木 賢一 (東京薬科大学薬学部臨床薬理学教室)
藤澤 知巳 (群馬県立がんセンター)

03-1 Improving Survival in Hepatocellular Carcinoma: The Benefits of Multidisciplinary Team Involvement

Nintita S Thokanit (Ramathibodi Comprehensive Cancer Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University)

03-2 Evaluating safety and outcomes of midline catheters for cancer patients receiving 5-FU chemotherapy(MLC45FU study)

Shinichiro Fukahori (Department of Nursing, Aichi Cancer Center Hospital)

5-FU 持続静注の投与経路としてのミッドラインカテーテルの有用性探索 (MLC45FU 試験)
深堀 慎一郎 (愛知県がんセンター看護部)

03-3 A Randomized Controlled Trial of Usefulness of Electronic Patient Reported Outcome for FN in Patients with Cancer

Kazuhiro Tsuruta (Matsudo City General Hospital Pharmaceuticals Department)

がん患者の FN-eDiary の有用性に関するコントロール対照無作為化比較試験 (最終報告)
鶴田 和裕 (松戸市立総合医療センター 薬局)

03-4 Hospitalization-required irAEs in cancer patients on immune checkpoint inhibitors: a single institution experience

Keita Miyashita (Department of Pharmacy, Kurashiki central hospital)

免疫チェックポイント阻害薬投与後に入院を要した免疫関連有害事象に対する治療と経過に関する単施設実態調査
宮下 佳大 (倉敷中央病院 薬剤部)

14:00-15:30 Symposium 5 / シンポジウム 5

SY5 Next-generation regimen management through multi-disciplinary collaboration
多職種連携による次世代レジメン管理



Chairs : Tomonobu Koizumi (Nagano Prefectural Kiso Hospital)
Junya Sato (Shonan University of Medical Science)
司会 : 小泉 知展 (県立木曽病院 内科)
佐藤 淳也 (湘南医療大学 薬学部)

SY5-1 < Keynote Lecture / 基調講演 >

How to implement feasible and evidence-based chemotherapy regimen

Koji Matsumoto (Division of Medical Oncology/ Clinical Genetics, Hyogo Cancer Center)

レジメン構築のポイント: エビデンスに基づきつつ、現場で実行可能なレジメンを構築するには

松本 光史 (兵庫県立がんセンター 腫瘍内科)

SY5-2	The Role of Pharmacists in Managing Cancer Chemotherapy Regimens Yasunari Okuda (Department of Pharmacy, Jichi Medical University Hospital) がん薬物療法レジメン管理における薬剤師の役割 奥田 泰考 (自治医科大学附属病院 薬剤部)	Day 1 (Thu) Day 2 (Fri) Day 3 (Sat)
SY5-3	Incorporating safe administration management from a nurse's perspective into regimen reviews Youta Yatagai (Nursing Department, Tochigi Cancer Center) 看護師の視点で安全な投与管理をレジメン審査に盛り込む 谷田貝 洋太 (地方独立行政法人栃木県立がんセンター)	Room 1
SY5-4	Effectiveness of Dietitian Interventions in Cancer Chemotherapy Review Committee Hideki Yanome (Aizawa Hospital of Jisenkai Healthcare Incorporated Foundation) レジメン審査に管理栄養士が入るとよいこと 矢野目 英樹 (社会医療法人財団慈泉会相澤病院)	Room 2
SY5-5	Possible roles of pharmacists in health insurance pharmacies with disclosure of drug dosage regimens by hospitals Toshiki Nakamura (Akebono Pharmacy Group, Akebono Pharmacy) 病院からのレジメン公開を受けて保険薬局薬剤師ができること 中村 俊貴 (あけぼのファーマシーグループ あけぼの薬局)	Room 3 Room 4
SY5-6	Pharmaceutical management leading to the AI hospital projects Hisanori Shimizu (Department of Pharmacy, Japanese Foundation for Cancer Research, Cancer Institute Hospital) AI ホスピタル事業に繋ぐ薬学的管理について 清水 久範 (がん研究会有明病院 薬剤部)	Room 5 Room 6 Room 7

15:30-16:30 Mini Oral Session 1

MO1	Palliative Care / Symptom Management 1 (Psycho-Oncology) 緩和ケア・支持療法 1 (サイコオンコロジー)	E
Chairs :	Daisuke Sakai (Osaka international cancer institute) Hiromichi Matsuoka (Department of Psychooncology/Palliative and Supportive Care Development Division, National Cancer Center Hospital)	Room 8 Room 9
司会 :	坂井 大介 (大阪国際がんセンター) 松岡 弘道 (国立がん研究センター中央病院 精神腫瘍科 / 支持・緩和医療開発部門)	Room 10
MO1-1	Exploring the Relationship Between Resilience and Posttraumatic Growth in Cancer Patients Bibiana Jozefiakova (Olomouc University Social Health Institute, Palacky University)	Room 11 Room 12
MO1-2	Depression and Anxiety in Patients with Cancer: Exploring the Role of Coping Resources through a Network Approach Gabriel Banik (Pavol Jozef Safarik University)	Room 13
MO1-3	Posttraumatic Growth in Cancer Patients: Understanding the Mechanism via the Network Analysis Approach Matus Adamkovic (Slovak Academy of Sciences)	Room 14
MO1-4	A Systematic Review of Symptom Management and Psycho-Oncology in Palliative Care for Colorectal Cancer Patients Ryan C Harliman (University of Pelita Harapan)	Meet the Experts Poster

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

M01-5 **Impact of Social Isolation on the clinical outcomes in advanced NSCLC patients**
Encore Yoh Yamaguchi (Department of Thoracic Oncology, National Cancer Center Hospital)
進行非小細胞肺がん患者の臨床転帰に対する社会的孤立の影響
 山口 曜 (国立がん研究センター中央病院 呼吸器内科)

M01-6 **Gender Differences in Chemotherapy-Induced Alopecia Distress Using Japanese Chemotherapy-Induced Alopecia Distress Scale**
Encore Hiroki Okumura (Department of Medical Oncology, Toranomon Hospital)
化学療法による脱毛に伴う苦痛の男女差の評価 :Chemotherapy-Induced Alopecia Distress Scale の日本語版 (CADS-J) を用いた検討
 奥村 浩基 (虎の門病院)

16:30-17:30 Mini Oral Session 2

MO2 Palliative Care / Symptom Management 2 (Palliative Medicine)
 緩和ケア・支持療法 2 (緩和医療)

Chairs : Masakazu Abe (Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine)
 Tomofumi Miura (Department of Palliative Medicine, National Cancer Center Hospital East)
 司会 : 安部 正和 (浜松医科大学医学部産婦人科学講座)
 三浦 智史 (国立がん研究センター東病院)

M02-1 **RCT and observational study on the efficacy of specialized rehabilitation for cancer patients in palliative care units**
 Kazuaki Kushi (Division of Palliative Medicine, NHO Okinawa National Hospital)
緩和ケア病棟入院中がん患者を対象とする Op-reha ガイドを用いた専門的リハビリテーションの有効性検証のための多施設共同ランダム化比較試験および観察研究
 久志 一期 (国立病院機構沖縄病院 緩和医療科)

M02-2 **The effect of contact needle therapy on fatigue in palliative care: a randomized controlled trial**
 Keiko Ogawa (Hiroshima University Hospital)
緩和ケア入院中のがん患者における倦怠感に対する接触鍼治療効果の検討
 小川 恵子 (広島大学病院)

M02-3 **Evaluation of pain in cancer patients using the AI app for cancer palliative care support, PalliEase**
 Kazuki Shimada (Associate Professor, Human Health Sciences, Graduate School of Medicine, Kyoto University)
がん緩和ケア支援 AI アプリ『PalliEase(パリース)』によるがん患者の痛みの評価
 嶋田 和貴 (京都大学)

M02-4 **Clinical Utility of Inflammation and Nutrition biomarkers of immune checkpoint inhibitors in Advanced Cancer**
 Kazuhiro Araki (Medical Oncology, Gunma Prefectural Cancer Center)
免疫チェックポイント阻害薬に対する栄養と炎症性バイオマーカーの臨床的有用性の検討
 荒木 和浩 (群馬県立がんセンター)

-
- MO2-5 **Relationship between hypovolemia from dysphagia and cisplatin-induced acute kidney injury in esophageal cancer patients**
Yuya Kawaguchi (Department of Medical Oncology, Osaka City General Hospital)
嚥下障害を伴う食道癌患者における潜在性血管内脱水とシスプラチン誘発性急性腎障害の関係について
川口 雄也 (Osaka City General Hospital)
-
- MO2-6 **Adherence to Recommended Osteoporosis Treatment Reduces Fracture Risk in Cancer Patients**
Nokitaka Setsu (Department of Orthopedic Surgery, NHO Kyushu Cancer Center)
がん骨粗鬆症外来における推奨治療の遵守は骨折リスクを低下させる
薛 宇孝 (九州がんセンター 整形外科)
-

第6会場 (神戸ポートピアホテル 南館 B1 階 エメラルド)

14:00-15:20 Oral Session 4

04 Gynecologic Cancer 婦人科

E

Chairs : Jae-Weon Kim (Department of Obstetrics and Gynecology, Seoul National University College of Medicine)

Kosei Hasegawa (Department of Gynecologic Oncology, Saitama Medical University International Medical Center)

Discussants : Mayu Yunokawa (Department of Gynecology and Medical Oncology, Cancer Institute hospital of JFCR)

Tadaaki Nishikawa (Department of Obstetrics and Gynecology, The Jikei University School of Medicine)

司会 : Jae-Weon Kim (Department of Obstetrics and Gynecology, Seoul National University College of Medicine)

長谷川 幸清 (埼玉医科大学国際医療センター婦人科腫瘍科)

ディスクサント : 温泉川 真由 (公益財団法人がん研究会有明病院)

西川 忠曉 (東京慈恵会医科大学)

04-1 AI-Driven Identification of ecDNA-Mediated Mechanisms Underlying Platinum Resistance in High-Grade Serous Ovarian Cancer

Prihantini Prihantini (Machine Learning for BioMedicine Laboratory, Bandung Institute of Technology)

04-2 Histology-specific long-term oncologic outcomes in epithelial ovarian cancer patients who underwent complete resection

Kazumasa Mogi (Department of Medical Genomics Center, Nagoya University Hospital)

完全切除された上皮性卵巣癌患者の組織型別腫瘍学的転帰の検討

茂木 一将 (名古屋大学医学部附属病院 ゲノム医療センター)

04-3 Real-world characteristics and treatment patterns of patients with recurrent or metastatic cervical cancer in Japan

Laura Liao (Genmab US Inc.)

04-4 RESULTS OF TREATMENT FOR OVARIAN CANCER OF THE GRANULOSA CELL TYPE AT VIETNAM NATIONAL CANCER HOSPITAL

Quang Anh Nguyen (Vietnam National cancer hospital)

15:30-16:20 Mini Oral Session 3

MO3 Gynecologic Cancer 1 婦人科 1

E

Chairs : Koji Nishino (Department of Familial and Hereditary Oncology (Obstetrics and Gynecology), Niigata University Graduate School of Medical and Dental Sciences)

Kasumi Yamamoto (Hyogo Cancer Center)

司会 : 西野 幸治 (新潟大学大学院医歯学総合研究科 家族性・遺伝性腫瘍学講座 (産科婦人科))

山本 香澄 (兵庫県立がんセンター)

MO3-1 The clinical course of Immune check point inhibitor for Gynecologic cancer with MS-H/dMMR/TMB-H

Mayu Yunokawa (Cancer Institute hospital of JFCR)

MSI-H/dMMR/TMB-H 婦人科腫瘍に対する免疫チェックポイント阻害剤使用時の臨床経過についての検討

温泉川 真由 (がん研究会有明病院)

- MO3-2 **Age disparities in poly(ADP-ribose) polymerase (PARP) inhibitor trials in high grade serous ovarian cancer (HGSOC)**
Omali Pitiyarachchi (School of Biomedical Sciences, Faculty of Medicine and Health, UNSW Sydney)
- MO3-3 **Evaluation of serum level of WT1 gene protein in the diagnosis of ovarian cancer**
Harshita Dubey (DR.BRAI-RCH, All India Institute of Medical Sciences)
- MO3-4 **Withdrawn**
- MO3-5 **Second-line Trastuzumab Deruxtecan for Metastatic HER2-Expressing Gastric-Type Mucinous Carcinoma of Cervix in Singapore**
Daniel Ang (Division of Medical Oncology, National Cancer Centre Singapore)

16:30-17:20 Mini Oral Session 4

MO4 Gynecologic Cancer 2
婦人科 2



- Chairs : Koji Matsumoto (Division of Medical Oncology, Hyogo Cancer Center)
JungYun Lee (Department of Obstetrics and Gynecology Yonsei University College of Medicine Seoul, Republic of Korea)
- 司会 : 松本 光史 (兵庫県立がんセンター腫瘍内科)
JungYun Lee (Department of Obstetrics and Gynecology Yonsei University College of Medicine Seoul, Republic of Korea)

- MO4-1 **Verification of treatment for VAIN diagnosed after TLH for CIN3**
Hiroaki Inui (Department of Obstetrics and Gynecology, Tokushima University School of Medicine)

当院で CIN3 の TLH 術後に発生した VAIN に対する治療についての検討
乾 宏彰 (徳島大学産婦人科)

- MO4-2 **Withdrawn**

- MO4-3 **Withdrawn**

- MO4-4 **Behavioral Economics for Cervical Cancer Prevention Programs: A Meta-Analysis and Qualitative Comparative Analysis**
Therdpong Thongseiratch (Faculty of Medicine, Prince of Songkla University)

- MO4-5 **Evaluating the efficacy and safety of pembrolizumab in dMMR and pMMR patients with advanced endometrial cancer**
Hasti H Tolani (Faculty of Medicine, Pelita Harapan University)

第7会場（神戸国際会議場 B1階 / 1階 メインホール）

8:30-10:00 Symposium 6 / シンポジウム 6

SY6 New drug treatments for gynecological cancers
婦人科がんの新規薬物療法について



Chairs : Kan Yonemori (Department of Medical Oncology, National Cancer Center Hospital)
Jae-Weon Kim (Seoul National University)
司会 : 米盛 勲 (国立がん研究センター中央病院腫瘍内科)
Jae-Weon Kim (Seoul National University)

SY6-1 **How Clinical Trials Enhance Patient Outcomes in Cervical Cancer**
Jung-Yun Lee (Department of Obstetrics and Gynecology, Yonsei University College of Medicine)

SY6-2 **State of Art Treatment of Advanced and Recurrent Endometrial Cancer: Immunotherapy and Beyond**
Shannon N Westin (University of Texas MD Anderson Cancer Center)

SY6-3 **New Drug Treatments for Ovarian Cancer**
Kathleen N Moore (Stephenson Cancer Center at OU Health)

10:10-11:40 Presidential Symposium 3 / 会長企画シンポジウム 3

PSY3 Open discussion for the revision of conditional approval system from Ministry of Health, Labour and Welfare in 2024
激論！「条件付き承認制度」の活用はドラッグ・ロス対策に有用か！？



Chairs : Kan Yonemori (Department of Medical Oncology, National Cancer Center Hospital)
Kiyohito Nakai (Ministry of Health, Labor and Welfare)
司会 : 米盛 勲 (国立がん研究センター中央病院腫瘍内科)
中井 清人 (厚生労働省)

PSY3-1 **From the standpoint of academia**
Taizo Hirata (Clinical Research Center in Hiroshima, Hiroshima University Hospital)
アカデミアの立場から
平田 泰三 (広島大学病院 広島臨床研究開発支援センター)

PSY3-2 **From the Perspective of Biostatistics and Regulatory Science**
Akihiro Hirakawa (Department of Clinical Biostatistics, Institute of Science Tokyo)
生物統計学・レギュラトリーサイエンスの立場から
平川 晃弘 (東京科学大学 臨床統計学分野)

PSY3-3 **Utilizing and Improving the Conditional Approval System from the Perspective of Patient Benefits**
Yoshiyuki Majima (NPO PanCAN Japan)
「患者利益から考える条件付き承認制度の活用と改善策」
眞島 喜幸 (NPO 法人パンキャンジャパン)

PSY3-4 **From the industry's perspective**
Takashi Owa (Eisai Co., Ltd.)
産業界の立場から
大和 隆志 (エーザイ株式会社)

PSY3-5 **Making everyone's lives brighter together ~From the Regulator's Perspective~**
Toyotaka Iguchi (Pharmaceuticals and Medical Devices Agency)
健やかに生きる世界を、ともに~規制当局の立場から~
井口 豊崇 (独立行政法人 医薬品医療機器総合機構)

14:00-15:30 SIOG/JSMO Joint Symposium

SJS **Lessons to Learn from the Leading Nations in Geriatric Oncology**
老年腫瘍学先進国から学ぶべきこと 

Chairs : Tomonori Mizutani (Department of Medical Oncology, Kyorin University Faculty of Medicine)
Hiroshi Yamamoto (Department of Respiratory Medicine, Tokyo Metropolitan Institute for Geriatrics and Gerontology)

司会 : 水谷 友紀 (杏林大学医学部 腫瘍内科学)
山本 寛 (東京都健康長寿医療センター 呼吸器内科)

SJS-1 **Current Status and Issues in Geriatric Oncology in Japan**

Hiroshi Yamamoto (Department of Respiratory Medicine, Tokyo Metropolitan Institute for Geriatrics and Gerontology)

日本における老年腫瘍学の現状と課題

山本 寛 (地方独立行政法人東京都健康長寿医療センター呼吸器内科)

SJS-2 **Organizing Cancer Care for Older Adults: France's Strategic Oncogeriatric Initiative**

Rabia Boulahssass (UCOG PACA EST Teaching Hospital of Nice France, University of Nice Sophia Antipolis)

SJS-3 **Implementation of geriatric assessment in Belgium**

Hans Wildiers (University Hospitals Leuven)

SJS-4 **Collaboration of Oncology and Geriatrics**

Ken Sugimoto (Geriatric General Medicine, Kawasaki Medical School)

腫瘍学と老年医学の協働

杉本 研 (川崎医科大学 総合老年医学)

16:00-17:30 ASCO/JSMO Joint Symposium

AJS **Drugging the Undruggable Targets** 

Chairs : Lynn Schuchter (ASCO - Chair of Board, University of Pennsylvania - Director, Tara Miller Melanoma Center)
Hironobu Minami (Medical Oncology/Hematology, Kobe University Graduate School of Medicine)

司会 : Lynn Schuchter (ASCO - Chair of Board, University of Pennsylvania - Director, Tara Miller Melanoma Center)
南 博信 (神戸大学大学院医学研究科 腫瘍・血液内科)

AJS-1 **Breaking Barriers: Advances in targeting the "undruggable" proteins in oncology**

Erika P. Hamilton (Sarah Cannon Research Institute)

AJS-2 **Unlocking Undruggable Targets: from Mission Impossible to Mission Achievable**

Anna Spreafico (Princess Margaret Cancer Centre, University Health Network)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

AJS-3 **SCRUM-MONSTAR Multiomics Platform: Advancing Precision Medicine through Novel Cancer Therapeutics**

Hideaki Bando (National Cancer Center Hospital East)

SCRUM-MONSTAR チームが目指す Multiomics Platform を用いたがん Precision Medicine の推進

坂東 英明 (国立がん研究センター東病院)

AJS-4 **The development of drugs targeting RNA splicing mechanisms in anti-cancer therapy**

Takafumi Koyama (National Cancer Center Hospital)

抗悪性腫瘍薬における RNA スプライシング機構を標的とした薬剤開発

小山 隆文 (国立がん研究センター中央病院)

第8会場 (神戸国際会議場 3階 国際会議室)

8:30-10:00 Symposium 7 / シンポジウム 7

SY7 How do we select the partner for the combination immunotherapy?
複合免疫療法を考える

E O

Chairs : Yosuke Togashi (Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)
Yasushi Goto (Thoracic Oncology, National Cancer Center Hospital)
司会 : 富樫 庸介 (岡山大学学術研究院医歯薬学域 腫瘍微小環境学分野)
後藤 悌 (国立がん研究センター中央病院 呼吸器内科)

SY7-1 **How Do We Select the Partner for Combination Immunotherapy?**

Yosuke Togashi (Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University)

複合免疫療法を考える

富樫 庸介 (岡山大学学術研究院医歯薬学域 腫瘍微小環境学分野)

SY7-2 **The role of cytotoxic chemotherapy in combination immunotherapy**

Kiichiro Ninomiya (Center for Comprehensive Genomic Medicine, Okayama University Hospital)

複合免疫療法における細胞傷害性抗癌薬の役割

二宮 貴一朗 (岡山大学病院 ゲノム医療総合推進センター)

SY7-3 **CTLA-4: Established Target, Next Antibodies, and Persistent Unknowns**

Hidetoshi Hayashi (Department of Medical Oncology, Kindai University, Faculty of Medicine)

CTLA-4: Established Target, Next Antibodies, and Persistent Unknowns

林 秀敏 (近畿大学医学部内科学腫瘍内科)

SY7-4 **The role of anti-angiogenic therapy in tumor immunity**

Satoru Miura (Niigata Cancer Center Hospital)

腫瘍免疫における抗血管新生治療の位置づけ

三浦 理 (新潟県立がんセンター新潟病院)

SY7-5 **Strategic Partnering in Cancer Immunotherapy**

Yasushi Goto (Thoracic Oncology, National Cancer Center Hospital)

がん免疫療法における戦略的組み合わせ

後藤 悌 (国立がん研究センター中央病院 呼吸器内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Room 14
Meet the Poster Experts

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Room 14
Meet the Experts
Poster

10:10-11:30 Oral Session 5

05 Translational Research / Clinical Pharmacology
TR・臨床薬理



Chairs : Kazuto Nishio (Department of Genome Biology, Kindai University Faculty of Medicine.)
Natsuko Chiba (Department of Cancer Biology, Institute of Development, Aging and Cancer, Tohoku University)

Discussants : Wataru Okamoto (Department of Clinical Oncology, Hiroshima University Hospital)
Yohei Funakoshi (Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine)

司会 : 西尾 和人 (近畿大学医学部 ゲノム生物学教室)
千葉 奈津子 (東北大学加齢医学研究所 腫瘍生物学分野)

ディスカッサント : 岡本 渉 (広島大学病院 がん化学療法科)
船越 洋平 (神戸大学医学部附属病院 腫瘍・血液内科)

05-1 **Real-world application of comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in Japan and East Asia**

Steven Olsen (Dept of Medical Affairs, Guardant Health AMEA)

05-2 **Prospective observational study to conduct whole genome sequencing for cancer patients: a progress report**

Masahiro Sekiguchi (Children's Cancer Center, National Center for Child Health and Development)

がん患者に対し全ゲノム解析を施行する前方視的観察研究：進捗報告

関口 昌央 (国立成育医療研究センター 小児がんセンター)

05-3 **Age-Related Trends in Druggable Genetic Alterations Across Major Solid Tumors: Analysis of C-CAT Data**

Tatsuki Ikoma (Department of Thoracic Oncology, Kansai Medical University)

C-CAT データを利用した若年者ならびに高齢者固形がん症例における治療標的遺伝子変異の特徴の検討

生駒 龍興 (関西医科大学 呼吸器腫瘍内科学講座)

05-4 **Livmoniplimab and budigalimab for advanced solid tumors: Results from dose expansion cohort for urothelial carcinoma**

Encore Nobuaki Matsubara (Department of Medical Oncology, National Cancer Center Hospital East)

進行固形癌を対象とした livmoniplimab 及び budigalimab の検討：尿路上皮癌を対象とした拡大コホートの結果報告

松原 伸晃 (国立がん研究センター東病院)

14:00-15:30 Symposium 8 / シンポジウム 8

SY8 Challenges for implementation of translational research in clinical trials
トランスレーショナルリサーチを実装した臨床試験の推進



Chairs : Yoshiaki Nakamura (National Cancer Center Hospital East)
Yu Sunakawa (Department of Clinical Oncology, St. Marianna University School of Medicine)

司会 : 中村 能章 (国立がん研究センター東病院)
砂川 優 (聖マリアンナ医科大学 臨床腫瘍学)

SY8-1 **Multimomics analysis using a large-scale sample set from clinical trials**

Hiromichi Ebi (Aichi Cancer Center)

大規模臨床研究に付随したマルチオミクス解析の実践

衣斐 寛倫 (愛知県がんセンター)

- SY8-2 **Translational Research in Early Drug Development**
Takafumi Koyama (National Cancer Center Hospital)
早期の薬剤開発における橋渡し研究
小山 隆文 (国立がん研究センター中央病院)
- SY8-3 **Translational research in gastrointestinal cancer using clinical samples**
Akihito Kawazoe (National Cancer Center Hospital East)
消化管癌における臨床検体を用いた TR 研究
川添 彬人 (国立がん研究センター東病院)
- SY8-4 **Challenges for implementation of translational research in large scale investigator-initiated clinical trials**
Chigusa Morizane (National Cancer Center Hospital)
研究者主導の大規模臨床試験における TR 付随研究の課題
森實 千種 (国立がん研究センター中央病院)
- SY8-5 **Spatial architecture of tumor microenvironment and therapeutic responses**
Woong-Yang Park (GxD Inc.)

15:40-17:30 Oral Session 6

06 Clinical Trial Facilitation Program
臨床試験推進プログラム

- Chairs : Hideo Harigae (Department of Hematology, Tohoku University Graduate School of Medicine)
Nobuaki Matsubara (Department of Medical Oncology, National Cancer Center Hospital East)
- Discussants : Takashi Shimamoto (Japan Development, MSD K.K.)
Tomonori Mizutani (Kyorin University Faculty of Medicine)
- 司会 : 張替 秀郎 (東北大学大学院医学系研究科血液内科学分野)
松原 伸晃 (国立がん研究センター東病院腫瘍内科)
- ディスカッサント: 嶋本 隆司 (MSD 株式会社研究開発本部)
水谷 友紀 (杏林大学医学部)

- 06-1 **Using hybrid trial-design approach in confirmatory non-inferiority trial for anti-cancer treatment**
Masashi Wakabayashi (Biostatistics Division, Center for Research Administration and Support, National Cancer Center)
がんを対象とした検証的非劣性試験における Hybrid design の適用
若林 将史 (国立研究開発法人国立がん研究センター 研究支援センター生物統計部)

- 06-2 **The status and challenges of “drug loss” in Japan, analyzed from survey to pharmaceutical companies conducted by CRO**
Kazunori Takemura (IQVIA Services Japan G.K.)
CRO による製薬企業を対象としたアンケート結果から分析した日本の臨床開発におけるドラッグロスの現状と課題
武村 和範 (IQVIA サービスーズ ジャパン合同会社)

- 06-3 **Development of a Novel Clinical Trial Search System for Genetic Abnormality Detected by Comprehensive Genomic Profiling**
Sadakatsu Ikeda (Tokyo Medical and Dental University)
がん遺伝子パネル検査にて検出された遺伝子異常に対する新規治験検索システムの研究開発
池田 貞勝 (東京医科歯科大学)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

06-4 **Importance of collaboration between Clinical Research Core Hospitals and other hospitals to accelerate clinical trials**

Yukiko Hibino (National Cancer Center Hospital)

臨床試験・治験の促進における臨床試験中核病院と非中核病院の連携の重要性

日比野 幸子 (国立がん研究センター中央病院)

06-5 **An evaluation of the “10-Year Strategy for Cancer Research”**

Toshio Ogawa (Setsunan University)

「がん研究 10 か年戦略」の評価に関する一考察

小川 俊夫 (学校法人常翔学園 摂南大学)

06-6 **A machine learning-based analysis of nationwide CGP data to identify features associated with mutation-based therapy**

Hiroaki Ikushima (Department of Respiratory Medicine, The University of Tokyo Hospital)

生島 弘彬 (東京大学医学部附属病院呼吸器内科)

MO5 Gastrointestinal Cancer 1 (Gastric Cancer 1 Basic)
消化管1 (胃1 基礎)

E

Chairs : Yoshiaki Nagatani (Department of Medical Oncology and Hematology, Kobe University Hospital)
Hiroshi Imazeki (Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital)

司会 : 長谷 善明 (神戸大学医学部附属病院 腫瘍・血液内科)
今関 洋 (国立がん研究センター中央病院頭頸部・食道内科)

MO5-1 **Telisotuzumab Adizutecan (ABBV-400), a c-Met-Targeting ADC, in Pts With Advanced GEA: Results From a Phase 1 Study**

Yasutoshi Kuboki (Department of Experimental Therapeutics, National Cancer Center Hospital East)

進行性胃食道接合部腺がん患者を対象とした c-Met を標的とする抗体薬物複合体 Telisotuzumab Adizutecan(ABBV-400) の第1 相試験の結果

久保木 恭利 (国立がん研究センター東病院)

MO5-2 **Complementary Relationship Between ERBB2 and Other Oncogenes Amplifications (Amp) in HER2 positive Gastric Cancer (GC)**

Hidekazu Hirano (Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital)

SOX+ トラスツズマブ併用化学療法が施行された HER2 陽性胃癌における、ERBB2 と ERBB2 以外のがん遺伝子増幅の補完的関係の臨床的意義

平野 秀和 (国立がん研究センター中央病院 消化管内科)

MO5-3 **Clinical Features and Evolution of Actionable Genomic Alterations in Recurrent Gastric/Gastroesophageal Junction Cancer**

Hiroyuki Takeda (Department of Clinical Oncology, St. Marianna University School of Medicine)

再発胃癌・胃食道接合部癌における Actionable な遺伝子異常の変化と臨床的特徴

武田 弘幸 (聖マリアンナ医科大学 臨床腫瘍学)

MO5-4 **Biomarkers of Neoadjuvant Anti-PD-1 in Combination with Chemoradiotherapy for Locally Advanced G/GEJ Adenocarcinoma**

Yue Wang (Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University)

MO5-5 **Fatty acid synthesis inhibition synergizes with PD1 blockade by regulating suppressive macrophages in gastric cancer**

Hanbing Wang (Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.)

MO5-6 **The impact of prior nivolumab on the treatment outcomes of taxane plus ramucirumab for advanced gastric cancer**

Yusuke Miyajima (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)

HER2 陰性切除不能胃癌に対するニボルマブ併用療法が2 次治療のタキサン + ラムシルマブ療法の治療成績に与える影響

宮嶋 佑輔 (静岡県立静岡がんセンター 消化器内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Room 14
Meet the Poster Experts

MO6 Gastrointestinal Cancer 2 (Gastric Cancer 2 Trial)
消化管 2 (胃 2 臨床)

Chairs : Yasushi Tsuji (Department of Medical Oncology, Tonan Hospital)
Yasunori Emi (Department of Oncology, Nakatsu Municipal Hospital)

司会 : 辻 靖 (国家公務員共済組合連合会 斗南病院)
江見 泰徳 (中津市民病院)

MO6-1 Zolbetuximab Plus mFOLFOX6 in Japanese Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (SPOTLIGHT)

Kensei Yamaguchi (Cancer Institute Hospital of JFCR)

MO6-2 Zolbetuximab Plus CAPOX in Japanese Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (GLOW Trial)

Hirokazu Shoji (National Cancer Center Hospital, Tokyo, Japan)

MO6-3 Prognostic Factors for T-DXd Treatment in HER2+ Unresectable Advanced/ Recurrent Gastric Cancer: EN-DEAVOR Sub-Analysis

Naotoshi Sugimoto (Department of Genetic Oncology, Osaka International Cancer Institute, Osaka, Japan)

HER2 陽性切除不能進行・再発胃癌患者におけるトラスツズマブ デルクステカン治療の予後因子:EN-DEAVOR 研究サブ解析

杉本 直俊 (大阪国際がんセンター遺伝子診療部)

MO6-4 Correlation between PD-L1 CPS and efficacy of Nivo-CT for gastric or GEJ cancer: a multi-center retrospective study**Encore**

Yosuke Kito (Ishikawa Prefectural Central Hospital)

進行胃癌における PD-L1 CPS とニボルマブ併用化学療法の有効性との関連についての多施設後方視的研究

木藤 陽介 (石川県立中央病院)

MO6-5 Overall Survival and Progression Free Survival of Pembrolizumab in Patients Advance Gastric Cancer : A Meta Analysis

Theodora Constantina E Adeodatia (Faculty of Medicine Pelita Harapan University, Tangerang, Indonesia)

MO6-6 Safety and Efficacy of Nivolumab for Gastric Cancer: A Meta-Analysis and Trial Sequential Analysis of Clinical Trials

Amos I Chandra (Faculty of Medicine, Pelita Harapan University)

MO7 Gastrointestinal Cancer 3 (Gastric Cancer 3 Surgical Department)
消化管 3 (胃 3 外科)

E

Chairs : Naotoshi Sugimoto (Department of Genetic Oncology, Osaka International Cancer Institute)
Shunsuke Kagawa (Center for Clinical Oncology, Okayama University Hospital)

司会 : 杉本 直俊 (大阪国際がんセンター 遺伝子診療部)
香川 俊輔 (岡山大学病院腫瘍センター)

MO7-1 Prediction of prognosis in stage III gastric cancer patients: Random survival forest analysis from the START-2 trial

Encore

Hiroki Sato (Oita University Hospital)

Random Survival Forest による Stage III 治癒切除胃癌患者の予後予測 -START-2 試験データを用いた後方視的研究 -

佐藤 弘樹 (大分大学医学部附属病院)

MO7-2 Long-term prognostic value of conversion surgery for unresectable gastric cancer: a propensity score matching analysis

Hiroyuki Ohnuma (Department of Medical Oncology, School of Medicine, Sapporo Medical University)

切除不能進行胃癌に対する conversion surgery の長期生存に対する有効性: 傾向スコアマッチング解析

大沼 啓之 (札幌医科大学 医学部 腫瘍内科学講座)

MO7-3 Mortality Disparities in Hospitalized Gastric Cancer Patients with Protein-Calorie Malnutrition by Gender and Race in US

Sakditad Saowapa (Department of Internal Medicine, Texas Tech University Health Sciences Center)

MO7-4 Discovery of Escapee tumour (ET) cells and its long term implication in gastric cancer

Kevin Wong (Department of Surgery, Tuen Mun Hospital)

MO7-5 Comparison of surgical outcomes between robotic gastrectomy versus laparoscopic gastrectomy in gastric cancer patients

Ulil Albab Habibah (Department of Surgery, Islamic University of Indonesia)

MO7-6 CapeOX for Elderly Patients with Advanced Gastric Cancer; Analysis for Appropriate G8 Cut-off Value for Survival

Keisho Chin (Cancer Institute Hospital of the Japanese Foundation for Cancer Research)

高齢者転移進行胃癌に対する CapeOX 第 2 相試験 (TCOG GI-1601) 予後予測 G8 cut off の探索

陳 勁松 (がん研究会有明病院)

07

Lung Cancer / Thoracic Cancer 1
呼吸器 1

E

- Chairs : Makoto Nishio (Department of Thoracic Medical Oncology Cancer Institute Hospital of Japanese Foundation for Cancer Research)
Nobuyuki Yamamoto (Internal Medicine III, Wakayama Medical University)
- Discussants : Motoko Tachihara (Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine)
Eiki Ichihara (Center for Clinical Oncology, Okayama University Hospital)
- 司会 : 西尾 誠人 (がん研有明病院呼吸器内科)
山本 信之 (和歌山県立医科大学医学部内科学第三講座)
- ディスカッサント : 立原 素子 (神戸大学大学院医学研究科内科学講座呼吸器内科学分野)
市原 英基 (岡山大学病院 腫瘍センター)

07-1 **First-line immunotherapy for KRAS-Mutant advanced NSCLC: A Systematic Review and Network Meta-analysis**

Akinari Tsukada (National Center for Global Health and Medicine)

KRAS 変異陽性進行非小細胞肺癌に対する最適な一次治療を評価するためのネットワークメタ解析

塚田 晃成 (国立国際医療研究センター病院)

07-2 **Resistance mechanisms and efficacy of first-line alectinib in patients (pts) with ALK+ non-small cell lung cancer**

Go Saito (Department of Respiriology, Graduate School of Medicine, Chiba University Hospital)

ALK 融合遺伝子陽性非小細胞肺癌における 1 次治療アレクチニブの耐性機序と有効性: 前向き観察研究 第 2 回中間公表 (ALCURE)

齋藤 合 (Department of Respiriology, Graduate School of Medicine, Chiba University Hospital)

07-3 **Lazertinib vs Osimertinib in 1L EGFR-mutant Advanced NSCLC: Exploratory Analysis from MARIPOSA study**

Encore

Byoung Chul Cho (Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine)

07-4 **Zongertinib in patients with HER2-mutant NSCLC: updated analysis of Beamion LUNG-1**

Encore

Kiyotaka Yoh (National Cancer Center Hospital East)

Zongertinib in patients with HER2-mutant NSCLC: updated analysis of Beamion LUNG-1

葉 清隆 (国立がん研究センター東病院)

07-5 **FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in Advanced NSCLC with EGFR PACC Mutations**

Xiuning Le (University of Texas MD Anderson Cancer Center)

MO8 Lung Cancer / Thoracic Cancer 1 (Small Cell Lung Cancer 1)
呼吸器 1 (小細胞肺癌 1)**E**

Chairs : Makoto Maemondo (Division of Pulmonary medicine, Department of Medicine, Jichi Medical University)
Toshiaki Takahashi (Division of Thoracic Oncology, Shizuoka Cancer Center)

司会 : 前門戸 任 (自治医科大学呼吸器内科)
高橋 利明 (静岡県立静岡がんセンター)

MO8-1 Final overall survival analysis of JCOG1205/1206; phase III study of IP versus EP for resected HGNEC of the lung**Encore**

Toshi Menju (Department of Thoracic Surgery, Graduate school of Medicine, Kyoto University)

完全切除された高悪性度神経内分泌肺癌に対する IP と EP を比較する第 III 相試験:
JCOG1205/1206 最終解析

毛受 暁史 (京都大学大学院医学研究科呼吸器外科)

MO8-2 Cost-effectiveness of atezolizumab (ATZ) vs. durvalumab (DUR) in elderly ED-SCLC patients: RWD on first-line Chemo-ICIs**Encore**

Tadashi Okamoto (Department of Respiratory Medicine, Takarazuka City Hospital)

高齢者進展型小細胞肺癌における免疫チェックポイント阻害薬併用化学療法の比較検討
(Atezolizumab vs. Durvalumab):RWD 費用対効果研究

岡本 忠司 (宝塚市立病院 呼吸器内科)

MO8-3 Phase II Study of Platinum plus Etoposide with Durvalumab for Extensive-Stage SCLC with Untreated Brain Metastases

Yoshimasa Shirashi (Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University)

未治療脳転移を有する進展型小細胞肺癌を対象としたプラチナ製剤 + エトポシド + デュルバルマブ併用療法の第 II 相試験 :SPEED(LOGIK2001)

白石 祥理 (九州大学病院)

MO8-4 Current Status of First-Line Treatment for Extensive-Stage Small Cell Lung Cancer and Review of Long-Term Responders

Takanori Enomoto (Kobe University Hospital Department of Respiratory Medicine)

進展型小細胞肺癌の 1 次治療の現状と長期奏効例の検討

榎本 隆則 (神戸大学医学部附属病院 呼吸器内科)

MO8-5 Third OS interim analysis from BEAT-SC: Addition of bevacizumab to atezolizumab & chemotherapy in patients with ES-SCLC

Shoichiro Yamamoto (Department of Cardiology, Pulmonology, Hypertension & Nephrology)

ES-SCLC 患者を対象にアテゾリズマブと化学療法へのベバシズマブ上乗せ効果を検討する
BEAT-SC 試験の第 3 回 OS 中間解析結果

山本 将一朗 (愛媛大学 大学院循環器・呼吸器・腎高血圧内科学講座 (第二内科))

MO8-6 Durvalumab plus carboplatin and etoposide for extensive-stage small-cell lung cancer patients with a poor PS (NEJ045A)

Takahiro Yoshizawa (Division of Respiratory Medicine, Toho University Omori Medical Center)

PS 不良進展型小細胞肺癌に対するカルボプラチン + エトポシド + デュルバルマブ療法の第 II 相試験 (NEJ045A)

吉澤 孝浩 (東邦大学医療センター大森病院)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Room 14
Meet the Experts
Poster

MO9 Lung Cancer / Thoracic Cancer 2 (Small Cell Lung Cancer 2)
呼吸器 2 (小細胞肺癌 2)

E

Chairs : Naoki Nishimura (Department of Respiratory Medicine, Center Hospital, National Center for Global Health and Medicine)
Yutaka Fujiwara (Department of Thoracic Oncology, Aichi Cancer Center)
司会 : 西村 直樹 (国立国際医療研究センター病院呼吸器内科)
藤原 豊 (愛知県がんセンター)

MO9-1 Chemotherapy Sensitivity for Recurrent Small-cell Lung Cancer Based on
Encore Chemotherapy-Free Interval and Treatment Regimens

Yuki Akazawa (NHO Osaka Toneyama Medical Center)

再発小細胞肺癌に対する化学療法への奏効率と化学療法フリー期間との相関
赤澤 結貴 (大阪刀根山医療センター)

MO9-2 Sacituzumab Govitecan (SG) as Second-Line Treatment in Patients with Extensive
Encore Stage Small Cell Lung Cancer (ES-SCLC)

Afshin Dowlati (University Hospitals Seidman Cancer Center and Case Western Reserve University)

MO9-3 Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC:
Encore DeLLphi-301 Phase 2 Extended Follow-up

Hiroki Izumi (National Cancer Center Hospital East)

進行・再発の進展型小細胞肺癌に対するタルラタマブの継続的な臨床的有益性と安全性 (第II相 DeLLphi-301 長期追跡試験)
Hiroki Izumi (National Cancer Center Hospital East)

MO9-4 Tarlatamab in previously treated SCLC: Subgroup analysis of patients from the
Encore Asia region (Phase 2 DeLLphi-301 study)

Kadoaki Ohashi (Okayama University Hospital)

進行・再発の進展型小細胞肺癌に対するタルラタマブのアジア地域患者でのサブグループ解析 (第II相 DeLLphi-301 試験)
Kadoaki Ohashi (Okayama University Hospital)

MO9-5 Interim analysis of a randomized study of 1L BMS-986012 (anti-fucosyl-GM-1) with
Encore Chemotherapy and nivolumab in ES-SCLC

Shunichi Sugawara (Sendai Kousei Hospital)

1L ES-SCLCにおけるBMS-986012 (anti-fucosyl-GM-1)、Chemotherapy および nivolumab 併用療法のランダム化試験の中間解析
菅原 俊一 (仙台厚生病院)

MO9-6 演題取下

MO9-7 Eligibility for durvalumab treatment after concurrent chemoradiotherapy in limited-stage small cell lung cancer

Toshiya Fujisaki (Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka Cancer Center)

限局型小細胞肺癌における同時化学放射線療法後のデュルバルマブ治療の適格性
藤崎 俊哉 (静岡県立静岡がんセンター 呼吸器内科)

第 10 会場 (神戸国際会議場 5 階 会議室 501)

8:30-9:50 Oral Session 8

08 Cross-sectional Program 臓器横断プログラム

E

- Chairs : Noriyuki Katsumata (Nippon Medical School Musashikosugi Hospital)
Kohichi Takada (Department of Medical Oncology, Sapporo Medical University School of Medicine)
- Discussants : Hisakazu Nishimori (Department of Hematology, Hiroshima City Hiroshima Citizens Hospital)
Yuki Shinno (Department of Thoracic Oncology, National Cancer Center Hospital)
- 司会 : 勝俣 範之 (日本医科大学武蔵小杉病院)
高田 弘一 (札幌医科大学医学部腫瘍内科学講座)
- ディスカッサント : 西森 久和 (広島市民病院血液内科)
新野 祐樹 (国立がん研究センター中央病院 呼吸器内科)
-
- 08-1 **Phase II trial of nivolumab in advanced solid tumors based on genomic profiling: BELIEVE trial (NCCH1901) subcohort**
Ichiro Kinoshita (Department of Medical Oncology, Hokkaido University Hospital, Hokkaido University Hospital)
進行固形腫瘍に対する包括的ゲノムプロファイリング (CGP) に基づくニボルマブ第 II 相試験:BELIEVE 試験 (NCCH1901) サブコホート
木下 一郎 (北海道大学病院)
-
- 08-2 **Peripheral CD4+T cell subsets as pretreatment biomarkers for predicting antitumor response to anti-PD-1/PD-L1 therapy**
Yoshimichi Haruna (Osaka Psychiatric Medical Center)
抗-PD-1/PD-L1 治療効果を予測するバイオマーカーとしての治療前末梢血中 CD4 陽性 T 細胞サブセットの検討
春名 能通 (大阪精神医療センター)
-
- 08-3 **Retrospective Study on the Impact of Hematological irAE on Cancer Treatment After Use of Immune Checkpoint Inhibitors**
Ryo Yoshimaru (National Cancer Center Hospital East, Department of Hematology and Oncology)
免疫チェックポイント阻害薬使用後の血液学的免疫関連有害事象 (Heme-irAE) ががん診療に与える影響に関する後方視的検討
吉丸 峻 (国立がん研究センター東病院 血液腫瘍科)
-
- 08-4 **Comparison between Japanese and Overall Data: Meta-analysis from Phase 3 Trials of Immune Checkpoint Inhibitor**
Yusuke Kajimoto (Graduate School of Pharmaceutical Sciences, The University of Tokyo)
免疫チェックポイント阻害剤を被験薬とした国際共同第 3 相治療における日本人集団と全体集団の比較 :PMDA 審査報告書を用いたメタアナリシス
梶本 裕介 (東京大学 大学院薬学系研究科 医療政策・公衆衛生学)

MO10 Cross-sectional Program 1
臓器横断プログラム 1

Chairs : Yoshitsugu Horio (Department of Outpatient Services, Aichi Cancer Center Hospital)
Takahiro Kogawa (Cancer Institute Hospital of JFCR)

司会 : 堀尾 芳嗣 (愛知県がんセンター 外来部)
古川 孝広 (がん研有明病院)

MO10-1 Phase Ia/Ib trial on the safety and efficacy of mobocertinib and T-DM1 for patients with HER2-mutant solid tumors**Encore**

Koji Matsumoto (Division of Medical Oncology/ Clinical Genetics, Hyogo Cancer Center)

HER2 遺伝子変異を有する固形癌に対する Mobocertinib+T-DM1 併用療法の安全性と有効性を検討する多施設共同第 Ia/Ib 相バスケッ試験 (WJOG16022M:HER2 Sand)

松本 光史 (兵庫県立がんセンター)

MO10-2 Multi-peptide vaccine plus agonistic anti-CD27 antibody induces peripheral effector memory T-cells in low grade glioma

Hirokazu Ogino (Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University)

マルチペプチドワクチンと抗 CD27 アゴニスト抗体併用療法は低悪性度神経膠腫患者末梢血において effector memory T 細胞を誘導する

萩野 広和 (徳島大学大学院医歯薬学研究所 呼吸器・膠原病内科学分野)

MO10-3 Acasunlimab Alone or in Combination With Pembrolizumab in Japanese Patients With Advanced or Metastatic Solid Tumors

Noboru Yamamoto (National Cancer Center Hospital)

MO10-4 Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification

Tomohiro Nakayama (Kishiwada City Hospital)

包括的ゲノムプロファイリングにより同定された PD-L1 遺伝子増幅を有する固形癌に対する免疫チェックポイント阻害薬の有効性の検討

中山 智裕 (市立岸和田市民病院)

MO10-5 Diagnostic Impact of Comprehensive Gene Profiling in Patients with Pathologically Diagnosed Advanced Solid Malignancies

Shiro Kimbara (Department of Medical Oncology and Hematology, Kobe University Graduate School of Medicine)

進行がん症例における包括的がん遺伝子パネル検査の臨床診断への影響

金原 史朗 (神戸大学大学院医学研究科 腫瘍・血液内科学分野)

MO10-6 The nationwide survey in Japanese public opinion about off-label drug use recommended by comprehensive genomic profiling**Encore**

Junichi Matsubara (Dept. of Medical Oncology, Kyoto Univ. Graduate School of Medicine)

がん遺伝子パネル検査結果に基づく抗がん薬の適応外使用についての国民意識調査

松原 淳一 (京都大学大学院医学研究科腫瘍内科学)

MO11 Hepatobiliary / Pancreatic Cancer 1 (Pancreatic Cancer 1)
肝胆膵 1 (臓臓 1)

Chairs : Hiroshi Miyamoto (Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences.)
Masaru Fukahori (Multidisciplinary Treatment Cancer Center, Kurume University Hospital.)
司会 : 宮本 弘志 (徳島大学大学院医歯薬学研究所消化器内科学分野)
深堀 理 (久留米大学病院がん集学治療センター)

MO11-1 Whipple vs Pylorus-Preserving Pancreaticoduodenectomy for Pancreatic Tumors: A Meta-Analysis of Surgical Techniques

Hans Michael G Gunawan (Faculty of Medicine, Pelita Harapan University)

MO11-2 Real-world utilisation of somatic tumour profiling in patients with advanced pancreas cancer: a single-centre study

Joycelyn J Lee (National Cancer Centre Singapore)

MO11-3 FOLFIRINOX vs FOLFIRINOX-surgery efficacy in Borderline Resectable and Locally Advanced Pancreatic Cancer: Meta-Analysis

Yewan Lim (Faculty of Medicine, Pelita Harapan University)

MO11-4 Association of Cholinergic Symptoms and Treatment Outcomes in Pancreatic Cancer Patients Receiving FOLFIRINOX Therapy

Yuki Miyai (Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital)

膵がん患者における FOLFIRINOX 療法中のコリン作動性症状と治療効果の関連

宮井 雄基 (名古屋大学医学部附属病院 化学療法部)

MO11-5 Post progression survival of modified FOLFIRINOX and gemcitabine with nab-paclitaxel for unresectable pancreatic cancer

Takafumi Mie (Hepato-biliary-pancreatic-medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research)

切除不能膵癌に対する modified FOLFIRINOX 及び GnP 後の post progression survival に関する検討

三重 堯文 (Cancer Institute Hospital of Japanese Foundation for Cancer Research)

MO11-6 The Impact of KRAS Mutations on Prognosis in Metastatic or Recurrent Pancreatic Cancer

Yuri Maegawa (Cancer Institute Hospital Department of Hepato-Biliary-Pancreatic Medicine)

遠隔転移・再発膵癌における KRAS 遺伝子変異の予後への影響

前川 有里 (がん研究会有明病院 肝胆膵内科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

MO12 Hepatobiliary / Pancreatic Cancer 2 (Pancreatic Cancer 2)
肝胆膵 2 (膵臓 2)



Chairs : Takuji Okusaka (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital)
Taro Shibuki (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East)
司会 : 奥坂 拓志 (国立がん研究センター中央病院 肝胆膵内科)
澁木 太郎 (国立がん研究センター東病院肝胆膵内科)

MO12-1 Tumor tissue and liquid comprehensive genomic profiling test for advanced pancreatic cancer in an institution

Toru Otsuru (Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center (NHO SCC))

膵癌のがん遺伝子パネルを用いたゲノムプロファイリングの検討

大鶴 徹 (National Hospital Organization Shikoku Cancer Center (NHO SCC))

MO12-2 The Prevalence and Prognostic Impact of Co-existing Gene Alterations in PDAC with or without HRR Gene Alteration

Yusuke Kawanaka (Department of Medical Oncology, Kindai University Faculty of Medicine)

相同組換え修復関連遺伝子変異異常を伴う膵癌における遺伝子変異共存による予後への影響

川中 雄介 (Department of Medical Oncology, Kindai University Faculty of Medicine)

MO12-3 The clinical validity of digital PCR for the identification of KRAS mutation by cytology specimens in pancreatic cancer

Kumiko Umemoto (Department of Clinical Oncology, St.Marianna University School of Medicine)

膵癌の細胞診検体を用いたデジタル PCR による KRAS 変異同定の臨床的妥当性の検討

梅本 久美子 (Department of Clinical Oncology, St.Marianna University School of Medicine)

MO12-4 Deciphering the oncogenic potential of SOX21-AS1 lncRNA in tumorigenesis of pancreatic ductal adenocarcinoma

Aishwarya Singh (Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Uttar Pradesh, India)

MO12-5 Machine Learning-Driven Identification of CAF Subtypes via Exosomal RNA Modifications in Immune-Exclusion Tumors

Rifaldy Fajar (Department of Mathematics and Computer Science, Karlstad University)

MO12-6 Mir-199a-3p in the exosome secreted from cancer-associated adipocytes promotes pancreatic cancer progression

Kazuyoshi Noda (Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences)

癌関連脂肪細胞から分泌されたエクソソーム中の mir-199a-3p は膵癌進行に寄与する

野田 和克 (徳島大学病院 消化器内科)

09 Hepatobiliary / Pancreatic Cancer
 肝胆腫


Chairs : Masashi Kanai (Department of Clinical Oncology, Kansai Medical University Hospital)
 Kelley Robin Kate (University of California, San Francisco)

Discussants : Teresa Macarulla (Vall d'Hebron University Hospital)
 Yasuyuki Kawamoto (Division of Cancer Center, Hokkaido University Hospital)

司会 : 金井 雅史 (関西医科大学附属病院臨床腫瘍科)
 Kelley Robin Kate (University of California, San Francisco)

ディスカッサント : Teresa Macarulla (Vall d'Hebron University Hospital)
 川本 泰之 (北海道大学病院腫瘍センター)

09-1 Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: 3-year follow-up of KEYNOTE-966

Masato Ozaka (Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR))
 尾阪 将人 (がん研究会有明病院)

09-2 Time-of-day patterns of Atezolizumab and Bevacizumab and Outcomes in Patients with Unresectable Hepatocellular Carcinoma

Atsushi Naganuma (NHO Takasaki General Medical Center)

切除不能肝細胞癌患者に対するアテゾリズマブ・ベバシズマブ併用療法の時間帯別投与と転帰との関連: 多施設共同後ろ向き観察研究

長沼 篤 (国立病院機構 高崎総合医療センター)

09-3 A Pilot Clinical Trial of Modified FOLFIRINOX plus Nivolumab in Borderline Resectable Pancreas Cancer

Encore

Zev Wainberg (UCLA)

09-4 A study on the time to treatment failure of nanoliposomal irinotecan+5-FU/l-LV for unresectable pancreatic cancer

Saki Tanaka (Osaka International Cancer Institute, Pharmacy)

切除不能膵癌患者における nanoliposomal irinotecan+5-FU/l-LV 療法の time to treatment failure に関する検討

田中 佐季 (地方独立行政法人大阪国際がんセンター 薬局)

09-5 Integration of Remote Deep Learning-Assisted Liver and Biliary Tract Cancer Screening System Using Portable Ultrasound

Teerapat Ungtrakul (Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Poster Experts

第 11 会場 (神戸国際会議場 5 階 会議室 502)

8:30-9:30 Mini Oral Session 13

M013 Head and Neck Cancer 1 (Head and Neck Cancer 1, Thyroid Cancer, Salivary Gland Cancer)
頭頸部 1 (頭頸部癌 1、甲状腺癌、唾液腺癌)

E

Chairs : Takenori Ogawa (Department of Otolaryngology-head and neck surgery, Gifu University)
Takao Fujisawa (Translational Research Support Office/Department of Head and Neck Medical
Oncology, National Cancer Center Hospital East)

司会 : 小川 武則 (岐阜大学)
藤澤 孝夫 (国立がん研究センター東病院 TR 支援室 / 頭頸部内科)

M013-1 **Genetic Alteration, RNA expression, and DNA Methylation profiling of LATS1 gene in Head-Neck Squamous Cell Carcinoma**

Harsh Goel (LABORATORY ONCOLOGY UNIT, ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHI)

M013-2 **Association of Daily Diet and Incidence of Head and Neck Cancer: A Prospective Cohort Study of UK Biobank Participants**

Ziyang Zhang (West China Hospital, Sichuan University)

M013-3 **Clinical outcomes of patients with locally advanced synchronous head and neck and esophageal cancer**

Satoshi Suzuki (Gastrointestinal Oncology, Shizuoka Cancer Center)

局所進行頭頸部と局所進行食道の同時性重複癌患者における臨床的治療成績
鈴木 哲史 (静岡県立静岡がんセンター 消化器内科)

M013-4 **Concordance of BRAF V600E mutation status between immunohistochemistry and genomic testing in thyroid cancer**

Ryutaro Onaga (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)

甲状腺癌に対し保険診療下に行われた遺伝子検査における BRAF V600E 遺伝子変異と、
BRAF V600E 抗体を用いた免疫組織化学染色との一致性の検討

翁長 龍太郎 (国立がん研究センター東病院 頭頸部内科)

M013-5 **Health-related Quality of Life in a Phase II Study of Encorafenib Plus Binimetinib for BRAF V600 Mutated Thyroid Cancer**

Naomi Kiyota (Kobe University Hospital)

BRAF V600 遺伝子変異を有する甲状腺がんに対するエンコラフェニブとビニメチニブの第
II 相試験における健康関連 QoL

清田 尚臣 (神戸大学医学部附属病院)

M013-6 **Retrospective Analysis of Taxane combination Chemotherapy for Recurrent or Metastatic salivary gland carcinoma**

Jun Taguchi (Hokkaido University Hospital Medical Oncology)

再発・転移唾液腺癌に対するタキサン併用療法治療症例の後方視的検討

田口 純 (北海道大学病院 腫瘍内科)

MO14 Head and Neck Cancer 2 (Head and Neck Cancer 2)
頭頸部 2 (頭頸部癌 2)

Chairs : Hisham Mehanna (InHANSE, School of Medical Sciences, University of Birmingham)
Ari Nishimura (Department of Otolaryngology-Head and Neck Surgery, Nara Medical University)

司会 : Hisham Mehanna (InHANSE, School of Medical Sciences, University of Birmingham)
西村 在 (奈良県立医科大学耳鼻咽喉・頭頸部外科)

MO14-1 HPV-Status-Dependent Associations of Cholesterol-Lowering Targets with Head and Neck Cancer Survival

Danni Cheng (West China Hospital, Sichuan University)

MO14-2 Associations between immune-mediated diseases (IMDs) and the risk of HPV-associated oropharyngeal cancer

Lan Feng (Department of Otolaryngology Head & Neck Surgery, Sichuan University West China Hospital, Chengdu, China)

MO14-3 Accuracy and prognosis of extranodal extension on radiologic imaging in HPV+ oropharyngeal cancer

Hisham Mehanna (Institute of Head and Neck Studies and Education, University of Birmingham)

MO14-4 Standardised definitions and reporting of pENE in head and neck cancer: HNCIG international consensus recommendations**Encore**

Ahmad K Abou-foul (Institute for Head and neck studies and education, University of Birmingham)

MO14-5 Postoperative RT With or Without Chemotherapy in Locally Advanced HNSCC with Intermediate Risk A Propensity Scores Match

Thun Leewiboonsilp (Division of medical oncology, Internal medicine department, Ramathibodi hospital, Mahidol university)

MO14-6 Inverse response between prior pembrolizumab and subsequent cetuximab plus paclitaxel in head and neck cancer patients

Ken Saijo (Tohoku University Hospital, Department of Medical Oncology)

再発転移頭頸部扁平上皮癌患者に対する二次治療のセツキシマブ + パクリタキセルの治療効果の検討～一次治療のペムブロリズマブの治療効果との関連～

西條 憲 (東北大学病院 腫瘍内科)

O10

Head and Neck Cancer

頭頸部

E

Chairs : Ulrich Keilholz (Charité Comprehensive Cancer Center)
 Sadamoto Zenda (Department of Radiation Oncology, National Cancer Center Hospital East)
 Discussants : Yasushi Shimizu (Department of Medical Oncology, Hokkaido University Hospital)
 Yoshinori Imamura (Cancer Care Promotion Center, University of Fukui Hospital)
 司会 : Ulrich Keilholz (Charité Comprehensive Cancer Center)
 全田 貞幹 (国立がん研究センター東病院)
 ディスカッサント : 清水 康 (北海道大学病院 腫瘍内科)
 今村 善宣 (福井大学医学部附属病院 がん診療推進センター)

O10-1 **Phase II study of trastuzumab deruxtecan for HER2-positive recurrent or metastatic salivary gland cancer (MYTHOS trial)**

Yoshitaka Honma (National Cancer Center Hospital)

HER2 発現の再発・転移唾液腺癌患者を対象としたトラスツズマブ デルクステカンの多施設共同非盲検第 II 相試験 (MYTHOS 試験)

本間 義崇 (国立がん研究センター中央病院)

O10-2 **Clinical Utility of Liquid Biopsy in HNSCC: Insights from the SHIZUKU-HN Study and C-CAT Data**

Yoshihito Kano (Department of Medical Oncology, Institute of Science Tokyo)

頭頸部癌におけるリキッドバイオプシー有用性解析

加納 嘉人 (東京科学大学病院 臨床腫瘍科)

O10-3 **Criteria for the diagnosis of ENE detected on imaging in head and neck cancer: HNCIG international recommendations**

Encore

Ahmad K Abou-foul (Institute for Head and neck studies and education, University of Birmingham)

O10-4 **Prognostic impact of gene alterations related to PI3K and cell cycle pathways in differentiated thyroid carcinoma**

Soji Toda (Department of Breast and Thyroid Surgery, Yokohama City University Medical Center)

PI3K や細胞周期経路に関連する遺伝子異常は甲状腺分化癌における予後不良因子である ;C-CAT データを用いた研究

戸田 宗治 (横浜市立大学附属市民総合医療センター 乳腺・甲状腺外科)

第13会場 (神戸国際展示場 2号館 2階 2A会議室)

8:30-9:30 Mini Oral Session 15

MO15 Patient Advocacy / Survivorship 1 (Treatment) 患者支援・サバイバーシップ1 (治療)

Chairs : Kazuhiko Shibata (Div. of Medical Oncology, Dept. of Medicine, Kouseiren Takaoka Hospital)
Fumie Fujisawa (Department of Medical Oncology, Shiga General Hospital)

司会 : 柴田 和彦 (厚生連高岡病院)
藤澤 文絵 (滋賀県立総合病院 腫瘍内科)

MO15-1 Association between geriatric assessment and serious adverse events in elderly patients with gastrointestinal cancer

Shohei Udagawa (Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research)

高齢者消化管がん患者に対する高齢者機能評価と化学療法による有害事象の関連
宇田川 翔平 (がん研究会有明病院 消化器化学療法科)

MO15-2 Evaluation of the Usefulness of geriatric assessment for Immune Checkpoint Inhibitor Administration

Yohei Osaki (MEDICAL ONCOLOGY, GUNMA UNIVERSITY HOSPITAL)

免疫チェックポイント阻害薬投与時の高齢者評価の有用性の検討
大崎 洋平 (群馬大学医学部附属病院)

MO15-3 Assessing the utility of G8 (Geriatric 8) screening tool for cancer patients

Yusuke Kurioka (Kochi Medical School)

当科がん患者における Geriatric-8(G8) スクリーニングツールの有用性に関する検討
栗岡 勇輔 (高知大学医学部)

MO15-4 Association between G8 Screening and treatment course in older patients with cancer

Ayako Mitsuma (Nagoya University Hospital)

高齢がん患者における G8 スクリーニングと治療経過との関連
満間 綾子 (名古屋大学医学部附属病院)

MO15-5 Fertility and menstrual disorder in female patients of AYA generation with hematological malignancies

Junji Hiraga (Department of Hematology, Toyota Kosei Hospital)

AYA 世代の血液悪性腫瘍患者における妊孕性の検討
平賀 潤二 (豊田厚生病院 血液内科)

MO15-6 演題取下

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Room 14
Meet the Experts
Poster

MO16 Patient Advocacy / Survivorship 2 (Social Context Surrounding Patients)
患者支援・サバイバーシップ 2 (患者をとりまく社会背景)

Chairs : Hisateru Yasui (Department of Medical Oncology, Kobe City Medical Center General Hospital)
Kokoro Kobayashi (Department of Medical Oncology, Saitama Red Cross Hospital)
司会 : 安井 久晃 (神戸市立医療センター中央市民病院腫瘍内科)
小林 心 (さいたま赤十字病院 腫瘍内科)

MO16-1 Challenges in Predicting Osteoporotic Fracture Risk in Cancer Patients: Insights from Machine Learning Model Analysis

Hiroataka Koyanagi (Dept. Rehabilitation, Saitama Cancer Center)

がん患者の骨粗鬆症性骨折リスク予測における課題：機械学習モデルの分析から
小柳 広高 (埼玉県立がんセンター リハビリテーション科)

MO16-2 A retrospective study on time toxicity of cancer chemotherapy

Hiroki Sakuyama (Oncology, TAKAMATSU Red Cross Hospita)

がん薬物療法における時間毒性の後ろ向きの検討
作山 浩希 (高松赤十字病院)

MO16-3 Tackling Cancer-Related Misinformation in Vietnam: A Model for Academic-Public Cooperation

Quy Phamnguyen (Kyoto Miniren Central Hospital)

ベトナムにおけるがん関連の誤情報への取り組み：アカデミアと一般市民の協力モデル
Quy Phamnguyen (京都民医連中央病院)

MO16-4 Development of a Mobile Application (AYABytes) to Improve Access to Cancer-related Information for AYA Patients

Evelyn Yi Ting Wong (Division of Medical Oncology, National Cancer Centre Singapore)

MO16-5 Longitudinal Study on the Understanding and Consideration of Cancer Patients by Employers, Supervisors, and Colleagues

Hideki Katayama (Dept. of Palliative and Supportive Care, Okayama University Hospital)

がん患者の就労状況における周囲の理解の経年変化～企業、上司、同僚の配慮の比較調査～
片山 英樹 (岡山大学病院 緩和支援医療科)

MO16-6 Questionnaire Survey of Healthcare Professionals on the Awareness and Conditions of Young Carers in the Oncology

Rika Kizawa (The Cancer Institute Hospital of Japanese Foundation for Cancer Research)

がん領域におけるヤングケアラーの認知度および実態に関する医療従事者へのアンケート調査
木澤 莉香 (公益財団法人がん研究会有明病院 乳腺内科)

10:30-11:20 Mini Oral Session 17

MO17 Brain Tumor
脳腫瘍



Chairs : Motoo Nagane (Department of Neurosurgery, Kyorin University Faculty of Medicine)
Hiroyuki Momota (Department of Neurosurgery, National Center for Geriatrics and Gerontology)
司会 : 永根 基雄 (杏林大学医学部脳神経外科)
百田 洋之 (国立長寿医療研究センター脳神経外科)

MO17-1 Cognitive decline in pediatric brain tumor survivors due to radiotherapy: a double-edged sword
Hasti H Tolani (Faculty of Medicine, Pelita Harapan University)

MO17-2 AI Model in Glioblastoma characterization: A novel approach to differentiate necrosis, vascular proliferation and tumour
Eva Cheung (University of Hong Kong)

MO17-3 Comparative Efficacy of Lomustine-Temozolomide Combination Therapy vs Other Regimen in Glioblastoma: A Systematic-Review
Dion Ravinder Theodeus Subroto (Faculty of Medicine, Pelita Harapan University)

MO17-4 Treatment of Low Grade Glioma: Radiation Therapy Plus PCV Regimen vs Radiation Therapy only: A Systematic Review
Abimanyu Sakh (Pelita Harapan University)

MO17-5 Anti-cancer effects of selective HDAC8 PROTAC on U-87 MG glioblastoma brain cancer cell line
Rapeewan Settaomkul (Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan 10540, Thailand)

14:00-14:50 Mini Oral Session 18

MO18 Breast Cancer 1 (Perioperative 1)
乳腺 1 (周術期 1)



Chairs : Daisuke Takabatake (NHO Shikoku Cancer Center, Breast Surgery)
Naoki Niikura (Department of Breast Oncology, Tokai University School of Medicine)
司会 : 高島 大典 (四国がんセンター 乳腺外科)
新倉 直樹 (東海大学 乳腺・腫瘍科)

MO18-1 ctDNA among HER2+ breast cancer patients receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab in the DAPHNe trial
Yi Chen (Personalis, Inc)

MO18-2 Prognostic Impact of ER-Staining Patterns and Tils in Breast Cancer Patients with Low to Intermediate ER Expression
Yumiko Akita (Department of Breast and Endocrine Surgery, Nagoya University Hospital)
ER 低発現から中発現の乳癌患者における ER 染色パターンと腫瘍浸潤リンパ球の予後への影響
秋田 由美子 (名古屋大学医学部付属病院 乳腺内分泌外科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Room 14
Meet the Poster Experts

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

MO18-3 **Prognostic Impact of Quantified Area of Residual Tumor After Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer**
 Mao Uematsu (Department of Medical Oncology)
HER2 陽性早期乳癌における術前化学療法後の残存腫瘍面積 (ART) のデジタル定量評価による予後の意義
 植松 真生 (国立がん研究センター東病院 腫瘍内科)

MO18-4 **Knowledge of symptoms and risk factors of breast cancer among women in a low socio-economic area of Mumbai, India**
 Monirujjaman Biswas (Jawaharlal Nehru University)

MO18-5 **Efficacy of Preoperative Pembrolizumab Plus Chemotherapy (KN-522 Regimen) for ER-Low HER2-Negative Early Breast Cancer**
 Maho Kusudo (breast oncology)
ER 低発現 HER2 陰性早期乳癌に対する術前ペムブロリズマブ + 化学療法併用療法 (KN-522 レジメン) の有効性の検討
 楠戸 真帆 (愛知県がんセンター)

15:00-16:00 Mini Oral Session 19

MO19 Breast Cancer 2 (Perioperative 2)
 乳腺 2 (周術期 2) E

Chairs : Tatsuya Toyama (Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences)
 Kanako Saito (Department of Medical Oncology, Mie University Hospital)
 司会 : 遠山 竜也 (名古屋市立大学大学院医学研究科乳腺外科学分野)
 齋藤 佳菜子 (三重大学医学部附属病院 腫瘍内科)

MO19-1 **Breast Cancer in very young female (less than 25 years): An Indian experience**
 Ajay Gogia (AIIMS, NEW DELHI)

MO19-2 **Validation of serum microRNA breast cancer markers in a screening cohort**
 Akihiko Shimomura (National Center for Global Health and Medicine)
検診コホートにおける血清マイクロ RNA を用いた乳がんマーカーの検討
 下村 昭彦 (国立国際医療研究センター病院)

MO19-3 **Awareness Survey on Tamoxifen-Induced Liver Injury Among Hepatologists in Japan**
 Ayako Ueno (Department of General Surgery, Kurashiki Central Hospital)
タモキシフェン投与中の肝障害に関する肝臓専門医の意識調査
 上野 彩子 (倉敷中央病院 外科)

MO19-4 **Impact of Hypoxia Mimetics on Hypoxia-Inducible Factors and Gene in Primary versus Metastatic Breast Cancer Cell**
 Pardeep Kumar (F H Medical College & Hospital)

MO19-5 **演題取下**

MO19-6 **Omission of pegfilgrastim in perioperative dose-dense paclitaxel therapy for breast cancer**
 Kaori Otake (Department of Internal Medicine, Tohoku Rosai Hospital)
乳がん周術期 dose dense パクリタキセル療法におけるペグフィルグラスチム省略の検討
 大竹 かおり (東北労災病院内科)

MO20 Breast Cancer 3 (Others)
乳腺 3 (その他)**E**

Chairs : Norikazu Masuda (Department of Breast Surgery, Graduate School of Medicine, Kyoto University)
Yukinori Ozaki (Department of Breast Medical Oncology, The Cancer Institute Hospital of JFCR)

司会 : 増田 慎三 (京都大学大学院医学研究科 乳腺外科学・名古屋大学大学院医学系研究科 乳腺内分泌外科)
尾崎 由記範 (がん研有明病院)

- MO20-1 Comparative Evaluation of Japanese Breast Cancer Treatment Websites Using Large Language Models**
Atsushi Fushimi (Department of Breast and Endocrine Surgery, The Jikei University School of Medicine)
大規模言語モデルを用いた日本の乳癌治療ウェブサイトの比較評価 :ChatGPT、Claude、専門家レビューによる分析
伏見 淳 (東京慈恵会医科大学 乳腺・内分泌外科)
- MO20-2 Breast lesion classification using ultrasound videos and image-quality guided deep learning method**
Mohamed Abdelnasser (Aswan University)
- MO20-3 B-blockers for the Prevention of Anthracycline-induced Cardiotoxicity Among Adult Cancer Patients: Updated meta-analysis**
Ajitpal Singh. Brar. (THE DOCTORS HOSPITAL INC.)
- MO20-4 Withdrawn**
- MO20-5 Cardioprotective Effect of ACEI/ARB in Breast Cancer Treated with Anthracycline: A Systematic Review and Meta analysis**
Kevin Kristianto (Faculty of Medicine, Universitas Pelita Harapan/Siloam Hospital Lippo Village)
- MO20-6 Efficacy of perioperative pembrolizumab for triple-negative breast cancer with apocrine feature or metaplastic carcinoma**
Nobuyuki Takahashi (National Cancer Center Hospital East)
アポクリン分化ないし化成癌を伴う早期トリプルネガティブ乳癌に対する周術期ペムブロリズマブ併用の有効性の検討
高橋 信行 (国立がん研究センター東病院)

第14会場 (神戸国際展示場 2号館3階 3A会議室)

8:30-10:00 Committee Program 1 / 委員会企画 1 (広報渉外委員会企画)

CP1-1 禁煙推進セッション

Chairs : Makoto Ueno (Department of Gastroenterology, Kanagawa Cancer Center)
Minoru Fukuda (Japanese Red Cross Nagasaki Genbaku Isahaya Hospital)
司会 : 上野 誠 (神奈川県立がんセンター 消化器内科)
福田 実 (日本赤十字社長崎原爆諫早病院 呼吸器科)

CP1-1-1 “Tobacco harm reduction” how should we build relationships with industry in health policy?

Kota Katanoda (Division of Population Data Science, National Cancer Center Institute for Cancer Control)

「たばこハームリダクション」 - 保健政策と産業のあるべき姿とは？

片野田 耕太 (国立がん研究センターがん対策研究所データサイエンス研究部)

CP1-2 SNS ワーキンググループシンポジウム オンコロジー領域における SNS 利用

CP1-2-1 Fact-Checking Cancer Information on Social Media in Japan

Nari Kureyama (Toyokawa City Hospital Breast Surgery)

SNS がん情報のファクトチェック

呉山 菜梨 (豊川市民病院)

CP1-2-2 Utilization of SNS in Medical Oncology Seminars for Medical Students and Residents

Daisuke Ogiya (Department of Hematology and Oncology, Tokai University School of Medicine)

医学生・研修医のための腫瘍内科セミナーにおける SNS の利活用

扇屋 大輔 (東海大学医学部 内科学系 血液・腫瘍内科学)

CP1-2-3 Bridging Divides in Medical Communication on Social Media: Building Trust Beyond Confrontation

Noboru Hagino (Division of Rheumatology, Teikyo University Medical Center in Chiba)

SNS における効果的な医療コミュニケーション - 対立を超えて信頼を構築する

萩野 昇 (帝京大学ちば総合医療センター 第三内科学講座 (リウマチ))

10:10-11:40 Committee Program 2 / 委員会企画 2 (教育企画部会)

CP2 Educational activities on Medical Oncology in Asia-Pacific region

アジア・パシフィック地域の各学会における腫瘍内科教育の取り組み



Chairs : Ichiro Kinoshita (Division of Clinical Genomics, Department of Medical Oncology, Hokkaido University Hospital)

Hidehito Horinouchi (Department of Thoracic Oncology, National Cancer Center Hospital)

司会 : 木下 一郎 (北海道大学病院 がん遺伝子診断部 / 腫瘍内科)

堀之内 秀仁 (国立がん研究センター中央病院呼吸器内科)

CP2-1 Oncology Education Initiatives at Medical Oncology Society in the Asia-Pacific Region - Medical Oncology Group of Australia

Melissa Eastgate (Medical Oncology Group of Australia)

CP2-2 Crisis in Medical Oncology Fellowship Education in Korea

Yeon Hee Park (Samsung Medical Center, Sungkunkwan University School of Medicine)

- CP2-3 **Educational Initiatives of Singapore Society of Oncology**
Eileen Poon (National Cancer Centre Singapore)
- CP2-4 **Oncology Education Initiatives in Taiwan Oncology Society**
Chih-Hung Hsu (Graduate Institute of Oncology, National Taiwan University College of Medicine)
- CP2-5 **Educational initiative at Japanese Society of Medical Oncology (JSMO): 2025 update**
Ichiro Kinoshita (Division of Clinical Genomics, Department of Medical Oncology, Hokkaido University Hospital)
JSMO における腫瘍内科教育の取組み
木下 一郎 (北海道大学病院 がん遺伝子診断部 / 腫瘍内科)

14:00-15:30 Committee Program 3 / 委員会企画 3 (キャリアエンパワメント委員会)

CP3 Generative AI will brighten the future of medical oncology!
生成 AI が腫瘍内科の未来を明るくする！！

- Chairs : Teruhisa Azuma (Nara Prefecture General Medical Center)
Takako Nakajima (Department of Early Clinical Development, Kyoto University Graduate School of Medicine)
- Discussants : Yosuke Kito (Ishikawa Prefectural Central Hospital)
Takuji Seo (Seo Clinic)
Reiji Namba (Kochi Health Sciences Center)
- 司会 : 東 光久 (奈良県総合医療センター)
中島 貴子 (京都大学大学院医学研究科 早期医療開発学)
- ディスカッサント: 木藤 陽介 (石川県立中央病院)
瀬尾 卓司 (瀬尾医院)
難波 伶至 (高知医療センター)

- CP3-1 **< Keynote Lecture 1 / 基調講演 1 >**
Potential Contributions of Generative AI to Clinical Oncology
Hiromizu Takahashi (Department of General Medicine, Juntendo University Urayasu Hospital)
生成 AI を用いた臨床腫瘍学への貢献の可能性
高橋 宏瑞 (順天堂大学附属浦安病院 総合診療科)

- CP3-2 **< Keynote Lecture 2 / 基調講演 2 >**
Expectations for AI in Drug Development
Takeshi Sawada (Kyoto University Hospital)
薬剤開発における AI への期待
澤田 武志 (京都大学医学部附属病院)

- CP3 **< ディスカッサント >**
AI and young doctors
Yosuke Kito (Ishikawa Prefectural Central Hospital)
若手医師の AI への親和性
木藤 陽介 (石川県立中央病院)

- CP3 **< ディスカッサント >**
Oncologist working in a medically underserved area, pioneering with AI
Takuji Seo (Seo Clinic)
AI と切り開く医療過疎地での腫瘍内科開業医
瀬尾 卓司 (瀬尾医院)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Room 14
Meet the Experts
Poster

16:00-17:30 Committee Program 4 / 委員会企画 4 (教育企画部会 / JSMO 大学 WG)

CP4 How do we communicate the appeal of Medical Oncology? [JSMO University]
腫瘍内科の魅力をどのように伝えるか?

- Chairs : Yu Sunakawa (Department of Clinical Oncology, St. Marianna University School of Medicine)
Tomoko Yamazaki (Saitama Medical University International Medical Center)
- Discussants : Makiko Ono (Department of Medical Oncology Advanced Medical Development Center Japanese
Foundation for Cancer Research Cancer Institute Hospital)
Hidetoshi Hayashi (Department of Medical Oncology, Kindai University)
- Reporting : Yu Sunakawa (Department of Clinical Oncology, St. Marianna University School of Medicine)
- 司会 : 砂川 優 (聖マリアンナ医科大学 臨床腫瘍学)
山崎 知子 (埼玉医科大学国際医療センター)
- ディスカッション : 小野 麻紀子 (がん研究会有明病院 総合腫瘍科 先端医療開発科)
林 秀敏 (近畿大学医学部内科学腫瘍内科部門)
- 報告 : 砂川 優 (聖マリアンナ医科大学 臨床腫瘍学)

CP4 <司会の言葉>
How do we communicate the appeal of Medical Oncology?
Yu Sunakawa (Department of Clinical Oncology, St. Marianna University School of Medicine)
腫瘍内科の魅力をどのように伝えるか? [JSMO 大学企画]
砂川 優 (聖マリアンナ医科大学 臨床腫瘍学)

CP4-1 <Keynote Lecture / 基調講演>
Seisyou Kou (Medical Education Development and Research, Department of Medical Education
and Humanities, St. Marianna University School of Medicine)
黄 世捷 (聖マリアンナ医科大学医学教育文化部門医学教育研究分野)

Meet the Experts ① (神戸ポートピアホテル 南館 B1 階 ローズ・アイリス)

10:40-11:40 Meet the Experts 1

ME1 Perioperative Pembrolizumab + Chemotherapy for Gastric and Gastroesophageal Junction Cancer: KEYNOTE-585 Asian Subgroup **E**

Facilitator: Kai Tsugaru (Department of Gastroenterology and Hepatology, Keio University School of Medicine)

司会: 津軽 開 (慶應義塾大学病院 消化器内科)

ME1 Perioperative Pembrolizumab + Chemotherapy for Gastric and Gastroesophageal Junction Cancer: KEYNOTE-585 Asian Subgroup

Sun Young Rha (Yonsei Cancer Center, Yonsei University College of Medicine)

14:00-15:00 Meet the Experts 2

ME2 Developing a Career in Clinical Trials **E** 

Facilitator: Aikou Okamoto (Department of Obstetrics and Gynecology, Jikei University School of Medicine)

司会: 岡本 愛光 (東京慈恵会医科大学 産婦人科学講座)

ME2 Developing a Career in Clinical Trials

Shannon N Westin (University of Texas MD Anderson Cancer Center)

16:00-17:00 Meet the Experts 3

ME3 Spatial transcriptome analysis on tumor microenvironment **E** 

Facilitator: Mitsuho Imai (National Cancer Center Hospital East)

司会: 今井 光穂 (国立がん研究センター東病院)

ME3 Spatial transcriptome analysis on tumor microenvironment

Woong-Yang Park (GxD Inc.)

Meet the Experts ② (神戸ポートピアホテル 南館 B1 階 カトリア・ライラック)

8:30-9:30 Meet the Experts 4

ME4 Pharmacotherapy and supportive care for aging head and neck cancer patients

E

Facilitator : Susumu Okano (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East)

司会 : 岡野 晋 (国立がん研究センター東病院 頭頸部内科)

ME4 Pharmacotherapy and supportive care for aging head and neck cancer patients Ulrich Keilholz (Charité Comprehensive Cancer Center)

10:40-11:40 Meet the Experts 5

ME5 The pancancer genomic landscape: biology, test strategies and precision medicine guidance

E

Facilitator : Kuniko Sunami (Department of Laboratory Medicine, National Cancer Center Hospital)

司会 : 角南 久仁子 (国立がん研究センター中央病院 臨床検査科)

ME5 The pancancer genomic landscape: biology, test strategies and precision medicine guidance Edwin Cuppen (Hartwig Medical Foundation)

14:00-15:00 Meet the Experts 6

ME6 Precision Therapy in Gastric Cancer

E

Facilitator : Tadayoshi Hashimoto (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)

司会 : 橋本 直佳 (国立がん研究センター東病院 消化管内科)

ME6 Precision Therapy in Gastric Cancer Zev A. Wainberg (UCLA School of Medicine)

16:00-17:00 Meet the Experts 7

ME7 Challenges in diagnosis and treatment of rare T-cell lymphomas

E

Facilitator : Eisei Kondo (Department of Hematology, Kawasaki Medical School)

司会 : 近藤 英生 (川崎医科大学 血液内科学)

ME7 Challenges in diagnosis and treatment of rare T-cell lymphomas Won Seog Kim (Sungkyunkwan University Samsung Medical Center)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

- P1-1 **Synergistic Effects of DNA-PKcs Inhibition and Irradiation in Esophageal Squamous Cancer**
Jiekun Qian (Department of Thoracic Surgery, Fujian Medical University Union Hospital)
- P1-2 **Analysis of prognostic factor in patients with untreated cStage IVB thoracic esophagus squamous cell carcinoma**
Munehiro Wakabayashi (Department of Gastroenterology and Hepatology, Faculty of Medicine, Toho University)
cStage IV b期胸部食道扁平上皮癌の1次治療における予後因子解析
若林 宗弘 (東邦大学医学部内科学講座 消化器内科学分野)
- P1-3 **Early Tumor Shrinkage-Velocity as a predictor for ICIs-Containing Regimens for Esophageal Cancer**
Takuya Sato (Department of Medical Oncology)
食道がんに対する免疫チェックポイント阻害薬併用療法の予後予測因子としての早期腫瘍縮小速度
佐藤 拓弥 (高知大学医学部附属病院)
- P1-4 **The efficacy and safety of immune checkpoint inhibitor for untreated advanced esophageal squamous cell carcinoma**
Kazuhiro Shiraishi (Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital)
進行食道扁平上皮がんに対する一次治療としての化学療法 + ニボルマブまたはペムブロリズマブとニボルマブ + イピリムマブのレトロスペクティブ研究
白石 和寛 (国立がん研究センター中央病院 頭頸部・食道内科)
- P1-5 **Efficacy of Chemotherapy plus Immune checkpoint inhibitors for Malignant Dysphagia of Advanced Esophageal Cancer**
Tomoyo Yasuda (Clinical Oncology, Kansai Medical University)
切除不能 / 再発食道癌における悪性狭窄症状に対する化学療法 + 免疫チェックポイント阻害薬の効果についての検討
安田 知代 (関西医科大学附属病院 臨床腫瘍科)
- P1-6 **Dysphagia score and nutrition status during immune checkpoint inhibitors plus chemotherapy in advanced esophageal cancer**
Hotaka Tamura (Department of Clinical Oncology, University of Miyazaki Hospital)
通過障害を伴う切除不能食道癌に対する免疫チェックポイント阻害薬の有効性の検討
田村 穂高 (宮崎大学医学部附属病院 臨床腫瘍科)
- P1-7 **First-line Treatment for Unresectable/Recurrent Squamous Esophageal Cancer Patients with Immune Checkpoint Inhibitors**
Takehiko Tsumura (Department of Medical Oncology)
切除不能 / 再発食道扁平上皮癌患者に対する免疫チェックポイント阻害剤を用いた一次治療の単施設における後方視的検討
津村 剛彦 (大阪赤十字病院 腫瘍内科)

- P1-8 **Comparison of chemotherapy plus PD-1 inhibitor with chemoradiotherapy for metastatic ESCC patients with severe dysphagia**
 Takanori Hama (Department of Gastroenterology, Kanagawa Cancer Center)
Stage IV B 食道扁平上皮癌における PD-1 阻害剤併用化学療法と化学放射線療法の嚥下障害改善効果の検討
 濱 崇哲 (Kanagawa Cancer Center)
-
- P1-9 **Curative treatment for locally advanced esophageal cancer in elderly patients**
 Kaito Kubo (Medical Oncology)
高齢患者における局所進行食道癌の治療法の検討
 久保 海斗 (大阪市立総合医療センター)
-
- P1-10 **IMMUNOCHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN RESECTABLE GASTRIC AND GASTROESOPHAGEAL CARCINOMAS: A METAANALYSIS**
 Raye Angeli B Abella-gavile (Cancer Institute, St. Luke's Medical Center)
-
- P1-11 **A phase 2 pragmatic trial of immune checkpoint inhibitor plus chemotherapy for esophageal cancer patients with dysphagia**
 Yusuke Nagata (Department of Clinical Oncology, St.Marianna University School of Medicine)
通過障害合併 Stage IVB 食道癌における免疫チェックポイント阻害薬併用化学療法の実用的第 2 相試験
 永田 祐介 (聖マリアンナ医科大学 臨床腫瘍学講座)
-
- P1-12 **Real-World Efficacy and Safety of First-Line Immunotherapy in Patients with Advanced Esophageal Squamous Cell Carcinoma**
 Mikako Tamba (Department of Gastroenterological Chemotherapy)
進行・再発食道扁平上皮癌における一次免疫療法の実臨床における有効性および予後因子の解析
 丹羽 美香子 (がん研究会有明病院)

13:05-13:50 Poster Session 2

P2 Gastrointestinal Cancer 2 (Gastric Cancer 1)
 消化管 2 (胃 1)

- P2-1 **演題取下**
-
- P2-2 **Clinical assessment of SOX plus nivolumab treatment for unresectable or recurrent gastric cancer in our hospital**
 Shigefumi Yoshino (Department of Surgery, National Hospital Organization Kanmon Medical Center)
当院における切除不能・再発胃癌に対する SOX+ ニボルマブ療法の臨床的検討
 吉野 茂文 (独立行政法人国立病院機構 関門医療センター 外科)
-
- P2-3 **Withdrawn**
-
- P2-4 **演題取下**

- P2-5 **Efficacy and Safety of FTD/TPI Combined with Ramucirumab in Advanced Gastric Cancer: A Retrospective Analysis**
 Kosuke Ichida (Department of Surgery, Saitama Medical Center, Jichi Medical University)
進行胃癌における FTD/TPI+ ラムシルマブ併用療法の効果と安全性
 市田 晃佑 (自治医科大学附属さいたま医療センター)
- P2-6 **Overall Survival and Clinical Factors in Advanced Gastric Cancer: A Retrospective Study from Maharat Nakhon Ratchasima**
 Jirawat Thanestada (Maharat Nakhon Ratchasima Hospital)
- P2-7 **Survival outcomes in stomach cancer patients:5-year follow-up from university hospital-based cancer registry in Bangkok**
 Tanapol Thonkamdee (1 Ramathibodi Comprehensive Cancer Center, Faculty of Medicine, Ramathibodi Hospital, Mahidol University)
- P2-8 **VDR, RXR, CYP27B1 and CYP24A1 expressions in early stages of Thai colorectal cancer patients after receiving vitamin D3**
 Sophida Sukprasert (Chulabhorn International College of Medicine, Thammasat University)
- P2-9 **Validity for chemotherapy and conversion surgery of gastric cancer at our hospital**
 Shigeru Sasaki (Medical Oncology)
当院胃癌化学療法及び conversion 手術の妥当性の検討
 佐々木 滋 (埼玉県済生会川口総合病院)

13:05-13:50 Poster Session 3

P3 Gastrointestinal Cancer 3 (Case Report 1)
 消化管 3 (ケースレポート 1)

- P3-1 **A case of malignant peritoneal mesothelioma with long-term disease maintenance of immune checkpoint inhibitors**
 Shunsuke Adachi (Department of Gastroenterology Juntendo University School of Medicine)
免疫チェックポイント阻害剤投与により長期の病勢維持を得ている悪性腹膜中皮腫の一例
 足立 駿輔 (順天堂大学付属順天堂医院消化器内科)
- P3-2 **A case of attenuated Li-Fraumeni syndrome diagnosed through comprehensive genomic profiling**
 Shinnosuke Yamamoto (Tohoku University School of Medicine, Department of Medicine)
遺伝子パネル検査を契機に診断された attenuated Li-Fraumeni 症候群の一例
 山本 新之助 (東北大学医学部医学科)
- P3-3 **Four cases of catheter rupture during chemotherapy for gastrointestinal cancer using a central venous port device**
 Toshimitsu Tanaka (Multidisciplinary Treatment Cancer Center, Kurume University Hospital)
消化器癌化学療法中に CV ポートカテーテル断裂した 4 症例
 田中 俊光 (久留米大学病院がん集学治療センター)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

P3-4 **Two Cases of the Abscopal Effect: Immune Checkpoint Inhibitors Shrinking Lesions Emerging After Radiotherapy**
Emiko Mura (Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University)

免疫チェックポイント阻害薬により放射線治療後に出現した病変が縮小したアブスコパル効果の2例
村 英美子 (昭和大学 医学部 内科学講座腫瘍内科学部門)

P3-5 **Nivolumab Treatment for Basaloid Squamous Cell Carcinoma of the Esophagus: A Case Report**
Satoshi Nishiyori (medical office)

食道原発基底扁平上皮癌に対するニボルマブ治療：症例報告
西依 慧 (県立宮崎病院)

P3-6 **A case of long-term palliation after bypass surgery followed by chemoradiotherapy for locally advanced esophageal cancer**
Masataka Ando (Department of Gastroenterological Surgery, Aichi Medical University)

食道バイパス術後にCRTを行い長期生存中の局所進行食道癌の1例
安藤 公隆 (愛知医科大学 消化器外科)

P3-7 **A case of fatal SVC syndrome during FP plus nivolumab therapy for esophageal cancer with advanced lymph node metastasis**
Takashi Matsumura (Department of Hematology and Oncology, JCHO Kyushu Hospital)

高度リンパ節転移を伴う食道癌に対してFP+ニボルマブ療法施行中に上大静脈症候群に至り死亡した一例
松村 尚 (JCHO Kyushu Hospital)

P3-8 **Genomic profiles of metastases with differing treatment responses in a patient with HER2-positive colorectal cancer**
Yutaro Usui (Medical Oncology and Hematology, Kobe University Graduate School of Medicine and Hospital)

治療効果が異なるHER2陽性大腸癌の転移巣のゲノム解析
白井 佑太郎 (神戸大学医学部附属病院 腫瘍・血液内科)

P3-9 **A severe adverse effect of oxaliplatin. Two cases report**
Yoshitomo Ashitate (Urakawa Red Cross Hospital)

オキサリプラチンによる副作用の検討
芦立 嘉智 (浦河赤十字病院)

13:05-13:50 Poster Session 4

P4 Gastrointestinal Cancer 4 (Colorectal Cancer 1)
消化管 4 (大腸 1)

P4-1 **Efficacy of Pertuzumab and Trastuzumab Combination in Colorectal Cancer: A Systematic Review**
Catrina Wendelin (Faculty of Medicine, Pelita Harapan University, Indonesia)

P4-2 **Proteomic profiling of Vitamin D and Lysiphyllum strychnifolium extract on a human colon carcinoma xenograft mouse model**
Natthaporn Kuendee (Faculty of Veterinary Medicine, Rajamangala University of Technology Tawan-ok)

- P4-3 **The efficacy and safety of carboplatin and paclitaxel for metastatic squamous cell carcinoma of the anal canal**
Hiroko Kaiume (Gastrointestinal Medical Oncology)
転移性肛門管癌（扁平上皮癌）に対するカルボプラチンとパクリタキセルの有効性と安全性
貝梅 絃子（国立がん研究センター中央病院）
- P4-4 **The experience of SOX + radiation therapy in the patients with colorectal cancer**
Noriko Wada (Gastroenterological surgery, Osaka University)
直腸・肛門管癌に対する SOX+RT 療法の治療経験
和田 範子（大阪大学大学院医学系研究科 消化器外科学）
- P4-5 **The Impact of Probiotics on Colectomy Complications in Colorectal Cancer Patients: A Systematic Review**
Jason M Prawira (Universitas Pelita Harapan, Faculty of Medicine)
- P4-6 **The Efficacy of Pertuzumab plus Trastuzumab in HER-2 Positive Metastatic Colorectal Cancer: A Systematic Review**
Tiffney T Setyoko (Faculty of Medicine, Pelita Harapan University)
- P4-7 **A retrospective analysis of the combination therapy of FTD/TPI and bevacizumab with advanced colorectal cancer**
Takahito Awatsu (Department of Gastroenterology, Juntendo University School of Medicine)
進行大腸癌に対する FTD/TPI とベバシズマブ併用療法の後方視的解析
粟津 崇仁（順天堂大学医学部附属順天堂医院 消化器内科）
- P4-8 **Living donor liver transplantation as a part of multidisciplinary treatment for unresectable colorectal liver metastases**
Ken Fukumitsu (Department of Surgery, Kyoto Katsura Hospital)
大腸癌の切除不能肝転移に対する集学的治療の一環としての生体肝移植
福光 剣（京都桂病院）
- P4-9 **The diagnostic value of Platelet-to-lymphocyte ratio (PLR) and Pan-immune-inflammation value(PIV) in Colorectal cancer**
Ubaldo Espindola Arias (Regional Hospital PEMEX Poza Rica)
- P4-10 **Withdrawn**

13:05-13:50 Poster Session 5

P5 Hepatobiliary / Pancreatic Cancer 1 (Liver Cancer 1)
肝胆癌 1 (肝臓 1)

- P5-1 **Withdrawn**
- P5-2 **Genetic Modulation in Persistent HCV Infection: miRNA Insights and the Potential of DAAs on Viral Epigenetic Effects**
Wen-hsiu Su (Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University)
- P5-3 **A Dynamic Model for Prediction of Hepatocellular Carcinoma in a Multi-round Screening Cohort: A Longitudinal Study**
Qianru Li (National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

P5-4	Intestine-specific homeobox regulates macrophage polarization in hepatocellular carcinoma Li-ting Wang (National Taiwan Normal University)
P5-5	Exploring the Role of Ferroptosis and Lipid Metabolism in the Progression of Liver Disease and Hepatocellular Carcinoma Chi-sheng Chen (Ph.D. Program in Environmental and Occupational Medicine, College of Medicine, Kaohsiung Medical University)
P5-6	Conessine inhibits cell proliferation, migration and invasion and induces apoptosis in liver cancer cells Yusheng Lin (kaohsiung medical university school of medicine)
P5-7	Mitochondrial biogenesis-related protein in Metabolic Dysfunction-Associated Steatotic Liver Disease Yu-ching Huang (Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University)
P5-8	The inhibitory effects of Kefir peptides in HCCs through regulating M1-type macrophage-derived exosomal miR-141-3p Kai Cheng Chuang (Department of Life Sciences, National Chung Hsing University)
P5-9	Landscapes of HBV integration in hepatocellular carcinoma: mechanistic characterization and functional implications Xueying Lyu (State Key Laboratory of Liver Research, The University of Hong Kong)
P5-10	演題取下
P5-11	Economic Analysis of Immunotherapy in the Treatment of Liver Cancer: A Quantitative Study Ester M Purba (Raff Tindal NT)
13:05-13:50 Poster Session 6	
P6	Hepatobiliary / Pancreatic Cancer 2 (Liver Cancer 2) 肝胆胰 2 (肝臟 2)
P6-1	Comparative Efficacy of Bevacizumab vs. Sorafenib in Treating Unresectable Hepatocellular Carcinoma: A Systematic Review Rocky V Sunaryo (Faculty of Medicine, Pelita Harapan University)
P6-2	Comparison of atezolizumab plus bevacizumab and durvalumab plus tremelimumab for hepatocellular carcinoma Tomoyuki Satake (National Cancer Center Hospital East) 進行肝細胞癌の一次治療におけるアテゾリズマブ + ベバシズマブ療法とデュルバルマブ + トレメリムマブ療法の比較 佐竹 智行 (国立がん研究センター東病院)
P6-3	Real-World Insights into Cabozantinib Efficacy in Hepatocellular Carcinoma Kuan-chang Lai (Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan)

- P6-4 **Efficacy and safety of durvalumab plus tremelimumab combination therapy in unresectable hepatocellular carcinoma**
Hironori Tanaka (Department of gastroenterology and oncology)
切除不能肝細胞癌に対するデュルバルマブとトレメリムマブの併用療法の有効性と安全性
田中 宏典 (徳島大学)
- P6-5 **Systemic treatment with multikinase inhibitors beyond Sorafenib for recurrent hepatocellular carcinoma: a meta-analysis**
Joshua Henrina (Department of Internal Medicine, Dr. Kariadi General Hospital, Universitas Diponegoro Faculty of Medicine)
- P6-6 **Withdrawn**
- P6-7 **Hepatitis B virus-associated hepatocellular carcinoma has a poorer prognosis in patients treated with FOLFOX**
Chaichana Chantharakhit (Buddhasothorn Cancer Center, Buddhasothorn Hospital)
- P6-8 **Durvalumab Plus Tremelimumab for Advanced Hepatocellular Carcinoma with Contraindications to Anti-Angiogenic Agents**
Seira Owaki (Department of Medical Oncology, NHO Nagoya Medical Center)
血管新生阻害薬が禁忌または慎重投与となる進行肝細胞癌患者に対するデュルバルマブ + トレメリムマブ療法
大脇 聖楽 (国立病院機構名古屋医療センター 腫瘍内科)
- P6-9 **Treatment Outcomes of Combination Therapy with Durvalumab and Tremelimumab at Our Hospital**
Akihiro Deguchi (Division of Gastroenterology, Kagawa Rosai Hospital)
当院における Durvalumab+Tremelimumab 併用療法の治療成績
出口 章広 (香川労災病院)
- P6-10 **Usage experience of tremelimumab+durvalumab in patients with unresectable hepatocellular carcinoma**
Yoshimi Fujishima (Kobe Minimally Invasive Cancer Center, Department of Medical Oncology)
切除不能肝細胞癌に対するトレメリムマブ + デュルバルマブ併用療法の使用経験
藤島 佳未 (神戸低侵襲がん医療センター腫瘍内科)

13:05-13:50 Poster Session 7

- P7** Hepatobiliary / Pancreatic Cancer 3 (Case Report 1)
肝胆腫 3 (ケースレポート 1)
- P7-1 **Hepatic Arterial Infusion Chemotherapy for Advanced HCC patient: A case reports**
Lkhagva-ochir Tovuu (Second State Central Hospital of Mongolia)
- P7-2 **Intrahepatic Cholangiocarcinoma with rare esophageal metastasis presenting as left shoulder pain: A Case Report**
Angelyn S Cruz (The Medical City)
- P7-3 **Capmatinib in Refractory Intrahepatic Cholangiocarcinoma (CCA) Harboring MET Amplification: A Case Report**
Shang-hsuan Peng (National Taiwan University Hospital Yunlin Branch)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

P7-4 **A Case of Biliary Tract Cancer Developed Acute Bilateral Sialadenitis as Immune-related Adverse Event**
 Ryuta Ohira (crinical oncology)
免疫関連有害事象として急性両側性唾液腺炎を発症した胆道癌の一例
 大衡 竜太 (亀田総合病院)

P7-5 **A case of cholangiocarcinoma with fibroblast growth factor receptor (FGFR) 2 gene alternation treated with pemigatinib**
 Shotaro Korehisa (Department of Medical Oncology, Matsuyama Red Cross Hospital)
FGFR2 遺伝子異常を伴う再発胆管癌に対してペミガチニブが奏効した 1 例
 是久 翔太郎 (松山赤十字病院 臨床腫瘍科)

P7-6 **FGFR2 inhibitor-induced nail disorder: A case report**
 Chiaki Kondo (Nagoya University Hospital)
FGFR2 阻害薬による爪障害に関する症例報告
 近藤 千晶 (名古屋大学医学部附属病院)

P7-7 **A response case of TMB-high gallbladder neuroendocrine carcinoma treated with Nivolumab at home visiting chemotherapy**
 Nobuhiro Tsuruta (Tsuruta clinic)
Guardant360® がん遺伝子パネル検査で TMB-High であった胆嚢神経内分泌癌に対して在宅で Nivolumab 療法を行い良好な腫瘍縮小効果を得た一例
 鶴田 展大 (鶴田クリニック)

P7-8 **Two cases of durable response after discontinuation of side effects of pembrolizumab therapy for MSI-H or TMB-H cancers**
 Masato Hayashi (Department of Medical Oncology, Kyorin University Faculty of Medicine)
MSI-H または TMB-H 腫瘍に対するペムブロリズマブ療法による有害事象中止後に持続的奏効が得られた胆道癌の 2 例
 林 雅人 (杏林大学医学部腫瘍内科学)

P7-9 **Durable response of platinum-based chemotherapy for cholangiocarcinoma with germline PALB2mutation: A case report**
 Hsiu-tzu Wang (Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital)

13:05-13:50 Poster Session 8

P8 Breast Cancer 1 (Other 1)
乳腺 1 (その他 1)

P8-1 **Analysis of non-surgical treatment of breast cancer for the oldest-patients**
 Tokiko Ito (Division of Breast and Endocrine surgery, Iida Municipal Hospital)
80 歳以上の高齢者乳癌非手術症例の検討
 伊藤 勲子 (飯田市立病院 乳腺内分泌外科)

- P8-2 **Skeletal muscle loss during NAC with pembrolizumab predicts non-pCR in patients with triple negative breast cancer**
Takaaki Oba (Division of Breast and Endocrine Surgery, Department of Surgery, Shinshu University Hospital)
トリプルネガティブ乳癌に対する Pembrolizumab 併用術前化学療法中の骨格筋量の低下は non-pCR と関連する
大場 崇旦 (信州大学医学部附属病院 乳腺・内分泌外科)
- P8-3 **A Study on A.E. and the Impact of Body Composition Analysis by CT in Postoperative Adjuvant Therapy for Breast Cancer**
Taijiro Kosaka (Saku Central Hospital Advanced Care Center)
乳癌の術後補助療法における有害事象と CT による体組成解析の相関についての検討
小坂 泰二郎 (JA 長野厚生連 佐久総合病院 佐久医療センター)
- P8-4 **AI-Driven Automated Breast Cancer Classification Framework Using a Wavelet-Based Network**
Vivek Kumar Singh (Centre for Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI), Queen Mary University of London, London, United Kingdom)
- P8-5 **Virtual Immunohistochemical Stain Generation from H&E for Breast Cancer using Attention based Adversarial Learning**
Alwin Koonan Lonappan (Centre for Biomarkers and Biotherapeutics, Barts Cancer Institute (BCI), Queen Mary University of London, London, United Kingdom)
- P8-6 **A multi center analysis of prevalence of BRCA mutation in patients with high riskbreast cancer**
Manoj K Behera (Cancer Center of America (CCA))

13:05-13:50 Poster Session 9

P9 Breast Cancer 2 (Perioperative 1)
乳腺 2 (周術期 1)

- P9-1 **Safety and Efficacy of Pembrolizumab with Early-Stage Triple-Negative Breast Cancer in Elderly Patients**
Masanori Matsuda (Saitama Medical Center Breast care)
高齢者における早期トリプルネガティブ乳癌に対するペムブロリズマブの安全性と効果
松田 正典 (埼玉医科大学総合医療センター)
- P9-2 **Efficacy and Safety of Chemotherapy Plus Pembrolizumab for Early Triple-Negative Breast Cancer**
Takumi Ito (Department of Medical Oncology, NHO Nagoya Medical Center)
早期トリプルネガティブ乳癌に対する化学療法 + ペムブロリズマブの有効性と安全性
伊藤 拓未 (NHO Nagoya Medical Center)
- P9-3 **Retrospective study of chemotherapy with pembrolizumab in patients with early-stage triple-negative breast cancer**
Hiroki Oka (Mie University Hospital, Medical Oncology)
早期トリプルネガティブ乳癌患者におけるペムブロリズマブ併用化学療法の後方視的研究
岡 弘毅 (三重大学医学部附属病院 腫瘍内科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

P9-4 **Retrospective case series of neoadjuvant pembrolizumab plus chemotherapy for TNBC**

Hideko Akagi (Department of Oncology, Nippon Medical School Musashi-kosugi hospital)

TNBC 乳がんの Pembrolizumab を導入した術前化学療法の後方視的検討

赤木 秀子 (日本医科大学武蔵小杉病院 腫瘍内科)

P9-5 **Cytokine-mediated Hypersensitivity Reactions to Carboplatin in Triple-Negative Breast Cancer with KEYNOTE522 regimen**

Masahiro Kuno (Breast Medical Oncology, Breast Center, The Cancer Institute Hospital of JFCR)

KEYNOTE522 レジメン投与中に発症するカルボプラチンに対するサイトカインを介した過敏性反応に対する検討

久野 真弘 (公益財団法人がん研究会有明病院 乳腺内科)

P9-6 **The Efficacy and Endocrine Toxicity of KEYNOTE-522 Regimen in Early Breast Cancer Patients at Kindai University Hospital**

Satomi Watanabe (Department of Medical Oncology, Kindai University Faculty of Medicine)

早期トリプルネガティブ乳癌に対する周期ペムブロリズマブ併用レジメン (KEYNOTE-522) による当院での治療効果および内分泌関連有害事象についての検討

渡邊 諭美 (近畿大学医学部内科学教室腫瘍内科部門)

P9-7 **Differences between cases with and without irAEs in combination with pembrolizumab for triple-negative breast cancer**

Rie Komaki (breast department)

トリプルネガティブ乳癌に対するペムブロリズマブ併用術前化学療法による irAE 発現と非発現症例の違い

小牧 里恵 (愛知県がんセンター)

13:05-13:50 Poster Session 10

P10 Breast Cancer 3 (Case Report 1) 乳腺 3 (ケースレポート 1)

P10-1 **Clinical Features and Incidence of Gastro-intestinal metastasis from Primary Breast Cancer, A Case Series**

Ann Willainne G Tan (The Medical City)

P10-2 **Small Bowel and Pancreatic Metastases in a Breast Cancer Patient, A Case Report**

Ann Willainne G Tan (The Medical City)

P10-3 **Metastatic Breast Carcinoma Presenting with Bowel Obstruction from A Signet Ring cell Gastroduodenal Mass, A Case Report**

Ann Willainne G Tan (The Medical City)

P10-4 **Invasive breast carcinoma with colonic metastasis: A case report**

Ana Carmela R Miranda (Cancer Research Center, Veterans Memorial Medical Center)

P10-5 **A case of recurrent breast cancer treated with paclitaxel and bevacizumab, followed by palliative reconstruction**

Yuki Ando (Department of Surgery, Kyushu University Beppu Hospital)

パクリタキセル + アバスチン療法が著効し腋窩動脈が露出した腋窩部皮膚欠損に緩和再建を行い自宅退院可能となった再発乳癌の 1 例

安東 由貴 (九州大学病院別府病院外科)

- P10-6 **A case of long-term control with abemaciclib and letrozole combination therapy in breast cancer with brain metastases**
Yumi Nozaki (Department of Medical Oncology, National Hospital Organization Saitama Hospital)
アベマシクリブとレトロゾール併用療法により長期に脳転移が制御された 1 例
野崎 由美 (国立病院機構 埼玉病院 腫瘍内科)
- P10-7 **PML in the patient with advanced breast cancer receiving Palbociclib previously treated for follicular lymphoma**
Mariko Nishihara (Department of Hematology)
濾胞性リンパ腫の治療後、進行乳癌に対しパルボシクリブ内服中に生じた PML の一例
西原 麻里子 (聖路加国際病院血液内科)
- P10-8 **Navigating Drug-Induced Liver Injury in Metastatic Breast Cancer: Diagnostic and Management Challenges**
Hitomi Suzuki (Department of Breast Surgery, Ichinomiya Nishi Hospital)
転移性乳癌治療中の薬剤性肝障害：診断と管理の課題
鈴木 瞳 (一宮西病院 乳腺外科)
- P10-9 **Case Report: A Case of HER2 Positive Breast Cancer with Leptomeningeal and Pituitary Relapse**
Seng Wee Cheo (Department of Radiotherapy, Oncology and Palliative Care, Sarawak General Hospital)

13:05-13:50 Poster Session 11

P11 Gynecologic Cancer 1
婦人科 1

- P11-1 **Case Report: CDK 4 Amplification in Endometrial Stromal Sarcoma**
Seng Wee Cheo (Department of Radiotherapy, Oncology and Palliative Care, Sarawak General Hospital)
- P11-2 **Two cases of PARPi switching during maintenance therapy for platinum-sensitive recurrent ovarian cancer**
Kento Kato (National Defense Medical College Hospital)
プラチナ感受性再発卵巣がんの維持療法中に他の PARPi への切り替えを行った 2 症例
加藤 顕人 (防衛医科大学校病院)
- P11-3 **Primary Ovarian Squamous Cell Carcinoma in a 51-year-old Filipino Female: A Case Report**
Mikael N Matunog (St. Lukes Medical Center)
- P11-4 **Krukenberg tumor in a 18-year-old-female**
Yasunori Hashiguchi (Department of Gynecology, Ishikiriseiki Hospital)
18 歳女性に発症したクルッケンベルグ腫瘍の一例
橋口 裕紀 (石切生喜病院)
- P11-5 **A case of PTEN-mutant endometrioid tumor arising in a background of endometriosis and atypical endometriosis**
Takeo Shibata (Kanazawa Medical University)
子宮内膜症のがん化過程を示す腹膜に発生した PTEN 変異陽性類内膜腫瘍の 1 例
柴田 健雄 (金沢医科大学)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

P11-6	<p>Successful Chemotherapy in a Case of Hypoxemia Caused by Metastatic Lung Lesions Managed with Mechanical Ventilation Tatsuyuki Kawahara (Department of General Internal Medicine 4, Kawasaki Medical School) 人工呼吸器管理下で化学療法が奏効した転移性肺病変による低酸素血症の症例 河原 辰由樹 (川崎医科大学 総合内科学 4)</p>
P11-7	Withdrawn
13:05-13:50 Poster Session 12	
P12	Gynecologic Cancer 2 婦人科 2
P12-1	Withdrawn
P12-2	Withdrawn
P12-3	演題取下
P12-4	<p>Portable Colposcopes for Cervical Cancer Screening: A Systematic Review and Meta-Analysis Therdpong Thongseiratch (Faculty of Medicine, Prince of Songkla University)</p>
P12-5	<p>Evaluating Progress in Cervical Cancer Prevention and Management: A Systematic Review Ryan C Harliman (Faculty of Medicine, University of Pelita Harapan)</p>
P12-6	<p>Neutrophil-Albumin Index as a Discriminative Tool for Distinguishing Uterine Leiomyosarcoma from Uterine Leiomyoma Wankyu Eo (Section of Medical Oncology, Kyung Hee University Hospital at Gangdong)</p>
P12-7	<p>Therapeutic Potential of Hinokitiol in Inhibiting Uterine Leiomyoma Proliferation and Extracellular Matrix Accumulation Yifen Chiang (School of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University)</p>
P12-8	<p>Effectiveness of Loop Electrosurgical Excision Procedure to Treat Cervical Intraepithelial Neoplasia Sultana Farzana (Jahurul Islam Medical College Hospital)</p>
P12-9	<p>Cemiplimab Extends Survival in Patients with Recurrent Cervical Cancer: Systematic Review and Meta-analysis Nabila N Nurisma (Faculty of Medicine Universitas Indonesia)</p>

13:05-13:50 Poster Session 13

- P13** Gynecologic Cancer 3
婦人科 3
- P13-1 **Withdrawn**
- P13-2 **Efficacy of Olaparib vs Olaparib + Bevacizumab in BRCA-Mutated Ovarian Cancer's Maintenance Therapy: A Systematic Review**
Angelina Wandana (Faculty of Medicine, Pelita Harapan University)
- P13-3 **Overall Outcomes of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer : A Systematic Review**
Carissa D Shafyra (Faculty of Medicine, Universitas Pelita Harapan)
- P13-4 **Efficacy of Olaparib Monotherapy for Advanced Ovarian Cancer with BRCA1/2 Mutation: A Systematic Review**
Levina K Tori (Faculty of Medicine Pelita Harapan University)
- P13-5 **Rucaparib as Maintenance Treatment for Ovarian Cancer Patients: A Systematic Review of Randomized Controlled Trials**
Clarissa A Cendera (Faculty of Medicine, Pelita Harapan University)
- P13-6 **Long-Term Use of PARP Inhibitor Use and Risk of Recurrence in Patients with Ovarian Carcinoma: A Systematic Review**
Ratanna Dharmawan (Pelita Harapan University, Faculty of Medicine)
- P13-7 **Early outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; first 15 patients from Nepal**
Deep Lamichhane (Bhaktapur Cancer Hospital)

13:05-13:50 Poster Session 14

- P14** Genitourinary Cancer 1 (Renal Cancer / Prostate Cancer / Urothelial Cancer, Clinical)
泌尿器 1 (腎癌・前立腺癌・尿路上皮癌 臨床)
- P14-1 **Characterization of patients with metastatic renal cell carcinoma who experienced serious immune-related adverse events**
Ryosuke Oki (Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research)
重篤な免疫関連有害事象を来した転移性腎細胞がん患者の特徴
大木 遼佑 (がん研究会有明病院 総合腫瘍科)
- P14-2 **Enhanced Efficacy of ICIs with RT in Renal Cell Carcinoma: A Statistical Analysis of 35 Cases from the DARC-MICAN Study**
Shunsuke Haga (Department of Urology, Ehime University Graduate School of Medicine)
腎細胞癌に対して ICI 治療における RT の治療相乗効果の検討 : 多施設共同研究 DARC-MICAN study の解析
芳賀 俊介 (愛媛大学医学部附属病院)
- P14-3 **MEDIASTINAL METASTASIS WITH POLYCYTHEMIA FROM A PRIMARY RENAL CELL CARCINOMA : A CASE REPORT**
Paul Timothy K Gabay (St. Luke's Medical Center)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Room 14
Meet the Poster Experts

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

P14-4 **Utilizing Cancer Databases to Identify Prognostic Biomarkers for Prostate Cancer**
Zi-wei Zhang (School of Medicine, College of Medicine, Kaohsiung Medical University)

P14-5 **Current Status and Issues of Gene Panel Testing for Prostate Cancer Patients at our Hospital**
Hiroyuki Sakashita (Department of Cancer Genome Center, Yokosuka Kyosai Hospital)
当院における前立腺がん患者に対する遺伝子パネル検査の現状と課題
坂下 博之 (横須賀共済病院 がんゲノムセンター)

P14-6 **Dose-escalation radiotherapy to dominant lesion for patients with localized prostate cancer**
Anna A Kufelkina (N.N. Blokhin NMRCO)

P14-7 **Lu-177 PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Single-Institution Experience**
Saruta Bubphapasom (Ramathibodi Comprehensive Cancer Center, Faculty of Medicine, Ramathibodi Hospital, Mahidol University)

P14-8 **Long-term outcomes of patients enrolled in the DANUBE trial; a single-center subgroup analysis**
Ryunosuke Nakagawa (Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science)
当院における DANUBE 試験に登録された患者の長期転帰; 単施設でのサブグループ解析
中川 竜之介 (金沢大学大学院医学系研究科 集学的治療分野)

13:05-13:50 Poster Session 15

P15 Genitourinary Cancer 2 (Renal Cancer / Prostate Cancer, Basic Research)
泌尿器 2 (腎癌・前立腺癌 基礎)

P15-1 **Chemoresistance in Prostate Cancers is regulated through the Modulation of the circDLGAP4 /miR143/HK2 Signaling Axis**
Shivali Duggal (King George Medical University)

P15-2 **Studies on Anticancer Mechanisms of Phenanthroindolizidine Alkaloids against Human Castration-Resistant Prostate Cancer**
Min Hsuan Yu (School of Pharmacy, National Taiwan University)

P15-3 **TCH-3179-1 inhibits castration-resistant prostate cancer cell migration and growth, and promotes apoptosis**
Sheng I Lee (Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University)

P15-4 **Caffeic acid phenethyl ester suppresses the expression of androgen receptor variant 7 via inhibition of CDK1 and AKT**
Ying-yu Kuo (Institute of Cellular and System Medicine, National Health Research Institutes)

P15-5 **Study of Novel Dual-Target Inhibitors on Tubulin and PARG against Castration-Resistant Prostate Cancer**
Tsai Ni Tseng (Department of Pharmacy, School of Pharmacy, National Taiwan University)

P15-6 **Exploring the therapeutic role of tumor-suppressive microRNA in Prostate Cancer**
Anveshika Manoj (King George's Medical University)

Encore

P15-7 **Transcriptome Analysis by RNA-Seq Reveals Genes Associated with Resistance to ENZA and Abiraterone in Prostate Cancer**
Hsin Yi Lin (Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University)

P15-8 **Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma**
Xin Lu (University of Notre Dame)

13:05-13:50 Poster Session 16

P16 Genitourinary Cancer 3 (Urothelial Cancer, Basic Research / Other)
泌尿器 3 (尿路上皮癌 基礎・その他)

P16-1 **Multi-regional profiling of EGFR L858R mutation-positive upper tract urothelial cancer**
Yoshiyuki Yamamoto (Department of Urology, Osaka University Graduate School of Medicine)
分子標的治療が奏功した EGFR L858R 変異陽性上部尿路上皮癌の多部位シークエンスによるプロファル解明
山本 致之 (大阪大学大学院医学系研究科器管制御外科学講座 (泌尿器科学))

P16-2 **OIP5-AS1 modulates cell proliferation, migration and invasion through ADAM9 via targeting miR-30c-5p in UTUC**
Wei-chi Hsu (Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University)

P16-3 **Alantolactone Suppresses Epithelial-Mesenchymal Transition (EMT) and Triggers Apoptosis in Bladder Cancer Cells**
Yun-cian Huang (Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan)

P16-4 **Inhibitory role of decitabine in heavy metal induced proliferation of urinary bladder cancer**
Deepika Saini (All India Institute of Medical Sciences)

P16-5 **Urachal Carcinoma : Challenging Treatment in Rare Cancer**
Saran Sanguanrungrasirikul (Maharaj Nakorn Chiang Mai Hospital)

P16-6 **METASTATIC PENILE CANCER IN A FILIPINO MAN LIVING WITH HIV: The Experience of a Government-Owned Hospital in Cebu City**
Josemari B Lozano (Cancer Center, Vicente Sotto Memorial Medical Center)

P16-7 **BATTLE SCARS: A BLEOMYCIN INDUCED FLAGELLATED DERMATITIS IN A NON SEMINOMATOUS GERM CELL TUMOR**
Hernel Mae D Sablan (St Lukes Medical Center Quezon City)

P16-8 **Retrospective Study on the Safety and Complications of PICC in Clinical Practice**
Shuhei Aoyama (Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science)
臨床における PICC の安全性と合併症に関する検討
青山 周平 (金沢大学大学院医薬保健学総合研究科 泌尿器集学的治療学)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

13:05-13:50 Poster Session 17

P17 Head and Neck Cancer 1
頭頸部 1

- P17-1 **Longitudinal health utility and symptom-toxicity trajectories in patients with head and neck cancers**
Jianjun Ren (West China Hospital, Sichuan University)
- P17-2 **Tobacco-free betel quid chewing and risk of head and neck cancer in Taiwan**
Encore Cheng-chih Huang (Department of Otolaryngology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University)
- P17-3 **The Association of Sarcopenia with Nasopharyngeal Cancer Patients Receiving Chemotherapy: A Literature Review**
Hayatun Nufus (University of Indonesia, Persahabatan General Hospital)
- P17-4 **Low vitamin D level associated with metastasis in head and neck cancer**
I Putu Gede Septiawan Saputra (Faculty of Medicine, Udayana University, Bali, Indonesia)
- P17-5 **Efficacy of Photobiomodulation Therapy for Oral Mucositis in Head and Neck Cancer: A Systematic Review**
Emily W Otto (Faculty of Medicine, Pelita Harapan University)
- P17-6 **Induction Chemotherapy Regimen in Advanced Unresectable Ear Canal Squamous Cell Carcinoma: A Systematic Review**
Andree Kurniawan (Internal Medicine, Faculty of medicine, Pelita Harapan University)
- P17-7 **Complete Response with Pembrolizumab Monotherapy in a Patient with Unresectable Locally Advanced Salivary Duct Carcinoma**
Taiju Ando (Fujita Health University Hospital, Department of Medical Oncology)
ペムブロリズマブ単剤療法によって完全奏功を得た切除不能な局所進行唾液腺導管癌の一例
安藤 泰樹 (藤田医科大学病院臨床腫瘍科)
- P17-8 **A case of maxillary malignant tumor with neuroendocrine differentiation achieving disease control by chemoradiotherapy**
Keichi Hisatsune (Hematology, Oncology & Cardiovascular medicine)
神経内分泌分化を伴う上顎洞悪性腫瘍に対し、化学放射線療法によって病勢制御を得られた一例
久恒 慶地 (九州大学病院血液腫瘍心血管内科)
- P17-9 **Leptomeningeal Metastasis in Nasopharyngeal Cancer: A Case Report**
Cristina G Domingo (Cancer Center, Mariano Marcos Memorial Hospital and Medical Center)

13:05-13:50 Poster Session 18

P18 Head and Neck Cancer 2
頭頸部 2

- P18-1 **Impact of Treatment Modalities on Survival in Oropharyngeal Carcinoma: A Comparative Analysis Across Diverse Populations**
Danni Cheng (West China Hospital, Sichuan University)

- P18-2 **Effect of induction chemotherapy in patients with head and neck cancer during the waiting period until surgery**
 Yoshiaki Kitamura (Department of Otorhinolaryngology-Head and Neck Surgery, Graduate School of Biomedical Sciences, Tokushima University)
再建術を行った局所進行頭頸部扁平上皮癌症例に対する導入化学療法の影響
 北村 嘉章 (徳島大学大学院医歯薬学研究所耳鼻咽喉科・頭頸部外科学分野)
- P18-3 **Effect of Pembrolizumab for elderly head and neck cancer by CPS status: Subanalysis of a multicenter retrospective study**
 Yuri Ueda (Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hospital)
高齢者頭頸部がんにおける CPS 別ペムブロリズマブの効果: 多施設後方視的検討のサブグループ解析
 上田 百合 (東京医科大学 耳鼻咽喉科・頭頸部外科学分野)
- P18-4 **Practical Treatment Selection of Pembrolizumab-based therapy, Tailored to Patient Backgrounds and PD-L1 Expression**
 Taiji Koyama (Medical oncology/hematology, Kobe university hospital/Oncolo)
患者背景と PD-L1 発現に基づいたペムブロリズマブ療法の選択
 小山 泰司 (神戸大学医学部附属病院 腫瘍・血液内科)
- P18-5 **ICT-TPF therapy for locally advanced squamous cell carcinoma of the head and neck: dosing cycle and efficacy**
 Ari Nishimura (Department of Otolaryngology-Head and Neck Surgery, Nara Medical University)
局所進行頭頸部扁平上皮癌に対する ICT-TPF 療法: 投与サイクルと有効性について
 西村 在 (奈良県立医科大学 耳鼻咽喉科・頭頸部外科)
- P18-6 **Long-term Efficacy of Nivolumab in Head and Neck Cancer and Clinical Features of Long-term Survivors**
 Yoichiro Iwasa (Department of Otorhinolaryngology-Head and Neck Surgery, Shinshu University School of Medicine)
再発転移頭頸部癌に対する Nivolumab の長期治療成績および長期生存例における臨床的特徴
 岩佐 陽一郎 (信州大学 医学部 耳鼻咽喉科頭頸部外科)
- P18-7 **INSTITUTIONAL EXPERIENCE OF CONCURRENT DOCE-AQUILIP IN HEAD AND NECK CANCER IN CISPLATIN INELIGIBLE PATIENTS**
 Vansh Arora (DNSH)
- P18-8 **Definitive Chemoradiotherapy with Weekly Cisplatin for Head and Neck Cancer Patients Unfit for 3-weekly Cisplatin**
 Gen Kanemori (Department of Medical Oncology and Hematology, Kobe University Hospital.)
3 週毎のシスプラチン投与が不適な局所進行頭頸部癌患者に対するシスプラチン毎週投与法併用化学放射線療法の遡及的解析
 兼森 玄 (神戸大学医学部附属病院 腫瘍・血液内科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

P18-9 **First line chemotherapy for elderly patients with head and neck squamous cell carcinoma: a retrospective analysis**
 Kazue Ito (Miyagi Cancer Center)
再発・転移頭頸部扁平上皮癌患者に対する緩和的薬物療法の後方視的解析から考える高齢患者に対する薬物療法
 伊東 和恵 (宮城県立がんセンター)

P18-10 **The Prognostic Value of Hematological Indices in Oropharyngeal Cancer Patients Treated with Radiotherapy**
Encore
 Yao Song (West China Hospital, Sichuan University)

13:05-13:50 Poster Session 19

P19 Head and Neck Cancer 3
 頭頸部 3

P19-1 **The Role of HPV Status in Patients with Overlapping Grey Zone Cancer in Oral Cavity and Oropharynx**
Encore
 Yao Song (West China Hospital, Sichuan University)

P19-2 **演題取下**

P19-3 **FABP5 promoting the metastasis of HPV+ oropharyngeal carcinoma through reprogramming of fatty acid metabolism**
 Yufang Rao (The Department of Otorhinolaryngology, Head&Neck Surgery, West China Hospital, West China Medical School, Sichuan University, Sichuan, China)

P19-4 **演題取下**

P19-5 **Potential of ACTL6A and ERCC1 gene for cisplatin resistance among Locally advanced Head and Neck Cancer Patients**
 Raushan Kumar Chaudhary (Department of Pharmacy Practice, NGS Institute of Pharmaceutical Sciences (NGSMIPS), Nitte (Deemed to be University))

P19-6 **Inhibition of hypopharyngeal squamous cell carcinoma by a proteolysis targeting chimera of histone deacetylase 8**
 Phurinut Somchai (Faculty of Medicine Ramathibodi Hospital, Mahidol University)

P19-7 **The diversity of inhibitory receptor co-expression patterns of exhausted CD8+ T cells in oropharyngeal carcinoma**
Encore
 Yufang Rao (The Department of Otorhinolaryngology, Head&Neck Surgery, West China Hospital, West China Medical School, Sichuan University, Sichuan, China)

P19-8 **Prognostic value of hematological biomarker kinetics in head and neck squamous cell carcinoma patients**
 Yuki Kasahara (Department of Medical Oncology, Tohoku University Hospital)
血液学的バイオマーカーの動態と頭頸部扁平上皮癌患者の予後との関連
 笠原 佑記 (東北大学病院)

P19-9 **Induction of S/G2-M Phase Arrest and Apoptosis in HPSCC Through HDAC8 Degradation Mediated by HDAC8 PROTAC**
 Jiranant Chotitumnavee (Department of Pharmacology, Faculty of Dentistry, Mahidol University)

- P20-1 **The novel fusion gene GOLGB1-RET is a promising therapeutic target with Selpercatinib in papillary thyroid cancer**
Shogen Boku (Clinical Oncology, Kansai Medical University Hospital)
GOLGB1-RET 融合遺伝子を有する甲状腺がんに対するセルペルカチニブの臨床効果
朴 将源 (関西医科大学附属病院 臨床腫瘍科)
- P20-2 **Experience with dabrafenib and trametinib combination therapy for BRAF V600E-positive thyroid cancer at our institution**
Yuta Okumura (Department of Gastrointestinal and Medical Oncology, NHO Kyushu Cancer Center)
当施設における BRAF V600E 遺伝子変異陽性甲状腺がんに対するダブラフェニブ + トラメチニブ併用療法の使用経験
奥村 祐太 (国立病院機構九州がんセンター消化管・腫瘍内科)
- P20-3 **Clinical features of patients with advanced papillary thyroid cancer harboring fusion driver genes**
Chie Masaki (Department of Surgery, Ito Hospital)
融合遺伝子を有する進行甲状腺乳頭癌の臨床像
正木 千恵 (伊藤病院 外科)
- P20-4 **Selpercatinib Introduction in Papillary Thyroid Carcinoma Based on Genetic Testing of Pleural Effusion Cell Block**
Toshiki Oguma (Kyushu University Beppu Hospital)
胸水セルブロック検体の遺伝子検査からセルペルカチニブ導入に至った甲状腺乳頭癌の一例
小熊 俊輝 (九州大学病院別府病院)
- P20-5 **A case of TMB-high anaplastic thyroid cancer sensitive to treatment with pembrolizumab and sequent lenvatinib**
Keigo Takeuchi (Tohoku University School of Medicine)
TMB-high 甲状腺未分化がんに対してペムブロリズマブ及びレンバチニブが奏功した 1 例
竹内 圭吾 (東北大学医学部)
- P20-6 **Acute coronary syndrome after long-term administration of Lenvatinib for thyroid cancer**
Sakuya Koreishi (Department of medical oncology, Kyushu University Beppu Hospital)
レンバチニブ長期投与中に急性冠症候群を発症した甲状腺癌の一例
是石 咲耶 (九州大学病院別府病院 腫瘍内科)

Day 1 (Thu)
Day 2 (Fri)
Day 3 (Sat)
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Room 8
Room 9
Room 10
Room 11
Room 12
Room 13
Room 14
Meet the Experts
Poster

13:05-13:50 Poster Session 21

P21

Translational Research / Clinical Pharmacology 1 (Basic Research 1)
TR・臨床薬理 1 (基礎医学 1)

- P21-1 **Oxyresveratrol and resveratrol reduce lead-induced inflammation in human astrocytoma cells by inhibiting MAPK activation**
Putin Nudaeng (Faculty of Medicine Ramathibodi Hospital, Mahidol University)
- P21-2 **Exposure to Ozone increase melanogenesis expression in B16F10 cells and zebrafish**
Chi-jie Chang (National Sun Yat-sen University)
- P21-3 **Cytotoxicity of UV filters to skin keratinocytes and risk of endocrine disruption in endometrial stromal cells**
She-hung Chan (Providence University)
- P21-4 **Chemoresistant characterization and mechanism of olaparib in prostate cancer cells**
Tzyh-chyuan Hour (Department of Biochemistry, School of Medicine, Kaohsiung Medical University)
- P21-5 **Arbutin enhances chemotherapy sensitivity and reduces indoleamine 2,3-dioxygenase expression in melanoma and lung cancer**
Szu-chi Su (National Sun Yat-sen University)
- P21-6 **Effect of Carbon quantum dots derived from Artemisia argyi (Ai Cao) and Kazakhstani honey on the cancer and normal cells**
Aigerim Tassanbiyeva (Nazarbayev University)
- P21-7 **Salmonella suppresses breast cancer growth through induced autophagy and ferroptosis**
Pei-hsuan Chen (National Sun Yat-sen University)
- P21-8 **Invasive AhR phosphorylated by TPL2 induces the polarization of TAMs to promote immune escape and metastasis**
Meei-ling Sheu (National Chung Hsing University)
- P21-9 演題取下

13:05-13:50 Poster Session 22

P22

Translational Research / Clinical Pharmacology 2 (Basic Research 2)
TR・臨床薬理 2 (基礎医学 2)

- P22-1 演題取下
- P22-2 **Salmonella reduced tumor growth by downregulating Glutathione peroxidase 4 protein**
Shih Han Chiu (National Sun Yat-sen University)
- P22-3 **Cysteine mediated Olaparib and Crizotinib combination therapy**
Aruzhan Onggarbek (Nazarbayev University)

- P22-4 **Unveiling the Oncogenic Roles of MGAM in colorectal cancer: Implications for Precision Oncology and Drug Repurposing**
Seyed Mahdi Hassanian Mehr (Dept of Medical Biochemistry, mashhad university of medical sciences)
- P22-5 **Simvastatin and Troglitazone Synergize to Inhibit ccRCC Progression via LKB1/ AMPK and PPARgamma-Dependent Mechanisms**
Shu-hui Juan (Department of Physiology, Taipei Medical University)
- P22-6 **AXL signaling promotes adaptive resistance to HER2 tyrosine kinase inhibitors in HER2 aberrant tumor cells**
Masaki Ishida (Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kajii-cho, Kamigyo-ku, Kyoto, Japan)
HER2 阻害薬治療による AXL シグナルを介した初期抵抗性機構とその克服法の開発
石田 真樹 (京都府立医科大学附属病院)
- P22-7 **Abatacept ameliorates cardiac hypertrophy in rats via altering T lymphocyte subpopulations and activating autophagy**
Vaishali Prajapati (All India Institute of Medical Sciences)
- P22-8 **Investigation of drugs that enhance the efficacy of hematopoietic stem cell pre-transplantation drugs**
Marin Sagawa (Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences)
造血幹細胞移植前処置薬の薬効を増強する薬剤の探索
佐川 真琳 (徳島大学大学院 医歯薬学研究部 臨床薬理学)

13:05-13:50 Poster Session 23

P23 Translational Research / Clinical Pharmacology 3 (Clinical Pharmacology)
TR・臨床薬理 3 (臨床薬理)

- P23-1 **Impact of Self-Medication Practices on Chronic Pain Management and Quality of Life in Oncology and Skin Cancer Patients**
Dinesh Joshi (Mahabaudha Medical Center)
- P23-2 **Association of Abemaciclib Plasma Concentration with Adverse Drug Reactions in Breast Cancer Patients**
Keisuke Ikegami (Department of Pharmacy, National Cancer Center Hospital)
乳がん患者における血漿アベマシクリブ濃度と薬物有害反応との関連性
池上 慶祐 (国立がん研究センター中央病院 薬剤部)
- P23-3 **Association between ABCC2 -24C>T and nab-paclitaxel-induced peripheral neuropathy in patients with pancreatic cancer**
Hana Nakayama (Department of Cancer Genome and Pharmacotherapy)
膵臓がん患者におけるナブパクリタキセル誘発性末梢神経障害と ABCC2 -24C>T との関連
中山 華 (昭和大学)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

- P23-4 **Dynamic Relationship Between Biomarkers and Global Longitudinal Strain in Breast Cancer Patients Receiving Anthracycline**
 Kyohei Daigo (Department of Cardiology, Keio University School of Medicine)
アントラサイクリンを投与された乳癌患者における、バイオマーカーと Global longitudinal strain の経時的な関係性について
 醍醐 恭平 (Department of Cardiology, Keio University School of Medicine)
-
- P23-5 **A polymorphism in ABCC3 is associated with capecitabine-induced hand-foot syndrome and capecitabine pharmacokinetics**
 Kengo Omata (Division of Cancer Genome and Pharmacotherapy, Showa University School of Pharmacy)
ABCC3 の遺伝子多型とカペシタビンによる手足症候群及びカペシタビンの体内動態との関連
 小俣 賢吾 (昭和大学薬学部がんゲノム医療薬学部門)
-
- P23-6 **演題取下**
-
- P23-7 **Transcriptomics-Based Drug Repurposing Meta-Analysis Identifies Compounds For Paclitaxel-Induced Peripheral Neuropathy**
 Kord M Kober (University of California San Francisco)
-
- P23-8 **Prognostic and clinicopathological insights of phosphodiesterase 9A gene as novel biomarker inhuman prostate cancer**
 Mst Mahmuda Khatun (Research Trainee, Oncology Department, University of Wisconsin-Madison, USA)
-
- P23-9 **In Vitro And In Vivo Study Of Antitumorigenic Effects Of Nanoparticles Of Berberine Against Glioblastoma Multiforme**
 Suimit Rajput (B V Deemed medical college and hospital)
-
- P23-10 **Antitumorigenic effect of silver nanoparticle in experimental breast cancer rat model**
 Ankush Kumar (Shakuntala Hospital And Research Center)
-
- 13:05-13:50 Poster Session 24
-
- P24** Multidisciplinary Team Program 1 (Interdisciplinary Approach to Cancer Care 1)
 多職種連携プログラム 1 (チーム医療 1)
-
- P24-1 **An Integrated Approach to Managing Cancer Cachexia: The Role of Acupuncture**
 Yuanti Yunus Konda (Medical Acupuncture Study Program, University of Indonesia)
-
- P24-2 **Demographic and Acupuncture Utilization of Cancer Patients Undergone Acupuncture Therapy at Cipto Mangunkusumo Hospital**
 Inria Chandra (Medical Acupuncture Study Program, Faculty of Medicine, Universitas Indonesia)
-
- P24-3 **Skin Cancer in Organ Transplant Recipients: Importance of Early Diagnosis and Care in Resource-Limited Settings**
 Mandeep D Joshi (Mahabaudha Medical Center)
-
- P24-4 **A Case Series of Local Ablative Therapy in Oligo-progressive EGFR-mutated Non-small Cell Lung Cancer in Singapore**
 Ke Xin Bok (National Cancer Centre Singapore)

- P24-5 **Thoracic Oncology MDTC: A survey study on the perceptions and opinions of healthcare teams**
Alfred Patrick D Mina (The Medical City, Augusto P. Sarmiento Cancer Institute)
- P24-6 **Application of modified PG-SGA tool in the diagnosis of malnutrition in patients with lung cancer**
Ning Lin (The General Hospital of the Western Theater Command, Southwest Jiaotong University)
- P24-7 **The impact of the introduction of a pegfilgrastim autoinjector on medical staff's time spent writing medical record**
Yudai Ishikawa (Department of Pharmacy, Toyama university hospital)
ペグフィルグラスチム自動注入型製剤の導入が医療者のカルテ記載時間に及ぼす影響
石川 雄大 (富山大学附属病院 薬剤部)
- P24-8 **Questionnaire for breast cancer patients and nurses on usage and satisfaction with pegfilgrastim automated dosing device**
Mutsuyo Takaesu (Department of nursing, Nahanishi Clinic)
乳がん患者および看護師を対象にしたペグフィルグラスチム自動投与デバイスの使用感と満足度に関するアンケート調査: 多施設共同、前向き、患者団体参画型調査 (最終報告)
高江洲 睦代 (医療法人那覇西会那覇西クリニック 看護部)
- 13:05-13:50 Poster Session 25
- P25** Multidisciplinary Team Program 2 (Interdisciplinary Approach to Cancer Care 2)
多職種連携プログラム 2 (チーム医療 2)
- P25-1 **Investigation of hypothyroidism caused by irAE and the involvement of the pharmacist**
Akiko Matsuda (Department of Pharmacy, Kitakyushu Municipal Medical Center)
当院における irAE による甲状腺機能低下症の検討と薬剤師の関わり
松田 亜希子 (北九州市立医療センター薬剤課)
- P25-2 **Kidney Toxicity of Immune Checkpoint Inhibitors: An Onconephrology Study from a Multi-Ethnic Cohort in Southeast Asia**
Jia Yee Wong (Faculty of Medicine, University of Malaya)
- P25-3 **Reformation of the Multidisciplinary irAE Management Team, ImPACT**
Izumi Ohno (Department of Medical Oncology, Chiba University Hospital)
多領域多職種 irAE 診療チーム ImPACT の進化
大野 泉 (千葉大学医学部附属病院 腫瘍内科)
- P25-4 **Safety of High-Dose Steroid Treatment for irAE in Outpatients**
Takako Inoue (Osaka International Cancer Institute)
免疫関連有害事象に対する外来における高用量ステロイド治療の安全性
井上 貴子 (大阪国際がんセンター)
- P25-5 **Fact-finding survey of immune-related adverse events (irAE) in patients receiving Nivolumab at our hospital**
Hiromi Fujimori (pharmacy)
当院におけるニボルマブ投与患者の免疫関連有害事象 (irAE) の実態調査
藤森 浩美 (岡山済生会総合病院薬剤部)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

P25-6 **The approach of pharmacists in cancer genomic medicine at National Cancer Center Hospital East**

Kaede Baba (Department of Pharmacy, National Cancer Center Hospital East)

国立がん研究センター東病院におけるがんゲノム医療への薬剤師の取り組み

馬場 楓 (Department of Pharmacy, National Cancer Center Hospital East)

P25-7 **Our efforts as a cooperative hospital for cancer genomic medicine expert panels can be conducted and future challenges**

Dai Inoue (Tokyo Metropolitan Tama Medical Center)

エキスパートパネル可能がんゲノム医療連携病院としての当院の取り組みと今後の課題

井上 大 (東京都立多摩総合医療センター)

ポスター② (神戸国際展示場 3号館 1階 展示室)

13:05-13:50 Poster Session 26

P26 Lung Cancer / Thoracic Cancer 1 (Non-Small Cell Lung Cancer 1 (Immunotherapy 1))
呼吸器 1 (非小細胞肺癌 1 (免疫療法 1))

- P26-1 **Characteristic of cytokines in non-small cell lung cancer and the correlation with efficacy of immunotherapy**
Jia-yi Deng (School of Medicine, South China University of Technology)
- P26-2 **FGA as Serum Biomarker for Predicting Response of Cisplatin and Gemcitabine Doublet Chemotherapy in Lung Adenocarcinoma**
Pritsana Raungrut (Prince of Songkhla University)
- P26-3 **Role of ctDNA in Monitoring Treatment Efficacy and Predicting Outcomes in NSCLC Patients: A Systematic Review**
Michelle G Kumala (Faculty of Medicine, Pelita Harapan University)
- P26-4 **Clinical impact of TTF-1 expression pattern on the efficacy of immune-checkpoint inhibitor in non-squamous NSCLC**
Kohei Shibayama (Department of Respiratory Medicine, Juntendo University)
進行非扁平上皮非小細胞肺癌における Thyroid Transcription Factor-1 発現様式が免疫チェックポイント阻害薬の治療効果に及ぼす臨床的影響
芝山 浩平 (順天堂大学呼吸器内科学講座)
- P26-5 **Efficacy of immune checkpoint inhibitors in invasive mucinous adenocarcinoma**
Naoki Inoshima (Department of Thoracic Oncology, National Cancer Center Hospital East)
浸潤性粘液産生性腺癌における免疫チェックポイント阻害薬の有効性についての検討
猪島 直樹 (国立がん研究センター東病院 呼吸器内科)
- P26-6 **Efficacy of ABCP Therapy in Non-Small Cell Lung Cancer Patients with Gene Mutations**
Tsunehiro Tanaka (Respiratory Medicine)
遺伝子変異を有する非小細胞肺癌患者における ABCP 療法の有用性について
田中 庸弘 (大阪国際がんセンター 呼吸器内科)
- P26-7 **Influence of renal function of immune checkpoint inhibitors with chemotherapy for NSCLC: a retrospective analysis**
Takayo Ota (Izumi City General Hospital)
非小細胞肺癌における免疫チェックポイント阻害剤 + 化学療法併用に対する腎機能の影響
大田 隆代 (和泉市立総合医療センター)

13:05-13:50 Poster Session 27

P27 Lung Cancer / Thoracic Cancer 2 (Non-Small Cell Lung Cancer 2 (Immunotherapy 2))
呼吸器 2 (非小細胞肺癌 2 (免疫療法 2))

- P27-1 **Influence of age difference on immune checkpoint inhibitors with chemotherapy for NSCLC: a retrospective analysis**
Takayo Ota (Izumi City General Hospital)
非小細胞肺癌における免疫チェックポイント阻害剤 + 化学療法併用療法に対する年齢の影響
大田 隆代 (和泉市立総合医療センター)

P27-2	Efficacy of Durvalumab and Tremelimumab versus Chemotherapy in Metastatic Non-small Cell Lung Cancer: A Meta-Analysis Yewan Lim (Faculty of Medicine, Pelita Harapan University)
P27-3	Prognostic utility of neutrophil-to-lymphocyte ratio in non-small cell lung cancer with brain metastases: A metaanalysis Pratik Lamichhane (Ministry of Health and Population, GP Koirala National Center for Respiratory Diseases)
P27-4	Stratifin/14-3-3 sigma and Therapeutic Efficacy of Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer Daiki Murata (Kurume University School of Medicine) Stratifin/14-3-3 σ と非小細胞肺癌に対する免疫チェックポイント阻害薬の治療効果に関する検討 村田 大樹 (久留米大学病院)
P27-5	Comparison of Overall Survival between Molecular Targeted Therapy and Immunotherapy in Advanced Lung Cancer Kei Kunimasa (Osaka International Cancer Institute) 進行期肺癌における分子標的治療と免疫療法の全生存率の比較：単施設の後向き研究 國政 啓 (大阪国際がんセンター)
P27-6	Effectiveness and Safety of Combination ICI and chemotherapy in Advanced NSCLC: A Single Facility Retrospective Study Naruo Yoshimura (Department of Respiratory Medicine, Tohoku Medical and Pharmaceutical University, Faculty of Medicine) 進行非小細胞肺癌がん症例に対する免疫チェックポイント阻害薬と化学療法併用の効果と安全性：単施設後方視的研究 吉村 成央 (東北医科薬科大学医学部 呼吸器内科)
P27-7	Neutrophil Count as a Predictive Marker for Efficacy of Combination Immunotherapy in Advanced Non-Small Cell Lung Cancer Yuki Akazawa (Department of Respiratory Medicine, Kitasato University School of Medicine) 進行非小細胞肺癌における免疫複合療法の予後予測マーカーとしての好中球数の影響 赤澤 悠希 (北里大学病院)
13:05-13:50 Poster Session 28	
P28	Lung Cancer / Thoracic Cancer 3 (Non-Small Cell Lung Cancer 3 (Immunotherapy 3)) 呼吸器 3 (非小細胞肺癌 3 (免疫療法 3))
P28-1	Efficacy and Safety of Cemiplimab in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis William S Atmaja (Pelita Harapan University, Faculty of Medicine)
P28-2	Modulating CXCR4, CXCL12, and S1PR5 with 1,5-Benzothiazepine Derivatives to Enhance Immune Response in NSCLC Rizki Rachmad Saputra (Department of Chemistry, Universitas Palangka Raya)
P28-3	A Comparative Analysis of Pembrolizumab vs Chemotherapy in Advanced PD-L1+ NSCLC: A meta-analysis Maria Georgina Wibisono (Faculty of Medicine, Pelita Harapan University)

- P28-4 **Comparison of chemoimmunotherapy regimens in patients with advanced non-squamous NSCLC with low PD-L1 expression**
 Yoshiki Negi (Department of Respiratory Medicine and Hematology, Hyogo Medical University, School of Medicine)
PD-L1 低発現進行非扁平上皮非小細胞肺癌における複合免疫療法レジメン別の評価：後方視的観察研究
 柘木 芳樹 (兵庫医科大学)
- P28-5 **Risk factor and prognosis of immune checkpoint inhibitor-induced pneumonia in lung cancer with interstitial lung disease**
 Tsukasa Ueda (Department of Respiratory Medicine)
間質性肺炎合併肺癌における免疫チェックポイント阻害薬による肺臓炎リスク因子と予後の検討
 上田 幸 (金沢大学附属病院 呼吸器内科)
- P28-6 **Comparison of the effects of ICI re-administration based on the presence or absence of local therapy in NSCLC**
 Satoshi Hirano (Department of Medical Oncology, Funabashi Municipal Medical Center)
ICI 開始後に増悪した非小細胞肺癌に対する、局所治療の有無別に見た ICI 再投与の効果の比較
 平野 聡 (船橋市立医療センター腫瘍内科)
- P28-7 **The Comparison of Single ICI versus Dual ICI-ICI for Untreated Non-small cell lung cancer with Negative PD-L1 Expression**
 Tomohiro Tanaka (Niigata University Medical & Dental Hospital)
当院における未治療 PD-L1 陰性の進行非小細胞肺癌に対する dual-ICI と single-ICI を比較する後方視的研究
 田中 知宏 (新潟大学医歯学総合病院)

13:05-13:50 Poster Session 29

P29 Lung Cancer / Thoracic Cancer 4 (Non-Small Cell Lung Cancer 4 (Locally Advanced))
 呼吸器 4 (非小細胞肺癌 4 (局所進行))

- P29-1 **The efficacy and safety of weekly CBDCA plus PTX with radiotherapy in older patients with locally advanced NSCLC**
 Manami Harada (Department of Pharmacy, National Cancer Center Hospital East)
高齢者非小細胞肺癌患者に対する weekly CBDCA+PTX を用いた化学放射線療法の有効性および安全性に関する後方視的研究
 原田 まなみ (国立がん研究センター東病院 薬剤部)
- P29-2 **Real-world treatment patterns/clinical outcomes in Japanese patients with unresectable stg III EGFRm NSCLC receiving CRT**
 KAZUMI NISHINO (Department of Thoracic Oncology, Osaka International Cancer Institute)
CRT が施行された EGFR 遺伝子変異を有する切除不能 stage III 期 NSCLC 日本人症例の実臨床における治療パターンと臨床効果
 西野 和美 (Department of Thoracic Oncology, Osaka International Cancer Institute)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

P29-3 **Analysis of patients who were treated with durvalumab after chemoradiotherapy in non-small-cell lung cancer**
Takafumi Okabe (Izumi City General Hospital)

当院において非小細胞肺癌に対して化学放射療法後にデュルバルマブを投与した症例の検討
岡部 嵩記 (和泉市立総合医療センター)

P29-4 **The prognostic relevance of LC3-II, Caspase-3, and Caspase-9, in non-small cell lung cancer (NSCLC) patients**
Mirza Masroor Ali A Beg (Faculty of Medicine, Alatoo International University)

P29-5 **Withdrawn**

P29-6 **Comparative Efficacy of Different ALK Inhibitors in Treating ALK-Positive NSCLC : A Network Meta-Analysis**
Diski Saisa (Clinical Clerkship Program, Faculty of Medicine, Dr. Cipto Mangunkusumo National General Hospital)

P29-7 **Risk factors for Durvalumab-Associated Pneumonitis after chemoradiotherapy in stage III nonsmall cell lung cancer**
Takashi Gohtsu (Tsuboi hospital)

非小細胞肺癌 stage IIIにおける化学放射線療法後のデュルバルマブ投与による肺障害発現のリスク因子の検討
合津 貴志 (一般財団法人 慈山会医学研究所付属 坪井病院 薬剤部)

P29-8 **Impact of EGFR mutation on the efficacy of Durvalumab following CRT in patients with locally advanced non-squamous NSCLC**
Keita Miura (Division of Thoracic Oncology, Shizuoka Cancer Center)

局所進行非扁平上皮非小細胞肺癌に対する CRT 後の Durvalumab の治療効果に EGFR 遺伝子変異が与える影響
三浦 啓太 (静岡県立静岡がんセンター 呼吸器内科)

13:05-13:50 Poster Session 30

P30 Lung Cancer / Thoracic Cancer 5 (Case Report 1)
呼吸器 5 (ケースレポート 1)

P30-1 **A case of lung adenocarcinoma with a rapid death outcome due to cytokine release syndrome during nivolumab monotherapy**
Tomomi Nakamura (JCHO Saga Cyubu Hospital)

ニボルマブ単剤療法中にサイトカイン放出症候群を来し、4日間で急速な転帰をたどった肺腺癌の一例
中村 朝美 (佐賀中部病院)

P30-2 **Structurally rare EML4-ALK identified by next generation sequencing in a NSCLC patient with bilateral ovarian metastases**
Ryusuke Maruta (Respiratory medicine)

次世代シーケンサーにより同定された両側卵巣転移を有する非小細胞肺癌患者における構造的に稀な EML4-ALK バリエーションの一例
丸田 竜介 (東京都立墨東病院 呼吸器内科)

- P30-3 **Pulmonary carcinoid harboring KRAS G12C mutation; a case report**
Kosuke Hamai (Onomichi General Hospital)
KRAS G12C 変異陽性の肺カルチノイドの一例
濱井 宏介 (尾道総合病院)
- P30-4 **Invasive mucinous adenocarcinoma treated with immune checkpoint inhibitors: A review of four cases**
Tatsuya Kato (Toranomon Hospital)
浸潤性粘液性腺癌に対して免疫チェックポイント阻害薬を使用した4例
加藤 達也 (虎の門病院)
- P30-5 **Marked Response to Chemo-immunotherapy in Lung Adenocarcinoma with de novo MET Amplification Presented with SVC Syndrome**
Eri Kimura (Medical oncology)
上大静脈症候群で発症し化学療法が著明に奏功した de novo MET amplification 低分化肺腺癌の1例
木村 恵理 (亀田総合病院腫瘍内科)
- P30-6 **Pathological Complete Response in Locally Advanced ALK Fusion Gene-Positive Lung Cancer Following Salvage Surgery**
Kazuki Ota (Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine)
ALK 融合遺伝子陽性局所進行肺癌に対するサルベージ手術の1例
太田 和貴 (大分大学医学部 呼吸器・乳腺外科学講座)
- P30-7 **Response of Crizotinib in Advanced non-small cell lung cancer harboring HLA-DRB1 MET fusion**
Pattarapong Satjaritanun (Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University)
- P30-8 **A novel strategy for the operation of pulmonary sequestration based on ICG fluorescence imaging**
Qing Liang (GuangDong Lung Cancer Institute)

13:05-13:50 Poster Session 31

- P31** Hematologic Malignancies 1 (Leukemia 1)
血液 1 (白血病 1)
- P31-1 **IL-3 enhances metaphase yield in leukemia bone marrow karyotyping**
Encore Sastrawut Zatun (Khon Kaen University)
- P31-2 **演題取下**
- P31-3 **RNA sequencing reveals potential therapeutic vulnerabilities in DUX4-rearranged B acute lymphoblastic leukemia**
Mercilena Benjamin (All India Institute of Medical Sciences)
- P31-4 **Unveiling the Genetic Landscape of Imatinib Resistance in Chronic Myeloid Leukemia: Implications for Targeted Therapies**
Sikha Morang (Department of Pharmacology, All India Institute of Medical Sciences-Rishikesh)
- P31-5 **Kinase Domain Mutations in Chronic Myeloid Leukemia: Characteristics and Clinical Implications**
Ganesh Kumar Viswanathan (All India Institute of Medical Sciences (AIIMS))

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

13:05-13:50 Poster Session 32

P32 Hematologic Malignancies 2 (Leukemia 2)
血液 2 (白血病 2)

- P32-1 **Maternal Smoking Exposure During Pregnancy and Childhood Acute lymphoblastic Leukemia incidence**
Elsye Susilo (Pelita Harapan University, Faculty of Medicine)
- P32-2 **Withdrawn**
- P32-3 **Clinical investigation of correlation between WT-1 mRNA expression and survival after treated with Bcl-2 inhibitor**
Aya Nakano (Dept of Oncol. & Hematol., Jikei Univ.)
Bcl-2 阻害薬による治療後の生存期間と WT-1mRNA 値の相関についての臨床的検証
仲野 彩 (東京慈恵会医科大学附属病院)
- P32-4 **VASH1 Expression in Acute Myeloid Leukemia: Implications for Prognosis and Therapeutic Targeting**
Avanish Kumar Pandey (All India Institute of Medical Sciences, New Delhi)
- P32-5 **演題取下**
- P32-6 **Study for establishment of BCR-ABL1 mutation analysis test using nanopore sequencing**
Hinako Ota (Clinical Development Section 1 Department of Fundamental Technology & Development Research & Development Division)
ナノポアシーケンシングを使用した BCR-ABL1 変異解析検査法の確立
大田 ひな子 (株式会社エスアールエル)
- P32-7 **Targeting Altered Autophagy in AML: A Pathway to Understanding Leukemic Stem Cell and Relapse**
Aafreen Khan (LABORATORY ONCOLOGY, DR B.R.A. IRCH, ALL INDIA INSTITUTE OF MEDICAL SCIENCES, DELHI)
- P32-8 **Outcomes of CAR T-Cell Therapy in Pediatric & Young Adult With B-Cell Acute Lymphoblastic Leukemia : A Systematic Review**
Melanie D Sembiring (Faculty of Medicine, Pelita Harapan University)

13:05-13:50 Poster Session 33

P33 Hematologic Malignancies 3 (Case Report 1)
血液 3 (ケースレポート 1)

- P33-1 **Genomic analysis of a rare lymphoma patient with periodic fever and dynamic changes in lactate dehydrogenase**
Shingen Nakamura (Department of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences)
周期的な発熱と LDH 上昇を呈する稀なリンパ腫症例のゲノム解析
中村 信元 (徳島大学大学院医歯薬学研究部実践地域診療・医科学分野)

- P33-2 **A case of IL-17 overproducing ALCL with multiple organ failure due to cytokine storm syndrome**
 Shohei Kikuchi (Department of Hematology, Toyama University Hospital)
サイトカインストーム症候群による多臓器不全を続発した IL-17 高産生未分化大細胞型リンパ腫
 菊地 尚平 (富山大学附属病院 血液内科)
- P33-3 **Withdrawn**
- P33-4 **Methotrexate-associated B-cell lymphoproliferative disease that exhibited hematuria due to urinary bladder lesions**
 Masahiro Manabe (Hematology, Osaka General Hospital of West Japan Railway Company)
膀胱病変に起因した血尿がみられたメントレキセート関連リンパ増殖性疾患
 間部 賢寛 (西日本旅客鉄道株式会社 大阪鉄道病院 血液内科)
- P33-5 **ASCT and subsequent dual specific BCMA/GPRC5D targeted CART for relapsed/refractory IgD multiple myeloma: A case report**
 Hai Yi (Institute of Hematology, Department of Hematology, People's Liberation Army The General Hospital of Western Theater Command, Sichuan Clinical Research Center for Hematological Disease, Branch of National Clinical Research Center for Hematological Disease, Chengdu, Sichuan, China)
- P33-6 **Primary Gastric Burkitt Lymphoma in an Adult Patient**
 Carl Lawrence Arenos (University of the Philippines-Philippine General Hospital)
- P33-7 **Using Point-of-Care Ultrasound-Guided Bone Marrow Biopsy in an Obese Patient: A Case Report and Literature Review**
 Yu-ting Lin (Division of Breast Surgery, Department of Surgery, Taichung Veterans General Hospital)
- P33-8 **Non-Hodgkin Lymphoma of the Nasopharynx with metastasis to the distal thigh- a case report**
 Paolo Reuben B Cardenas (Section of Medical Oncology, Veterans Memorial Medical Center)

13:05-13:50 Poster Session 34

P34 Rare Cancer / Cancer of Unknown Primary 1 (Sarcoma 1)
 希少がん・原発不明がん 1 (肉腫 1)

- P34-1 **Osteosarcoma of the Maxilla, an unusual presentation from a common tumor, a case report**
 Paolo Reuben B Cardenas (Section of Medical Oncology, Veterans Memorial Medical Center)
- P34-2 **A case of ALK-positive epithelioid and spindle rhabdomyosarcoma (RMS) achieving disease control with Alectinib**
 Kyosuke Seguchi (Kameda Medical Center)
Alectinib にて病勢制御が得られた ALK 陽性 epithelioid and spindle rhabdomyosarcoma の一例
 瀬口 京介 (亀田総合病院)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

- P34-3 **A case of MDM2-amplified prostate leiomyosarcoma that responded chemotherapy, but had ultimately poor prognosis**
Toshiki Oba (Oncology)
予後不良であった再発性前立腺平滑筋肉腫の一例
大場 俊輝 (亀田総合病院)
- P34-4 **A CASE OF NONMETASTATIC UNRESECTABLE EWING SARCOMA**
Peres P Girisa (AIC Kijabe Hospital)
- P34-5 **Unravelling the Enigma: A Rare Case of Pleural Spindle Cell Carcinoma in National Cancer Institute, Putrajaya**
Patricia S Soosainathan (Department of Radiotherapy and Oncology, National Cancer Institute (NCI), Putrajaya)
- P34-6 **Rhabdomyosarcoma-Related Myocardial Metastasis Leading to Refractory Lethal Arrhythmia: A Case Report**
Koji Hikino (Department of Clinical Oncology, Shonan Kamakura General Hospital)
難治性致死性不整脈が併発した横紋筋肉腫の一例
引野 幸司 (湘南鎌倉総合病院)
- P34-7 **PROFILE OF GASTRO-INTESTINAL STROMAL TUMOR (GIST) PATIENTS IN DR CIPTO MANGUNKUSOMO HOSPITAL INDONESIA**
Nugraheny P Purlikasari (RSUPN Cipto Mangunkusumo)
- P34-8 **PRIMARY OSTEOSARCOMA OF THE RIB IN ASYMPTOMATIC 31-YEAR-OLD MALE: A CASE REPORT**
Gervie Flor S Batucan (Southwestern University Medical Center)
- P34-9 **Role of Adjuvant Radiotherapy Post-Surgery of Osteosarcoma: A Systematic Review and Meta-Analysis**
Indra Kusuma (Faculty of Medicine, Pelita Harapan University)
- P34-10 **Primary renal Ewing's sarcoma with bone and lung metastasis, along with brachial plexus involvement**
Pichamon Chaloeprat (Faculty of Medicine Ramathibodi Hospital, Department of Medicine)
- P34-11 **A case of epithelioid hemangioendothelioma with three years of tumor control with pazopanib**
Makoto Usami (Department of Medical Oncology, Steel Memorial Muroran Hospital)
パゾパニブにより3年間の腫瘍制御が得られた類上皮血管内皮腫の1例
宇佐美 信 (製鉄記念室蘭病院 腫瘍内科)

13:05-13:50 Poster Session 35

P35 Rare Cancer / Cancer of Unknown Primary 2 (Sarcoma 2)
希少がん・原発不明がん 2 (肉腫 2)

- P35-1 **Effective immune-based treatment of extraskeletal myxoid chondrosarcoma guided by next-generation gene profiling**
Evgeniy Galitskiy (BostonGene, Corp.)
- P35-2 **Dedifferentiated liposarcoma of the spermatic cord presented with a growing inguinal mass: A case report**
Tanwimon Techasatian (Great Life Cancer Center, Phyathai Hospital)

P35-3	Desmoid tumour growth post-surgery - fact or fiction Han Yi Lee (National Cancer Centre Singapore)
P35-4	A Case of Emergency Surgery for Undiagnosed Arterial Angiosarcoma Anna Tsuji (Department of Cardiovascular Surgery, Nippon Medical School Musashi Kosugi Hospital) 呼吸不全により緊急摘除術を要した、未診断左房血管肉腫の一例 辻 杏奈 (日本医科大学武蔵小杉病院 心臓血管外科)
P35-5	The treatment experience of desmoplastic small round cell tumor (DSRCT) Mai Shimura (Department of Medical Oncology, National Cancer Center Hospital East) 当院における線維形成性小円形細胞性腫瘍 (desmoplastic small round cell tumor: DSRCT) の治療成績 志村 麻衣 (国立がん研究センター東病院 腫瘍内科)
P35-6	Retrospective analysis on the frequency of Cardiotoxicity in soft tissue sarcoma patients treated with doxorubicin Kenji Nakano (Cancer Institute Hospital of Japanese Foundation for Cancer Research) ドキソルビシン治療を受けた軟部肉腫症例における心毒性の頻度並びにモニタリング体制についての後方視的報告 仲野 兼司 (がん研究会有明病院)
P35-7	Case report: Effective use of blood comprehensive genomic profiling test in managing carcinosarcoma with heterogeneity Masaki Takinami (Iwata city hospital) 不均一性を伴う癌肉腫において血液での包括的がんゲノムプロファイリング検査が有効であった一例 瀧浪 将貴 (磐田市立総合病院)
P35-8	Soft Tissue Ameloblastoma - A Rare Case and Diagnostic Challenge Farah Mardhiyah (Research Assistant, Oncology Surgery Division, Department of Surgery, Arifin Achmad General Hospital)
P35-9	Targeting Lysine-specific demethylase 1 as a valid therapeutic approach for MPNST therapy Guan-yi Lai (Taipei Medical University)
P35-10	Pathological complete response after neoadjuvant treatment for Primary Pulmonary Undifferentiated Pleomorphic Sarcoma Tanaporn Prateepchaiboon (Medical Oncology Unit, Department of Internal Medicine, Hatyai Hospital)
P35-11	Chemotherapy for retroperitoneal sarcoma: real world experience in a single institute Osamu Maeda (Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital) 後腹膜肉腫に対する化学療法 前田 修 (名古屋大学医学部附属病院 化学療法部)

P36 Rare Cancer / Cancer of Unknown Primary 3 (Other 1)
 希少がん・原発不明がん 3 (その他 1)

- P36-1** **A carcinoma of unknown primary case with NTRK1 fusion concomitant with TMB-High and MSI-High**
 Hirofumi Sato (Department of Surgery, Takagi hospital)
NTRK1 融合遺伝子と高い腫瘍遺伝子変異量, 高頻度マイクロサテライト不安定性を合併した原発不明がんの一例
 佐藤 博文 (高木病院 外科)
- P36-2** **Unknown Primary Cancer Similar to Histology of Cervical Cancer with Long-Term Survival by Multidisciplinary Treatment**
 Norio Emoto (Takeda General Hospital)
集学的治療により 10 年以上の長期生存が得られている子宮頸癌の組織像に類似する原発不明癌の一例
 江本 憲央 (医仁会武田総合病院)
- P36-3** **A case of adenocarcinoma of unknown primary with germline BRCA2 mutation achieved long-term response to PARP inhibitor**
 Misako Muraoka (Department of Medical Oncology, Kindai University Hospital)
生殖細胞系列 BRCA2 変異に対する個別化治療として投与されたオラパリブにより長期奏効が得られた原発不明癌の 1 例
 村岡 未沙子 (近畿大学病院 腫瘍内科)
- P36-4** **A case of cancer of unknown primary with enteric phenotype and cancerous meningitis, showed response to mFOLFOX regimen**
 Haruka Yamanokawa (Department of Hematology and Medical Oncology, Kanagawa Cancer Center)
癌性髄膜炎で発症した CUP に対し、mFOLFOX 療法を導入し奏効がみられてきている症例
 山ノ川 晴花 (Department of Hematology and Medical Oncology, Kanagawa Cancer Center)
- P36-5** **A Rare Case of Pseudomyxoma Peritonei in a 70-year-old Male Presenting with Massive Ascites**
 Eleni Marie G Turno (Northern Mindanao Medical Center)
- P36-6** **Laparoscopic visual therapeutic effect of nivolumab plus ipilimumab in a malignant peritoneal mesothelioma patient**
 Ren Seike (Department of Respiratory Medicine, Hiroshima City Hiroshima Citizens Hospital)
ニボルマブ + イピリムマブ併用療法による著明な腫瘍縮小効果を腹腔鏡で視認できた悪性腹膜中皮腫の 1 例
 清家 廉 (広島市立広島市民病院)
- P36-7** **A case of Ipilimumab plus Nivolumab combination therapy for malignant peritoneal mesothelioma**
 Masaru Fukahori (Multidisciplinary Treatment Cancer Center, Kurume University Hospital)
診断に難渋した悪性腹膜中皮腫に対して Ipilimumab+Nivolumab 併用療法を行った 1 例
 深堀 理 (久留米大学病院)
- P36-8** **Heat to hope: Outcomes of Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery - A Sri Lankan Experience**
 Heshan D Siriwardena (Teaching Hospital, Kurunegala)

P36-9 **Complete Response of mTOR Inhibitor Everolimus against Malignant Perivascular Epithelioid Cell Tumor**

Rika Sasaki (Department of Cancer Genomics and Medical Oncology, Nara medical University)

mTOR 阻害薬エベロリムスにより完全寛解に至った悪性 PEComa の一例

佐々木 里歌 (奈良県立医科大学 がんゲノム・腫瘍内科)

P36-10 **Angiosarcoma of the scalp that was successfully treated with concurrent paclitaxel and radiation in an elderly patient**

Nae Itagaki (Kameda General Hospital Oncology Department)

頭部血管肉腫に対してパクリタキセルを用いた化学放射線療法が奏効した超高齢患者の一例

板垣 奈恵 (亀田総合病院)

P36-11 **Lesion-level immune microenvironment relates with personalized neoantigen vaccine responses in a liposarcoma patient**

Hanbing Wang (Department of Oncology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China)

13:05-13:50 Poster Session 37

P37 Cross-sectional Program 1

臓器横断プログラム 1

P37-1 **Evaluating the Association of Genetic Versus Organ Factors in Chemotherapy Response Across Multiple Drug Classes**

Naoya Ishibashi (Department of Precision Cancer Medicine, Tokyo Medical and Dental University Hospital)

化学療法奏効における遺伝子異常要因と臓器要因の比較分析

石橋 直弥 (東京医科歯科大学病院 がんゲノム診療科)

P37-2 **Four cases treated with off-label use based on comprehensive genomic profiling (CGP)**

Ryuji Hayashi (Toyama University Hospital)

がん遺伝子パネル検査の結果に基づき保険適用のない薬剤を使用した 4 例

林 龍二 (富山大学附属病院)

P37-3 **Accessibility to off-label drugs after Cancer Genomic Profiling tests in Japan -patients with BRAF V600E mutation**

Yayoi Ando (National Cancer Center Hospital)

本邦における遺伝子パネル検査後の適応外薬へのアクセスに関する研究—BRAF V600E 変異を有する症例の検討

安藤 弥生 (国立がん研究センター中央病院)

P37-4 **Progress and Challenges in Cancer Genomic Medicine from a Clinician's Perspective**

Ayaka Igarashi (INTAGE Healthcare Inc.)

臨床医の視点で見るがんゲノム医療の進展と課題 ～アンケート調査から浮かび上がる CGP 検査の保険償還後の浸透と今後の展望～

五十嵐 彩香 (株式会社インテージヘルスケア)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Room 8 Room 9 Room 10 Room 11 Room 12 Room 13 Room 14 Meet the Experts Poster

P37-5 **Progress and Challenges in Cancer Genomic Medicine from a Patients' Perspective**
 Miu Adachi (INTAGE Healthcare Inc.)
患者視点で見るがんゲノム医療の進展と課題 ～がんゲノムプロファイリング検査を受けた106名の患者と臨床医のギャップ分析～
 安達 未羽 (株式会社インテージヘルスケア)

13:05-13:50 Poster Session 38

P38 Cross-sectional Program 2 臓器横断プログラム 2

P38-1 **Withdrawn**

P38-2 **Practice of screening for relatives of Lynch syndrome-related tumors built from counseling from relatives of patients**
 Shoichi Inoue (Department of Medical Oncology, Tane General Hospital)
Lynch 症候群関連腫瘍患者の血縁者の遺伝カウンセリングから構築した当院の Lynch 症候群関連腫瘍スクリーニングの実際
 井上 正一 (多根総合病院 腫瘍内科)

P38-3 **Evaluating Hereditary Breast and Ovarian Cancer Syndrome Surveillance in Older Patients : Current Practice and Outcomes**
 Ayaka Sakakibara (Department of Breast Oncology, Saitama Medical University International Medical Center)
高齢癌患者における HBOC サーベイランスの評価：現状と転帰
 榑原 彩花 (Department of Breast Oncology, Saitama Medical University International Medical Center)

P38-4 **Trends over time and regional differences in the prevalence of BRCA1/2 genetic testing in Japan**
 Masahiro Iwasaku (Kyoto Prefectural University of Medicine, Respiratory medicine)
BRCA1/2 遺伝子検査の全国的な普及状況と地域差の検討
 岩破 将博 (京都府立医科大学大学院医学研究科 呼吸器内科)

P38-5 **Treatment Course and Clinical Features in Familial Adenomatous Colorectal Disease**
 Yukiko Asakawa (Gastroenterology)
家族性大腸腺腫症における治療経過とその臨床的特徴の検討
 浅川 幸子 (山梨県立中央病院)

P38-6 **Clinical and pathological features of SMARCA4-deficient tumors**
 Norito Suzuki (Department of Medical Oncology)
SMARCA4 機能欠損腫瘍の臨床病理学的検討
 鈴木 慎人 (札幌医科大学附属病院)

P39 Cross-sectional Program 3
 臓器横断プログラム 3

- P39-1** **Meanings and Problems of National Cancer Registry in a General Hospital (Second Report)**
 Kan Kato (Department of Internal Medicine, Tokyo Kensei Hospital)
一般病院における全国がん登録の意義と課題 (続報)
 加藤 冠 (東京健生病院 内科)
- P39-2** **Development of a real world data (RWD) collection infrastructure independent of EMR vendors, based on CyberOncology**
 Manabu Muto (Department of Medical Oncology, Kyoto University Graduate School of Medicine)
CyberOncology を軸とした電子カルテベンダーによらないリアルワールドデータ (RWD) 収集基盤の整備
 武藤 学 (京都大学大学院医学研究科 腫瘍内科学講座)
- P39-3** **Retrospective research of tumor agnostic clinical development using a master protocol in Japan**
 Keiko Yamamoto (Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Meiji Pharmaceutical University)
マスタープロトコルを用いた癌種横断的な国内開発におけるレトロスペクティブ研究
 山本 景子 (明治薬科大学 大学院薬学研究科 レギュラトリーサイエンス研究室)
- P39-4** **Investigation on the development of a chief complaint extraction program for irAE-related symptoms using generative AI**
 Masakazu Sato (TXP Medical Co., Ltd.)
生成 AI を用いた irAE 関連主訴抽出プログラム構築に関する検討
 佐藤 雅和 (TXP Medical 株式会社)
- P39-5** **Digital monitoring of cancer patients in routine clinical practice in Japan --A retrospective analysis of a cancer PHR**
 Satoko Zenitani (Welby, Inc.)
本邦の実臨床におけるがん患者のデジタルモニタリングの実態 ~日々の症状を記録するがん患者向け PHR の後方視的解析~
 銭谷 聖子 (株式会社 Welby)
- P39-6** **A CGA screening G8 score is associated with survival in non-elderly cancer patients with chemotherapy**
 Yuya Yoshida (Department of Clinical Oncology)
CGA スクリーニング G8 スコアは若年・中年がん患者の予後と関連する
 吉田 裕也 (東北大学病院)
- P39-7** **Usefulness of G8 screening tools on introduction of chemotherapy for older cancer patients**
 Satoru Yamaga (Department of Medical Oncology, Sasebo Kyosai Hospital)
高齢者のがん化学療法導入時の G8 スクリーニングツールの有用性
 山家 覚 (Department of Medical Oncology, Sasebo Kyosai Hospital)